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Outline of the thesis
Radiolabeled peptides have become very important in nuclear medicine for tumor diagnosis 
and therapy. The specific receptor binding property of the peptide can be exploited by labeling 
the peptide with a radionuclide and using the radiolabeled peptide as a vehicle to guide the 
radioactivity to the tissues expressing a particular receptor. Chapter 1 provides an overview of 
peptides, receptors, and therapy.
Radiolabeled RGD peptides can be used to visualize and quantify α
v
β
3
 expression non-invasively. 
The aim of this thesis was to develop improved radiolabeled ligands for α
v
β
3
 expressing tumors. In 
this thesis, the in vivo targeting properties of α
v
β
3
 binding ligands were optimized by:
Synthesis of new αvβ3 targeting analogs
In chapter 2, the synthesis of a cyclic RGD peptide, a cyclic peptoid-peptide hybrid in which the 
arginine residue is replaced by the corresponding peptoid residue, an all-peptoid in which all the 
amino acid residues are replaced by their corresponding peptoid residues, and a peptidomimetic 
α
v
β
3
 receptor antagonist is described. After the radiolabeling of these compounds with 111In, the 
stability, in vitro and in vivo α
v
β
3
 binding characteristics were systematically studied.
Multimerization
To develop improved tracers for α
v
β
3
 targeting, we aimed to increase the affinity of the peptide 
by multimerization. In chapter 3, the α
v
β
3
 binding characteristics of an 111In-labeled monomeric, 
dimeric, and tetrameric RGD analog were compared. In addition, chapter 4 describes the design, 
synthesis and in vitro evaluation of a series of α
v
β
3
 integrin-directed c(RGDfK) containing 
dendrimers.
Linker variation
The effect of modification of the linker between the dimeric RGD peptide and the DOTA chelator 
on the in vitro and in vivo characteristics was systematically investigated in chapter 5.
A new application of one of the α
v
β
3
 binding ligands is described in chapter 6. In this chapter, 
the tumor targeting potential of an 111In-labeled cyclic RGD peptide in athymic BALB/c nude mice 
with intraperitoneally growing NIH:OVCAR-3 ovarian carcinoma tumors was studied. In addition, 
the therapeutic potential of the 177Lu-labeled cyclic RGD peptide was investigated.
Chapter 7 provides a summary and general discussion.
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General introduction
During the past decade, radiolabeled receptor binding peptides have emerged as an important 
class of radiopharmaceuticals for tumor diagnosis and therapy. The specific receptor binding 
property of the ligand can be exploited by labeling the ligand with a radionuclide and using the 
radiolabeled ligand as a vehicle to guide the radioactivity to the tissues expressing a particular 
receptor. The concept of using radiolabeled receptor binding peptides to target receptor expressing 
tissues in vivo has stimulated a large body of research in nuclear medicine. Small peptides for 
receptor imaging and targeted radiotherapy have some advantages over proteins, antibodies, and 
antibody fragments. Peptides are small molecules and show rapid diffusion in target tissue. They 
clear rapidly from the blood and non-target tissues, resulting in high tumor-to-background ratios. 
Furthermore, peptides have a low toxicity and generally they are not immunogenic.
Apart from planar imaging, single photon emission computed tomography (SPECT) and 
positron emission tomography (PET) are the two main imaging modalities in nuclear medicine. 
SPECT requires compounds labeled with single photon emitters or so-called gamma emitters. 
Commonly used gamma emitters are: 123I, 111In, and 99mTc. Receptor binding peptides labeled with 
gamma emitters can be used to non-invasively visualize receptor expressing tissues, a technique 
referred to as peptide-receptor radionuclide imaging (PRRI). To date, the 111In-labeled somatostatin 
analog octreotide (OctreoScan®) is the most successful radiopeptide for tumor imaging and has 
been the first that was approved for diagnostic use. 111In-octreotide is considered the gold standard 
for imaging several types of neuroendocrine tumors. Receptor targeting with other peptides such 
as cholecystokinin (CCK) analogs, bombesin, substance P, neurotensin, glucagon-like peptide 1 
(GLP-1), and RGD peptides are currently under development or undergoing clinical trials.
Compared to SPECT, PET has a higher spatial resolution and the possibility to more accurately 
quantitate the uptake in tumor and in normal organs. For PET imaging, peptides are radiolabeled 
with positron-emitting radionuclides such as 18F, 68Ga, 64Cu, 86Y, 89Zr, and 124I. Peptide-receptor 
radionuclide therapy (PRRT) can be used to treat cancers. For this purpose, peptides with 
specific affinity for tumor-associated receptors on cancer cells are radiolabeled with cytotoxic, 
β-emitting radionuclides like 131I, 90Y, 188Re, and 177Lu. Here we discuss the criteria for peptide ligand 
development, the selection of radioisotopes and of chelators, including various chemical aspects 
of radiopeptide development. In addition, the current state of clinical use of radiopeptides for 
diagnosis and therapy of tumors is discussed.
Regulatory peptides and their receptors
Regulatory peptides are potent small messenger molecules binding to specific receptors. 
Physiologically, these regulatory peptides are very potent molecules and usually they are not larger 
than 40 amino acids. Regulatory peptides are synthesized mainly in the brain and the digestive tract. 
Due to their relatively small size, they are able to rapidly penetrate almost any tissue, except the brain. 
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Because of the hydrophilicity of regulatory peptides, the blood-brain barrier is non-permeable for 
these peptides. Therefore, the central nervous system and the periphery (e.g., the digestive tract) 
form two independent regulatory systems that can use the same messenger molecules without 
any danger of confusing interaction of both [1, 2, 3]. All regulatory peptides bind to and act 
through transmembrane G-protein-coupled receptors. The signal transduction of these receptors is 
triggered by the binding of the respective peptide to the extracellular domain of the receptor, which 
in turn, activates the intracellular guanine nucleotide binding proteins (G-proteins).
Regulatory peptides influence many aspects of mammalian physiology. Their role as flexible 
messenger molecules requires rapid degradation in the blood to prevent prolonged action 
of secreted peptides. Due to ubiquitously occurring peptidases, most regulatory peptides are 
rapidly degraded. The application of (radio)peptides as (radio)pharmaceutical may therefore be 
hampered by enzymatic degradation since the half-life of most peptides is relatively short and in 
some cases too short to reach the target tissue in sufficient quantities. Therefore, most peptides 
have to be modified to prevent rapid enzymatic degradation [4, 5].
Application of peptides as radiopharmaceuticals
The ideal peptide-based radiopharmaceutical should have a high in vivo stability, high uptake 
in tumors, low uptake in non-target tissues, and rapid clearance from the blood preferably via 
the kidneys [6]. It is obvious that the peptide should preserve its receptor binding affinity and 
biological activity during the radiolabeling procedure. Peptide-based radiopharmaceuticals offer 
some advantages over antibodies and proteins, like rapid clearance from blood and non-target 
tissues, rapid penetration into tumor tissue, toleration of harsh conditions of chemical modifications 
or radiolabeling, low toxicity, and low immunogenicity. As described above, the application of 
peptides can be hampered by the limited in vivo stability of the peptide. To overcome the enzymatic 
degradation of peptides, several methods of inhibiting proteolysis of peptides have been developed. 
These methods commonly used include: substitution of L-amino acids by D-amino acids, substitution 
of peptide bonds, insertion of unusual amino acids or side chains, amidation, cyclization, and use of 
peptidomimetics. Cyclization of peptides results not only in resistance to enzymatic degradation, it 
could also lead to conformationally more constrained compounds with enhanced receptor affinity 
and biological activity [4, 7].
As stated above, the preferred route of clearance of a peptide-based radiopharmaceutical is via 
the kidneys. For rapid renal excretion, hydrophilicity is required as lipophilic peptides are cleared 
via the hepatobiliary route. As a result, lipophilic peptide-based radiopharmaceuticals will show 
a higher background activity in the abdomen and slow clearance, possibly masking tumors in the 
abdomen, making them less suitable for diagnostic and therapeutic purposes. The route and rate 
of excretion of peptides can be modified by introduction of specific hydrophilic or lipophilic amino 
acids into the peptide chain [8]. Peptides can also be modified by linking them to polyethylene 
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glycol (PEG) chains, a technique called PEGylation. PEG is a hydrophilic polymer which is non-toxic 
and non-immunogenic. In general, by PEGylation peptides become more hydrophilic and are less 
susceptible to enzymatic degradation. In addition, PEGylation could enhance the circulatory half-
life of a peptide [9, 10].
Another method to improve the pharmacokinetics of a peptide is glycosylation. The attachment 
of carbohydrates enhances the hydrophilicity of a peptide, resulting in reduced hepatobiliary 
uptake, enhanced urinary excretion, and reduced non-specific binding [11]. However, modification 
of a peptide by for example PEGylation, glycosylation or conjugation to a chelator, could also affect 
the affinity of a peptide for the receptor.
Radiolabeling of peptides
For the radiolabeling of peptides, the radiolabeling procedure should not affect the receptor 
binding affinity of the peptide. Various techniques have been developed that enable efficient 
labeling of peptides with radionuclides such as 123I, 99mTc, 111In, 64Cu, 18F, and 66/67/68Ga (Table 1).
Table 1. Half-life and decay type of several radionuclides. Half-life is given in hours, unless stated otherwise.
Isotope Half-life (h) Decay type
γ-emitter 99mTc 6.02 IT
111In 67.2 EC, γ
123I 13.0 EC, γ, e-
β+-emitter 18F 1.83 β+, EC
11C 20.4 min β+, EC, γ
15O 122 s β+,
13N 10.0 min β+,
64Cu 12.9 β-, EC
68Ga 1.14 β+, EC
124I 76.8 EC, β+, γ
β-emitter 90Y 64.1 β-
177Lu 161 β-
186Re 91 β-, EC, γ
188Re 17.0 β-
131I 192 β-, γ, e-
α-emitter 211At 7.21 α
212Bi 1.01 β-, α
213Bi 45.6 min β-, α
225Ac 10 d α
α = alpha decay, β- = negative beta decay, β+ = positive beta decay, γ = gamma transition, IT = isometric transition,  
EC = electron capture.
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Radioiodination
Radioiodination of peptides with 125I, 123I, or 131I can be performed by either direct labeling or 
indirect labeling via an auxiliary group [8]. During direct radioiodination, radioactive iodine is 
incorporated covalently into the side chains of tyrosyl or histidyl residues in the presence of an 
oxidizing agent such as chloramine-T or iodogen. If no tyrosyl or histidyl residue is available, free 
amino groups in the peptide may be radioiodinated by auxiliary groups, including N-succinimidyl-
3-(4-hydroxyphenyl)propionate, known as Bolton-Hunter reagent [12]. Other auxiliary groups for 
radioiodination of peptides are N-succinimidyl-3-iodobenzoate (SIB) and N-succinimidyl-5-iodo-
3-pyridinecarboxylate (SIPC) (Figure 1) [13-15]. 
Figure 1. The auxiliary groups Bolton-Hunter reagent, SIB, and SIPC for the radioiodination of peptides.
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A major drawback of radioiodinated peptides is that upon internalization and lysosomal 
degradation, the radioiodinated amino acid residues will be rapidly excreted out of the cell. 
This so-called non-residualizing property of iodine results in reduced tumor-to-background 
ratios. In contrast to radioiodinated amino acids, radiometal labeled amino acids are trapped 
in the lysosomes as no metabolic transport pathway exists for the processing and transport of 
these molecules. These residualizing labels will show enhanced retention in tumor cells following 
internalization. Recently, the residualizing radioiodine labels dilactitol-tyramine (DLT) and DTPA-
appended peptide moieties have been developed to increase the tumor uptake of radioiodinated 
targeting vehicles. In nude mice with human lung tumor xenografts, antibodies labeled with 
these residualizing iodine labels showed superior tumor-to-non-tumor ratios. In addition, the 
therapeutic efficacy of these radioiodinated antibodies was significantly improved compared to 
the conventional 131I-labeled antibody [16, 17, 18]. To our knowledge, this concept has not been 
applied to receptor binding peptides yet.
Labeling of peptides with radiometals
Radiolabeling of peptides with metals such as 111In or 177Lu is performed by conjugating peptides 
with bifunctional chelators (BFCs) that complex free metal ions. Several acyclic and cyclic 
bifunctional chelators have been developed for both diagnostic and therapeutic applications 
(Figure 2). The most widely used chelators are diethylenetriaminepentaacetic acid (DTPA) and 
1,4,7,10-tetraazacyclododecane-N’,N’’,N’’’,N’’’’-tetraacetic acid (DOTA) or derivatives thereof. For 
diagnostic purposes, DTPA chelates 111In with sufficient stability. This DTPA chelator is used in 
the commercially available somatostatin analog OctreoScan®. For therapeutic purposes, the DTPA 
chelator is not suited as the 90Y- and 177Lu-DTPA complex is not stable in vivo over longer time. Some 
substituted DTPA analogs such as 2-(4-Isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid 
(p-SCN-Bn-DTPA) have been synthesized showing improved in vivo stability [19]. In contrast, the 
macrocyclic chelator DOTA provides sufficient stability for a broad range of metallic radionuclides, 
like 90Y, 67/68Ga, 177Lu, or 212Pb [20, 21]. A stable radiometal-chelator complex is particularly required 
for therapeutic applications. The macrocyclic DOTA chelator is the most frequently used chelator 
for peptide-receptor radionuclide therapy (PRRT). A major drawback of the use of DOTA is that 
high labeling efficiencies require heating during the labeling procedure, which could affect the 
structure and receptor binding properties of the peptide.
Other chelators such as 1,4,7-triazacyclononane-N,N’,N’’-triacetic acid (NOTA) and 1,4,8,11-
tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) and derivatives of these have been 
developed. For example, Prata et al. demonstrated the high in vivo stability of NOTA and its 
derivative 1,4,7-triazacyclononane-N,N’,N’’’-tris(methylenephosphonate-monoethylester) (NOTPME) 
complexed with 67Ga3+ [22]. In addition, for copper radionuclides TETA has been extensively used. 
However, Anderson et al. showed the dissociation of 64Cu from TETA-D-Phe1-octreotide resulting 
in subsequent binding of 64Cu to superoxide dismutase (SOD) [23]. Furthermore, DeNardo and 
coworkers reported the transfer of 67Cu from a TETA derivative to ceruloplasmin [24]. To overcome 
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this problem, Boswell et al. developed a “cross-bridged” TETA derivative, which proved to have 
significant potential for labeling copper radionuclides to biological molecules for diagnostic imaging 
and targeted radiotherapy [25].
Figure 2. Structural formula of different chelators for radiolabeling of peptides.
Radiolabeling of peptides with 99mTc
Nowadays there is considerable interest in labeling peptides with 99mTc for nuclear medicine 
imaging because of the excellent chemical and imaging characteristics of this radionuclide. Three 
main methods for radiolabeling peptides with 99mTc can be distinguished: (I) direct labeling, (II) 
preformed chelate approach, and (III) indirect labeling using a bifunctional coupling agent (BCA) 
[26, 27]. The direct labeling approach uses a reducing agent to convert the cystine disulfide bridges 
of a peptide into free cysteine thiols, which are able to efficiently bind 99mTc. However, this method 
applies only to peptides and proteins with disulfide bonds. More importantly, these bonds are 
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often critical for maintaining the biological and receptor binding properties of the peptide. In 
the preformed chelate approach, first a complex of 99mTc with a BCA is formed. In a second step 
the 99mTc-BCA complex is conjugated to a peptide. However, a two-step radiochemical synthesis 
is not optimal for routine clinical applications. In the indirect labeling approach, first the BCA is 
attached to the peptide to form a BCA-peptide conjugate. Secondly, the conjugate is labeled with 
99mTc either by reduction of 99mTcO
4
- or indirectly by ligand exchange with an intermediate 99mTc-
complex, such as 99mTc-glucoheptonate, 99mTc-diphosphonate, or 99mTc-tricine. A variety of BCAs 
has been developed including MAG
3
 [28, 29, 30], MAG
2
 [31], HYNIC [32, 33], DADT [34], EC [35], 
and tetraamine [36]. Succinimidyl-hydrazinonicotinamide (S-HYNIC) as developed by Abrams 
and coworkers [37] appears to be an ideal BCA for 99mTc-labeling, because it allows rapid and 
efficient labeling of peptides and proteins even at room temperature. In addition, the HYNIC-99mTc 
complex is very stable in vivo, especially when used in combination with the proper coligands such 
as ethylenediaminediacetic acid (EDDA), tricine, and nicotinic acid.
Radiolabeling of peptides with 18F
For radiolabeling of peptides with 18F, an auxiliary group is necessary. N-succinimidyl-4-18F 
fluorobenzoate ([18F]SFB) is a very suitable 18F-labeling agent (Figure 3). However, the efficiency of 
the labeling is low. Several improvements in the synthesis of [18F]SFB have been achieved, including 
reduced synthesis time and increased radiochemical yield [38, 39, 40, 41, 42]. Recently, a high-yield 
two-step radiohalogenation method via chemoselective oxime formation between an aminooxy-
functionalized peptide and a radiohalogenated aldehyde or ketone was developed. This method 
offers new perspectives for large-scale radiofluorination of bioactive peptides [43, 44].
Figure 3. Radiolabeling of peptides with 18F using [18F]SFB.
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Peptides for peptide receptor radionuclide imaging and 
therapy
Somatostatins
Natural somatostatin is a cyclic 14 amino acid, which was discovered in 1973. The amino acids 
7-11 and the cyclic structure of this peptide are required for receptor binding. In the central 
nervous system, somatostatin acts as a neurotransmitter and this peptide can inhibit the release 
of growth hormone, insulin, glucagon, and gastrin [45]. Somatostatin receptors are expressed in 
most neuroendocrine tumors, in neuroblastomas, in some medullary thyroid cancers (MTC), in 
small cell lung carcinoma (SCLC), and in many other cancers. Five subtypes of human somatostatin 
receptors (hSSTR) have been identified [46] and natural somatostatin has a high affinity for all 
these subtypes. However, somatostatin-14 has a very short biological half-life due to enzymatic 
degradation, which limits targeting of SST receptor expressing tissues in vivo. By rational design, 
the somatostatin analog octreotide with enhanced stability towards enzymatic degradation was 
developed. For radioiodination of this 8 amino acid peptide, phenylalanine in position 3 was 
replaced by a tyrosyl residue. The resulting 123I-Tyr3-octreotide was the first radiopeptide used 
for imaging of neuroendocrine tumors (NET) in a patient [47]. However, this compound cleared 
mainly via the hepatobiliary route and its complicated radioiodination method hampered its wide 
spread clinical application. By N-terminal conjugation of octreotide to the chelator DTPA, the 
so-called “pentreotide” was developed. DTPA conjugation enabled radiolabeling with 111In, which 
allows a simpler labeling method compared to labeling with 123I and results in a residualizing label. 
Furthermore, in contrast to 123I-Tyr3-octreotide, 111In-DTPA-D-Phe1-octreotide is mainly cleared via 
the kidneys, making interpretation of scintigraphic images of the upper abdomen easier [48]. 111In-
DTPA-D-Phe1-octreotide became the first peptide-based radiopharmaceutical that has obtained 
regulatory approval in Europe and the United States [4, 49]. These days, 111In-DTPA-D-Phe1-
octreotide or trade named OctreoScan® is commercially available as a kit.
Since the chelator DTPA is not suitable for labeling with radionuclides such as 90Y and 177Lu, 
because of in vivo instability, DOTA-conjugated somatostatin analogs were developed which 
ensure better stability of the radiometal-peptide complex over time. Labeled with 90Y or 111In, 
DOTA-D-Phe1-Tyr3-octreotide showed a more favorable biodistribution and tumor uptake in 
animal models compared to 111In-DTPA-D-Phe1-octreotide (Figure 4) [50, 51, 52]. Their clinical 
application has been tested in several studies [53, 54, 55].
Another promising somatostatin analog is 99mTc-HYNIC-D-Phe1-Tyr3-octreotide, which was first 
developed by the group in Basel [56]. This 99mTc-labeled somatostatin analog showed favorable 
detection capabilities of extrahepatic lesions as compared to 111In-DTPA-D-Phe1-octreotide. The 
patterns of accumulation of 99mTc-HYNIC-D-Phe1-Tyr3-octreotide in tumors and normal organs 
were comparable to those of 111In-DTPA-D-Phe1-octreotide. Further clinical studies are necessary 
to definitively determine whether this interesting compound may be able to replace 111In-labeled 
somatostatin analogs in clinical routine [56, 57].
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Figure 4. Structural formulas of DTPA-D-Phe1-octreotide (top) and DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) (bottom).
For the development of somatostatin analogs suitable for PET imaging, several studies have 
been performed. For example, several 64Cu-labeled somatostatin analogs have been developed 
and these compounds demonstrated favorable results in animal models [58, 59]. 64Cu-TETA-
octreotide appeared to be a promising radiopharmaceutical for PET imaging of patients with 
neuroendrocrine tumors [60]. 18F-labeled octreotide was successfully synthesized by Wester et 
al., however, this compound showed a fast tumor washout and high liver uptake. As a result, 
visualization of abdominal tumors was hampered and therefore its clinical application was limited 
[61]. Recently, a glycosylated 18F-labeled somatostatin analog, Nα-(1-deoxy-D-fructosyl)-Nε-(2-
[18F]fluoropropionyl)-Lys0-Tyr3-octreotate (Gluc-Lys([18F]FP)-TOCA showed promising results in 
an animal model [62]. In patients with SSTR-positive tumors, PET with Gluc-Lys([18F]FP)-TOCA 
allowed fast, high-contrast imaging of these tumors. The diagnostic performance of Gluc-
Lys([18F]FP)-TOCA was clearly superior to that of 111In-DTPA-octreotide [63].
68Ga is another interesting radionuclide for PET imaging, because it is available from an inhouse 
68Ge/68Ga generator and therefore PET centers are not dependent on a cyclotron. Hofmann et 
al. evaluated 68Ga-DOTA-D-Phe1-Tyr3-octreotide (68Ga-DOTATOC) in patients [64]. This PET 
radiopharmaceutical appeared to be promising for imaging SSTR-positive tumors. Compared 
to 111In-DTPA-octreotide, 68Ga-DOTATOC seems to be favorable especially in detecting tumors 
with a low SSTR expression and small tumors [65]. Another somatostatin-based radiotracer with 
a high affinity for sstr2 and sstr5 is 68GA-DOTA-1-NaI3-octreotide (68Ga-DOTANOC) [66]. It was 
shown that 68Ga-DOTANOC is a good tracer for primary diagnostic and follow-up investigations 
in patients with suspected or proven somatostatin receptor-positive tumors.
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Cholecystokinin/gastrin
The cholecystokinin (CCK) receptor is expressed on a variety of tumors [67]. CCK receptors can 
be distinguished pharmacologically by their affinity for gastrin, a 33 amino acid peptide hormone 
involved in gastric motility [68]. The CCK
1
 (or formerly CCK-A) receptor has a low affinity for 
gastrin, whereas the CCK
2
 (or formerly CCK-B) receptor has a high affinity for gastrin. Medullary 
thyroid carcinomas, small cell lung cancers, astrocytomas, and stromal ovarian cancers frequently 
express CCK
2
 receptors. The expression of CCK
1
 receptors in normal tissues in humans is quite 
restricted. CCK
1
 receptors are found in gastroenteropancreatic tumors, meningiomas, and 
neuroblastoma [67].
Several radiolabeled gastrin analogs have been developed and their potential for targeted 
diagnostic imaging and radionuclide therapy of CCK
2
 receptor expressing tumors have been 
investigated. For example, Behr et al. showed favorable results for the diagnostic and therapeutic 
application of 131I-radioiodinated human gastrin-I [69]. In addition, Reubi et al. developed a series 
of non-sulfated CCK analogs, which were conjugated with DTPA or DOTA at the N-terminus [70]. 
Two of these analogs had a high affinity for the CCK
2
 receptor and a low affinity for the CCK
1
 
receptor. In rats, one of these analogs conjugated with either DTPA or DOTA specifically localized 
in CCK
2
 receptor expressing tumors [71]. However, in medullary thyroid cancer patients this CCK 
analog had a relatively low uptake in the strong CCK receptor-positive stomach and small lesions 
could not be detected [72]. First clinical studies using 111In-DTPA-D-Glu1-minigastrin, showed that 
this CCK analog can visualize metastatic MTC with high sensitivity [73, 74].
Bombesin
Bombesin, a 14 amino acid neuropeptide, has a high affinity for the human gastrin-releasing 
peptide receptor (GRP). These receptors are expressed in various types of cancer, such as colon 
cancer, glioblastoma, prostate cancer, and small cell lung cancer [2]. In analogy with the clinical 
usefulness of somatostatin receptor targeting [75, 76, 77], the use of radiolabeled bombesin 
analogs for GRP targeting has been explored. For example, in mice a 99mTc-labeled bombesin 
analog – demobesin - showed rapid background clearance and high and prolonged localization in 
PC-3 human prostate cancer xenografts [78]. In addition, an 111In-labeled DTPA-bombesin analog 
appeared to be a promising radioligand for scintigraphy of GRP receptor expressing tumors. 
Phase I studies in patients with invasive prostate carcinoma are currently being undertaken [79]. 
However, the loss of bombesin receptors upon dedifferentiation of prostate cancer cells from 
androgen-controlled to androgen-independent growth may hamper clinical utility [80].
Substance P
Substance P is an 11 amino acid neuropeptide that plays an important role in a variety of 
processes, such as pain perception and cross-links in the neurocrine network through neurokinin 
1 and 2 receptors. Receptors for substance P are mainly expressed in breast cancer, MTC, SCLC, 
and in brain tumors, such as astrocytoma and glioblastoma [81]. So far, no visualization of tumors 
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after intravenous application of radiolabeled substance P has been reported. Severe side-effects 
could occur after injection of substance P [82] and intravenous application is not tolerated well by 
patients. However, local application into tumor tissue does not cause these problems. 90Y-labeled 
substance P has been used for intracavitary therapy of high grade gliomas [83].
GLP-1
The glucagon-like peptide 1 (GLP-1) receptor is overexpressed in nearly all insulinomas and 
gastrinomas. In addition, this receptor is expressed in a large number of intestinal and bronchial 
carcinoids. GLP-1 is an intestinal hormone that stimulates postprandial insulin secretion from 
pancreatic β-cells. However, GLP-1 is rapidly degraded in vivo. Therefore, a more stable GLP-1 
receptor selective analog, exendin, was developed. This compound showed successful tumor 
targeting in a rat insulinoma model [84, 85]. Radioiodinated exendin showed a more pronounced 
pancreatic and tumor uptake as compared to GLP-1 and seems to have potential for scintigraphic 
purposes. Because of the very high expression of GLP-1 receptors in insulinomas and a few other 
tumors, radiolabeled GLP-1 analogs could also be used for therapy of these tumors. For tumor 
scintigraphy, radiometals have certain advantages over radioiodine. 111In-labeled exendin is 
currently under development.
Vasoactive intestinal peptide
Vasoactive intestinal peptide (VIP) is a 28 amino acid neuroendocrine mediator isolated from 
the small intestine [86] and it is a member of the group of secretin-like peptides. VIP is a potent 
vasodilator and stimulates the secretion of several hormones. VIP receptors are expressed 
by most human epithelial cancers. Large numbers of high affinity receptors are expressed on 
adenocarcinomas of the gastroenteropancreatic system. Virgolini and coworkers claimed that 
radioiodinated VIP can be used to image and localize intestinal adenocarcinomas and endocrine 
tumors [87]. However, these findings were refined by the study of Hessenius et al., indicating that 
123I-VIP did not adequately accumulate in pancreatic adenocarcinomas [88]. These findings were 
confirmed by autoradiography studies of resected tumors, demonstrating lower VIP receptor 
expression in the tumor as compared to surrounding tissue. Recently, two studies with 99mTc-
labeled VIP analogs in patients with high grade spindle cell sarcoma, ductal epithelial hyperplasia, 
and colorectal cancer suggested that labeling with this radionuclide may lead to better results [89, 
90]. 
Neurotensin
In contrast to neuroendocrine pancreatic tumors, exocrine pancreatic tumors express only low 
numbers of somatostatin receptors. For the diagnosis of exocrine pancreatic tumors overexpression 
of other receptors in these tumors needed to be found. Reubi et al. reported that 75% of all 
ductal adenocarcinomas overexpress neurotensin (NT) receptors, and that normal pancreatic 
tissue, pancreatitis and endocrine pancreatic cancers do not express neurotensin receptors [91]. 
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The neurotensin receptor has a high affinity for neurotensin, a 13 amino acid peptide found in 
brain and gut. However, the possible application of neurotensin in cancer diagnosis and therapy 
is limited due to its rapid degradation in vivo. Preclinical studies using 111In-labeled DTPA- and 
DOTA-conjugated neurotensin analogs with modified lysine and arginine derivatives to enhance 
stability, suggest that these analogs may be applied in the management of patients with exocrine 
pancreatic cancer [92]. In vitro these NT analogs showed a high receptor affinity and enhanced 
stability. Indeed, the DTPA-conjugated NT analog showed receptor-mediated tumor uptake in 
mice with HT29 tumors.
RGD peptides
The α
v
β
3
 integrin is a transmembrane protein consisting of two non-covalently bound subunits, α 
and β. Integrin α
v
β
3
 is preferentially expressed on proliferating endothelial cells [93], whereas it is 
absent on quiescent endothelial cells. For growth beyond the size of 1-2 mm in diameter, tumors 
require the formation of new blood vessels. Consequently, α
v
β
3
 expression on tumor vasculature is 
considered to be a marker of tumor-induced angiogenesis [94, 95, 96]. In addition, α
v
β
3
 is expressed 
on the cell membrane of various tumor cell types, such as ovarian cancer, neuroblastoma, breast 
cancer, and melanoma. Due to this restricted expression of α
v
β
3
 on the neovasculature of growing 
tumors and on certain tumor cell types, α
v
β
3
 is considered a suitable target for tumor targeting 
[97]. Radiolabeled ligands for this integrin could be used as tracers to non-invasively visualize α
v
β
3
 
expression in tumors. Non-invasive visualization of α
v
β
3
 expression might supply information 
about the angiogenic process and the responsiveness of a tumor for antiangiogenic drugs. 
Furthermore, non-invasive determination of α
v
β
3
 expression potentially can be used to monitor 
the effect of antiangiogenic drugs in patients.
This integrin can bind to the arginine-glycine-aspartic acid (RGD) amino acid sequence present 
in extracellular matrix proteins, such as vitronectin, fibrinogen, and laminin [98]. Based on the 
RGD tripeptide sequence, a series of small peptides have been designed to antagonize the function 
of the α
v
β
3
 integrin [99]. A series of RGD sequence containing peptides has been tested for their 
ability to bind the α
v
β
3
 integrin. It was found that the cyclic derivative cyclic(Arg-Gly-Asp-D-Phe-
Val) inhibited a 100-fold better the cell adhesion to vitronectin compared to the linear variant, 
having an IC
50
 value in the nanomolar range [100, 101]. Especially cyclic RGD peptides consisting 
of five amino acids have a high affinity for α
v
β
3
. It was shown that besides the essential RGD 
sequence, a hydrophobic amino acid in position 4 increased the affinity, whereas the amino acid in 
position 5 had no influence on the affinity [102].
The first radiolabeled α
v
β
3
 antagonist for the investigation of angiogenesis and metastasis in vivo, 
was [125I]-3-iodo-D-Tyr4-cyclo(-Arg-Gly-Asp-D-Tyr-Val-) [103]. This radioiodinated α
v
β
3
 integrin 
antagonist had a high affinity for α
v
β
3
, however, it was mainly excreted via the hepatobiliary route. 
To develop a clinically useful radiolabeled α
v
β
3
 integrin antagonist, a variety of factors must be 
considered such as receptor affinity, α
v
β
3
 specificity, hydrophilicity, and metabolic stability [104]. 
Subsequently, a glycosylated version, cyclo(Arg-Gly-Asp-D-Tyr-Lys[SAA]), was synthesized in 
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an attempt to produce a more hydrophilic compound that would clear predominantly via the 
kidneys [105]. This glycosylated peptide was radioiodinated and tested in vivo. In a mouse tumor 
model the glycosylated version showed a longer circulatory half-life and a significantly reduced 
uptake in the liver compared to the non-glycosylated peptide. In addition, the glycosylated RGD 
peptide had a clearly enhanced uptake in the tumor.
A non-glycosylated version of the peptide, cyclo(Arg-Gly-Asp-D-Tyr-Lys) was conjugated 
with DTPA. After radiolabeling this peptide with 111In, this peptide was tested in vivo. This study 
showed that the introduction of the DTPA-moiety in the peptide via the ε-aminogroup of the 
lysine residue made the peptide hydrophilic and facilitated renal clearance, while the non-DTPA-
conjugated peptide predominantly cleared via the liver [106].
A stable hydrophilic 18F-labeled galactosylated cyclic pentapeptide has recently been developed, 
with a high affinity and selectivity for α
v
β
3
 that accumulates specifically in α
v
β
3
-positive tumors 
[107]. In a recent study it was shown that this PET-tracer can be used to visualize α
v
β
3
 expression 
in tumors in patients [108]. In addition, comparison with immunohistochemical analysis of the 
tumor lesion indicated that PET using this tracer correctly identified the level of α
v
β
3
 expression 
in tissue non-invasively [109].
Peptide-receptor radionuclide therapy
While a diagnostic radiopharmaceutical depends on a high tumor-to-background ratio for the 
best contrast, a therapeutic radiopharmaceutical also needs to have a high uptake in the tumor for 
a prolonged time. Since retention of the therapeutic radiopharmaceutical in the tumor is crucial, 
a high in vivo stability of radiolabeled peptide is indispensable. High affinity of the peptide for its 
receptor and rapid internalization of the peptide-receptor complex can enhance the retention of 
the radionuclide in receptor expressing tumors.
The selection of the appropiate isotope is an important issue in developing a therapeutic 
radiopharmaceutical. For receptor targeted radiotherapy, radionuclides with high cytotoxic 
potential have to be used. β-Particle emitters are good cytotoxic agents and have a relatively 
long penetration range. β-Particles are electrons that are emitted from the nucleus of a decaying 
radioactive atom. This results in a daughter nucleus in which one neutron is replaced by one 
proton. Depending on the energy of the commonly used β-particles, their penetration range 
varies from 2 to 12 mm in tissue. So far, PRRT has been performed mostly with β-particle emitters. 
The most frequently used radionuclides are 90Y (β
max
 2.3 MeV, t
1/2
 64 h), 186Re (β
max
 1.1 MeV, t
1/2
 
91 h), 188Re (β
max
 2.1 MeV, t
1/2
 17 h), 131I (β
max
 0.6 MeV, t
1/2
 192 h), and 177Lu (β
max
 0.5 MeV, t
1/2
 161 
h). High energy β-radiation with a corresponding long penetration range in tissue is less efficient 
when treating tumors with a relatively small diameter as most of the energy is deposited outside 
the lesion. Therefore, high energy particles such as 90Y and 188Re are considered more appropiate for 
the treatment of relatively larger tumors and tumors with a heterogeneous receptor distribution, 
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whereas low energy particles such as 177Lu and 131I could be better suited for the treatment of 
smaller tumor lesions [110].
Compared to β-particle emitters, α-particle emitters are mostly heavy elements with a relatively 
short penetration range of only a few cell diameters. These particles are positively charged with 
a mass and charge equal to the helium nucleus. Their emission results in a daughter nucleus 
with two fewer protons and two fewer neutrons. The emitted particles have energies ranging 
from 5-9 MeV with a relatively short penetration range of about 50 µm in tissue [111, 112]. 
Interesting candidates for peptide-receptor radionuclide therapy (PRRT) are α-emitters such as 
211At, 212Bi, 213Bi, and 225Ac. So far, α-emitters have mainly been used to radiolabel antibodies for 
radioimmunotherapy (RIT) in animal studies. Recently, Vaidyanathan et al. labeled octreotate 
conjugates with 211At. The application of this 211At-labeled peptide conjugates for PRRT still has 
to prove its value [113]. In addition, Norenberg et al. demonstrated that 213Bi-labeled DOTA0-Tyr3-
octreotide (213Bi-DOTATOC) had dose-related antitumor effects with minimal treatment-related 
organ toxicity [114].
Most experience with PRRT is based on the use of somatostatin analogs. Four of these analogs 
labeled with 177Lu or 90Y are in clinical use: DTPA0-octreotide, DOTA0-Tyr3-octreotide (DOTATOC) 
[115], DOTA0-Tyr3-Thr8-octreotide (DOTATATE) [116], and DOTA0-2-NaI-Tyr3-Thr-NH
2
8-octreotide 
(DOTA-lanreotide) [117]. In general, PRRT is well tolerated and only a limited number of patients 
shows relevant hematologic toxicity above greater than 3 (National Cancer Institute Common 
Toxicity Criteria). However, in PRRT with octreotide analogs the kidneys are the organs responsible 
for dose-limiting toxicity. Such toxicity is due to the retention of radiolabeled peptides in the 
renal cortex, leading to a relatively high radiation dose that may result in irreversible loss of kidney 
function. Several studies focussed on blocking the tubular reabsorption of radiolabeled peptides, 
thereby reducing the renal retention of these peptides [118, 119, 120, 121, 122, 123].
Peptides other than somatostatin analogs have gained clinical application in PRRT. 90Y-labeled 
minigastrin has successfully been used for PRRT in patients with medullary thyroid carcinoma 
with response rates above 30% without severe side-effects [124, 125]. As mentioned above, the 
selection of the appropiate isotope is an important issue in PRRT; the response rate dropped when 
111In was used instead of 90Y as radionuclide in gastrin receptor targeted therapy [126].
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Abstract
The α
v
β
3
 integrin is expressed on sprouting endothelial cells as present in growing tumors, whereas 
it is absent on quiescent blood vessels. In addition, various tumor cell types express the α
v
β
3
 
integrin. The α
v
β
3
 integrin, a transmembrane heterodimeric protein, binds to the arginine-glycine-
aspartic acid (RGD) amino acid sequence of extracellular matrix proteins such as vitronectin and 
plays a pivotal role in invasion, proliferation, and metastasis. Due to the selective expression of α
v
β
3
 
integrin in tumors, radiolabeled RGD peptides and peptidomimetics are attractive candidates for 
tumor targeting.
Methods: A cyclic RGD peptide, a peptoid-peptide hybrid, an all-peptoid, and a peptidomimetic 
compound were synthesized, conjugated with DOTA, and radiolabeled with 111In. Their in vitro 
and in vivo α
v
β
3
 binding characteristics were determined.
Results: The IC
50
 values were 236 nM for DOTA-E-c(RGDfK), 219 nM for DOTA-peptidomimetic, > 
10 mM for DOTA-all-peptoid, and 9.25 mM for the peptoid-peptide hybrid, DOTA-E-c(nRGDfK). 
The 111In-labeled compounds, except the 111In-DOTA-all-peptoid, showed specific uptake in 
human α
v
β
3
 expressing tumors xenografted in athymic mice. Tumor uptake for 111In-DOTA-E-
c(RGDfK) was 1.73 ± 0.4 %ID/g (2 h p.i.), and that of 111In-DOTA-peptidomimetic was 2.04 ± 0.3 
%ID/g. Tumor uptake for the peptoid-peptide hybrid, 111In-DOTA-E-c(nRGDfK), was markedly 
lower: 0.45 ± 0.07 %ID/g. The all-peptoid, 111In-DOTA-E-c(nRGnDnFnK), did not show specific 
uptake in the tumor (0.11 ± 0.04 %ID/g).
Conclusions: The peptidomimetic compound and the cyclic RGD peptide have a high affinity 
for the α
v
β
3
 integrin and these compounds have better tumor targeting characteristics than the 
peptoid-peptide hybrid and the all-peptoid.
Introduction
Integrins are an important class of receptors involved in cell-cell and cell-matrix interactions [1]. 
Integrins are heterodimeric, transmembrane glycoproteins consisting of an α- and a β-subunit. 
One of the most prominent members of this class of adhesion molecules is the α
v
β
3
 integrin 
which plays a role in a series of pathological processes such as osteoporosis [2], restenosis after 
balloon angioplasty [3], inflammation [4], rheumatoid arthritis [5], metastasis [6], and tumor-
induced angiogenesis [7]. The α
v
β
3
 integrin is expressed on sprouting endothelial cells during 
angiogenesis, but not on quiescent endothelial cells. In addition, α
v
β
3
 is expressed on various 
tumor cell types such as melanoma, ovarian carcinoma, gliomas, a.o.. This integrin interacts with 
the arginine-glycine-aspartic acid (RGD) amino acid sequence of extracellular matrix proteins 
such as vitronectin [8]. Based on this RGD tripeptide sequence a series of small peptides has been 
designed to antagonize the function of the α
v
β
3
 integrin [9]. Some of these peptides, particularly 
the cyclic ones, have a relatively high and specific affinity for the α
v
β
3
 integrin [10, 11].
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Potentially, radiolabeled RGD peptides and analogs could be used to visualize angiogenesis in 
tumors. Therefore, several radiolabeled ligands for the α
v
β
3
 integrin have been synthesized. The 
first radiolabeled α
v
β
3
 antagonist for the investigation of angiogenesis and metastasis in vivo, was 
125I-3-iodo-D-Tyr4-cyclo(-Arg-Gly-Asp-D-Tyr-Val-) [12]. To develop a clinically useful radiolabeled 
α
v
β
3
 integrin antagonist, a variety of factors must be considered, such as receptor affinity, α
v
β
3
 
specificity, hydrophilicity, and metabolic stability [13]. After a systematic search, the group in 
Munich developed a stable 18F-labeled galactosylated cyclic pentapeptide, with a high affinity and 
selectivity for α
v
β
3
 that accumulated specifically in α
v
β
3
-positive tumors and cleared rapidly via 
the kidneys [14]. In a recent study they showed that this PET tracer can be used to visualize α
v
β
3
 
expression in tumors in patients [15].
In peptidomimetic compounds, amino acids are replaced by non-peptidic building blocks 
[16]. These modifications can be divided into backbone modifications, like N-methylation and 
side chain modification, introducing unnatural amino acids. N-Methylation of peptide bonds 
could improve the binding characteristics of a peptide. For example, N-methylation of the valine 
residue of the α
v
β
3
 antagonist cyclo(RGDfV) resulted in a more active compound, cyclo(RGDf-
N(Me)V-). The antiangiogenic activity of this compound, Cilengitide, is currently in clinical phase 
II studies [17]. Peptoids are a class of peptidomimetics built from N-substituted glycine residues. 
In these so-called peptoid residues, the position of the amino acid side chain is shifted from the 
α-carbon atom to the nitrogen atom [18]. Evidently, these modifications have consequences for 
the biological activity of a peptoid or peptoid-peptide hybrid compared to the parent peptide.
The aim of this study was to develop RGD analogs with improved in vivo α
v
β
3
 targeting 
characteristics. Here, we describe the synthesis and the radiolabeling of four 1,4,7,10-
tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA)-conjugated compounds: a cyclic 
pentapeptide RGDfK (Figure 1A), a cyclic peptoid-peptide hybrid in which the arginine residue 
is replaced by the corresponding peptoid residue (Figure 1B), an all-peptoid in which all the 
amino acid residues are replaced by their corresponding peptoid residues (Figure 1C), and a 
peptidomimetic α
v
β
3
 receptor antagonist recently described by Hood et al. [19] (Figure 1D). 
Stability, in vitro and in vivo α
v
β
3
 binding characteristics are systematically studied.
Figure 1A. Structural formula of the DOTA-conjugated monomeric RGD peptide, DOTA-E-c(RGDfK).
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Figure 1B. Structural formula of the DOTA-conjugated peptoid-peptide hybrid, DOTA-E-c(nRGDfK).
Figure 1C. Structural formula of the DOTA-conjugated all-peptoid, DOTA-E-c(nRGnDnFnK).
Figure 1D. Structural formula of the DOTA-conjugated peptidomimetic.
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Materials and methods
General
Chemicals and resins were obtained from commercial sources and used without further purification 
unless stated otherwise. N,N-diisopropylethylamine (DiPEA) was distilled over ninhydrin and 
KOH. 9-Fluorenylmethoxycarbonyl (Fmoc) amino acids were purchased from MultiSynTech 
(Witten, Germany). Fmoc-D-Phe-OH was purchased from Alexis (Lausen, Switzerland). Arginine 
and lysine were protected by the 2,2,4,6,7-pentamethyldihydro-benzofuran-5-sulfonyl (Pbf) and 
tert-butoxycarbonyl (Boc) groups, respectively. Aspartic acid was protected as a tert-butyl ester 
(OtBu). Synthesis of the peptoid monomers Fmoc-NArg(Boc)
2
-OH, Fmoc-NPhe-OH, Fmoc-
NLys(Boc)-OH, and Fmoc-NAsp(OtBu)-OH was carried out as described previously [20]. Glycine 
was chosen as the C-terminal amino acid in order to avoid racemization during the cyclization 
step. The other amino acids were coupled using standard Fmoc chemistry. ArgoGel-MB-OH 
resin was purchased from Argonaut (Hengoed, United Kingdom). Solvents were purchased from 
Biosolve (Valkenswaard, The Netherlands). Solvents were stored on molecular sieves (Merck, 0.4 
nm), when dry solvents were required. Electrospray ionization (ESI) mass spectrometry was carried 
out using a Shimadzu LCMS QP-8000 single quadrupole bench top mass spectrometer, coupled 
with a QP-8000 data system. Analytical HPLC was performed on a Shimadzu LC-10AT Class-VP 
automated HPLC using an analytical reversed-phase column (Alltech Adsorbosphere C18, 300 Å, 
5 µm, 4.6 mm × 250 mm or Alltech Adsorbosphere C8, 90 Å, 5 µm, 4.6 mm × 250 mm) and a UV 
detector operating at 214 nm and 220 nm. Elution was effected using an appropriate gradient from 
0.1% trifluoroacetic acid (TFA) in H
2
O/CH
3
CN (95/5, v/v) to 0.1% TFA in CH
3
CN/H
2
O (95/5, v/v). 
Preparative HPLC was performed using an Alltech Adsorbosphere C8 (10 µm, 22 mm × 250 mm) 
column with an appropriate gradient from 0.1% TFA in H
2
O/CH
3
CN (95/5, v/v) to 0.1% TFA in 
CH
3
CN/H
2
O (70/30, v/v).
Loading of the ArgoGel-MB-OH resin
The coupling of Fmoc-Gly-OH to ArgoGel-MB-OH was performed as described by Sieber 
[21]. Briefly, 2.94 g ArgoGel-MB-OH and 3.42 g (11.5 mmol) Fmoc-Gly-OH were placed in a 
roundbottom flask and dried in a desiccator overnight. Then, 20 mL dry N,N-dimethylformamide 
(DMF) and 0.93 mL (11.5 mmol) pyridine were added. Subsequently, 1.7 mL (11.9 mmol) 2,6-
Dichloro-benzoyl chloride (DCB) was added. After swirling for 72 h at room temperature, 
the reaction mixture was filtered and the resin was washed three times with DMF, MeOH, 
dichloromethane (DCM), and Et
2
O. The loading of the resin was 0.30 mmol/g.
Synthesis of peptide (1), peptoid-peptide hybrid (2), and all-peptoid (3)
The peptide, the peptoid-peptide hybrid, and the all-peptoid were synthesized using Fmoc-based 
solid-phase peptide chemistry on Fmoc-Gly-MB-ArgoGel resin in an automatic ABI 433A peptide 
synthesizer instrument in which the couplings of amino acid residues 2-5 were carried out using 
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the ABI FastMoc 0.25 mmol protocol with a coupling time of 45 min instead of 20 min [22, 23]. The 
deprotection and coupling reactions were followed by monitoring the dibenzofulvene-piperidine 
adduct at 301 nm [23]. The α-amino Fmoc protecting group was removed using 20% piperidine 
in N-methyl-2-pyrrolidone (NMP). 0.36 M 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU)/1-hydroxybenzotriazole (HOBt) in NMP was used as coupling 
solution. The peptoid-peptide hybrid and the all-peptoid were synthesized analogously, with 
minor modifications: coupling of the amino acids and the peptoid monomers was carried out 
with 1 equivalent O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HATU) and 1 equivalent 1-hydroxy-7-azabenzotriazole (HOAt). After cleavage of the protected 
peptide from the resin with 1% TFA/DCM the protected peptide, peptoid-peptide hybrid 
and all-peptoid were cyclized in DMF (1 mg/mL) using 1 equivalent benzotriazole-1-yl-oxy-
tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP), 1 equivalent HOBt, and 2 
equivalents DiPEA. Subsequent final deprotection of the protecting groups was performed by 
treatment with TFA/triisopropylsilane (TIS)/H
2
O (95/2.5/2.5; 10 mL).
Boc-Glu(OBzl)-NHMe (5)
Boc-Glu(OBzl)-OH (4) (1.69 g, 5.0 mmol) and BOP (2.19 g, 5.0 mmol) were dissolved in 22 mL 
DCM. Subsequently, 1.8 mL (10 mmol) DiPEA was added. After stirring for 1 minute at ambient 
temperature, 10 mL (20 mmol) 2 M methylamine in tetrahydrofuran (THF) was added. After 
stirring for 1.5 h at room temperature, the reaction mixture was concentrated in vacuo to remove 
DCM and excess methylamine and resuspended in EtOAc. The organic layer was washed with 
saturated NaHCO
3
 (2 × 50 mL), 1 N KHSO
4
 (2 × 50 mL), water (1 × 80 mL), and brine (1 × 80 mL). 
The organic layer was dried over MgSO
4
 and concentrated in vacuo to give a white solid which 
was crystallized from EtOAc/hexane to afford Boc-Glu(OBzl)-NHMe (5) (1.06 g, 3.0 mmol) in 
60% yield. The resulting crude product can be used without further purification. R
f
 (chloroform/
methanol/acetic acid 95:20:3) = 0.79.
Boc-Glu-NHMe (6)
Boc-Glu(OBzl)-NHMe (5) (0.98 g, 2.8 mmol) was dissolved in MeOH and hydrogenated (1 atm) 
in the presence of 10% Pd/C (ca. 100 mg). After stirring for 2 h, the reaction mixture was filtered 
through Hyflo and evaporation of the solvent in vacuo yielded Boc-Glu-NHMe (6) as a white 
solid. Crystallization from EtOAc/hexane afforded 0.7 g (2.7 mmol) Boc-Glu-NHMe in 96% yield. 
R
f
 (chloroform/methanol/acetic acid 95:20:3) = 0.55; ESI-MS: m/z = 283.3 (M + Na+); 1H NMR 
(DMSO-d
6
, 300 MHz): 7.76 (d, 1H, NHCH); 6.90 (s, br, 1H, NHCH
3
); 3.85 (m, 1H, CHCH
2
); 2.54 (d, 
3H, NHCH
3
); 2.18 (t, 2H, CH
2
COOH); 1.73 (m, 2H, CHCH
2
); 1.37 (s, 9H, 3 CH
3
).
Boc-Glu-NHMe coupling to c(RGDfK), c(nRGDfK), and c(nRGnDnFnK)
132 mg (0.51 mmol) Boc-Glu-NHMe and 57.4 mg (0.50 mmol) N-hydroxysuccinimide were 
placed in a rondbottom flask. Then, 109 mg (0.53 mmol) 1,3-Dicyclohexylcarbodiimide (DCC) 
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was dissolved in 5 mL DCM and added to Boc-Glu-NHMe and N-hydroxysuccinimide (HOSu). 
After stirring for 2 h at room temperature, the reaction mixture was concentrated in vacuo and 
the residue was titurated in EtOAc. This was filtrated and the filtrate was concentrated in vacuo. 
The residue was redissolved in 5 mL DCM. The unprotected cyclic pentapeptide, cyclic peptoid-
peptide hybrid or cyclic all-peptoid and 131 µL DiPEA (0.75 mmol) were dissolved in 5 mL DMF. 
Subsequently, this mixture was added to the Boc-Glu(OSu)-NHMe ester dissolved in 5 mL DCM.
Synthesis of peptidomimetic
The peptidomimetic, 2-(2-Amino-ethanesulfonylamino)-3-{4-[2-(1,4,5,6-tetrahydro-pyrimidin-
2-ylamino)-ethoxy]-benzoylamino}-propionic acid, was synthesized essentially as described 
by Hood et al. [19], with minor modifications. The required Cbz-taurylsulfonyl chloride was 
synthesized according to Brouwer et al. [24]. For the hydrogenation of 4-[2-(pyrimidin-2-
ylamino)ethyloxy]benzoyl-2-(S)-benzyloxycarbonylaminoethylsulfonylamino-β-alanine (0.27 g) 
was dissolved in 65 mL water. This solution was treated with 10% palladium over carbon (0.13 g) 
and hydrogenated at 45 psi of hydrogen gas for 22 h.
DOTA-conjugation
c(RGDfK)-E(Boc) (7) was deprotected by dissolving the compound in DCM/TFA (1:1). After 
stirring for 2.5 h at room temperature, the reaction mixture was concentrated in vacuo and 
coevaporated with CHCl
3
.
84.8 mg (0.22 mmol) HBTU and 70 µL (0.40 mmol) DiPEA were dissolved in 10 mL dry DMF. 1 
mL of this solution was added to 14 mg (24 µmol) DOTA-tris(tertBu) (9) (Macrocyclics, Dallas, TX, 
USA) and stirred for 5 minutes at room temperature. The c(RGDfK)-E (13.6 mg) was added and the 
mixture was stirred for 4.5 h under nitrogen at room temperature. Then the reaction mixture was 
concentrated in vacuo and the residue was dissolved in 4.75 mL TFA and 250 µL H
2
O for deprotection 
of the Boc-group. This reaction mixture was stirred under nitrogen for 5 h. Subsequently, the reaction 
mixture was concentrated in vacuo and the residue was dissolved in MeCN/H
2
O (1/1) and lyophilized 
to afford a fluffy solid. The conjugation of DOTA-tris(tertBu) to c(nRGDfK)-E, c(nRGnDnFnK)-E, and 
to the peptidomimetic and the subsequent deprotection was performed analogously. The crude 
DOTA-conjugated c(RGDfK)-E, c(nRGDfK)-E, c(nRGnDnFnK)-E, and peptidomimetic were purified 
by preparative RP-HPLC. Analytical data, including mass spectrometry data, are given in Table 1.
Table 1. Analytical data of DOTA-E-c(RGDfK), DOTA-E-c(nRGDfK), DOTA-E-c(nRGnDnFnK), and DOTA-peptidomimetic.
 
compound formula MW (g/mol)
ESI-MS (M+H)+ 
calculated
ESI-MS (M+H)+ 
measured t
r
 (min)
DOTA-E-c(RGDfK) C
49
H
77
N
15
O
16
1132.23 1132.58 1132.65 18.98
DOTA-E-c(nRGDfK) C
49
H
77
N
15
O
16
1132.23 1132.58 1132.65 20.00
DOTA-E-c(nRGnDnFnK) C
49
H
77
N
15
O
16
1132.23 1132.58 1132.75 20.00
DOTA-peptidomimetic C
34
H
54
N
10
O
13
S 842.92 843.47 843.90 19.61
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Radiolabeling of the RGD peptides and RGD peptidomimetics
111In-DOTA-E-c(RGDfK), 111In-DOTA-E-c(nRGDfK), and 111In-DOTA-E-c(nRGnDnFnK) were 
prepared by adding 18.5 MBq 111InCl
3
 (Mallinckrodt, Petten, The Netherlands) to 18.6 µg (16.4 
nmol) DOTA-E-c(RGDfK), DOTA-E-c(nRGDfK) or DOTA-E-c(nRGnDnFnK) dissolved in 300 
µL 0.5 M ammonium acetate buffer, pH 6.0, containing 0.6 mg/mL gentisic acid. The DOTA-
peptidomimetic was radiolabeled with 111InCl
3
 analogously, except that the DOTA-peptidomimetic 
(14 µg, 16.6 nmol) was dissolved in 500 µL instead of 300 µL 0.5 M ammonium acetate buffer pH 
6.0, containing 0.6 mg/mL gentisic acid. The reaction mixtures were degassed under vacuum and 
the mixtures were heated at 100 °C for 15 minutes. The radiochemical purity was determined 
by reversed-phase high-performance liquid chromatography (RP-HPLC) (HP 1100 series, Hewlett 
Packard, Palo Alto, CA, USA) using a C18 column (RX-C18, 4.6 × 250 mm, Zorbax) eluted with 
a gradient mobile phase (8-20% B over 25 min, solvent A = 25 mM ammonium acetate buffer, 
solvent B = acetonitrile) at 1 mL/min. The radioactivity of the eluate was monitored using an in-
line radiodetector (Flo-One Beta series, Radiomatic, Meriden, CT, USA).
In vitro stability
The stability of the 111In-labeled compounds was determined by incubating the compounds in 
90-110 µL human serum for 2 h, 6 h, and 24 h at 37 °C. The stability of the compounds was also 
determined after 4 h of incubation in phosphate-buffered saline (PBS) at 37 °C. Before analysis of 
the serum samples the serum proteins were precipitated by adding an equal volume of MeCN to 
the samples. Samples were centrifuged for 5 minutes at 14000 rpm and 20 µL of supernatant was 
analyzed on RP-HPLC. The PBS samples were analyzed without any sample preparation.
Solid-phase receptor binding assay
The IC
50
 of DOTA-E-c(RGDfK), DOTA-E-c(nRGDfK), DOTA-E-c(nRGnDnFnK), and the DOTA-
peptidomimetic for α
v
β
3
 integrin was determined using a solid-phase competitive binding assay. 
111In-labeled DOTA-E-[c(RGDfK)]
2
 (3 MBq/µg) was prepared as described previously [25] and was 
used as the tracer in this assay.
Microtiter 96-well vinyl assay plates (Corning B.V., Schiphol-Rijk, The Netherlands) were coated 
with 100 µL/well of a solution of purified human integrin α
v
β
3
 (150 ng/mL) in Triton X-100 
Formulation (Chemicon International, Temecula, CA, USA) in coating buffer (25 mM Tris-HCl, 
pH 7.4, 150 mM NaCl, 1 mM CaCl
2
, 0.5 mM MgCl
2
 and 1 mM MnCl
2
) for 17 h at 4 °C. The plate 
was washed twice with binding buffer (0.1% bovine serum albumin (BSA) in coating buffer). The 
wells were blocked for 2 h with 200 µL blocking buffer (1% BSA in coating buffer). The wells were 
washed twice with binding buffer. Then 100 µL binding buffer containing 11.1 kBq of 111In-DOTA-
E-[c(RGDfK)]
2
 and appropiate dilutions of non-labeled DOTA-E-c(RGDfK), DOTA-E-c(nRGDfK), 
DOTA-E-c(nRGnDnFnK), DOTA-peptidomimetic, and DOTA-E-[c(RGDfK)]
2
 in binding buffer 
were incubated in the wells at 37 °C for 1 h. After incubation, the plate was washed three times 
with binding buffer. The wells were cut and radioactivity in each well was counted in a γ-counter 
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(1480 Wizard, Wallac, Turku, Finland). IC
50
 values of the RGD peptides and peptidomimetics were 
calculated by non-linear regression using GraphPad Prism (GraphPad Prism 4.0 Software Package, 
San Diego, CA, USA). Each data point is the average of triplicate wells. K
i
 values were calculated 
from IC
50
 values using the Cheng-Prusoff equation as described by Cheng [26, 27]. The Hill slope 
(K) of DOTA-E-[c(RGDfK)]
2
 concentration-response curve was 0.6.
Biodistribution studies
6-8 Weeks old female nude BALB/c mice were injected subcutaneously (s.c.) in the left flank with 
0.2 mL of a cell suspension of IGROV1 human ovarian carcinoma cells (1×107 cells/mL). Two weeks 
after inoculation of the tumor cells, when the diameter of the tumor was 6-8 mm, mice were 
randomly divided in three groups (4 mice/group).
For biodistribution studies, mice received 370 kBq of each of the 111In-labeled compounds via a tail 
vein. Mice were killed at 2 h postinjection (p.i.). Blood, tumor, and the major organs and tissues 
were collected, weighed, and counted in a γ-counter. The percentage injected dose per gram (%ID/
g) was determined for each sample.
The receptor-mediated localization of the 111In-labeled compounds was investigated by 
determining the biodistribution of the 111In-labeled compounds in the presence of an excess 
unlabeled compound (n=2).
Results
Radiolabeling
RP-HPLC analysis indicated that the radiochemical purity of 111In-DOTA-E-c(RGDfK), 111In-
DOTA-E-c(nRGDfK), 111In-DOTA-E-c(nRGnDnFnK), and 111In-DOTA-peptidomimetic used in the 
experiments always exceeded 95%, when radiolabeled at a specific activity of 1 MBq/nmol. The 
elution profile of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-c(nRGDfK), 111In-DOTA-E-c(nRGnDnFnK), 
and 111In-DOTA-peptidomimetic showed a single peak for each of the four compounds with a 
retention time of 14 min for 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-c(nRGDfK), and 111In-DOTA-E-
c(nRGnDnFnK). The retention time of the 111In-DOTA-peptidomimetic was 9 min.
In vitro stability
111In-DOTA-E-c(RGDfK), 111In-DOTA-E-c(nRGDfK), and 111In-DOTA-peptidomimetic were stable 
for at least 4 h in PBS. There was no evidence of degradation of 111In-DOTA-E-c(RGDfK) and 111In-
DOTA-E-c(nRGDfK) after incubation for 6 h in human serum. The 111In-DOTA-peptidomimetic 
was less stable. After incubation in human serum for 6 h, only 50% of the activity was still 
associated with the labeled compound.
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Solid-phase receptor binding assay
The results of a competitive displacement study to compare the affinity of DOTA-E-c(RGDfK), 
DOTA-E-c(nRGDfK), DOTA-E-c(nRGnDnFnK), and the DOTA-peptidomimetic for the α
v
β
3
 
integrin are summarized in Figure 2. The IC
50
 values were 236 nM for DOTA-E-c(RGDfK), 9.25 
mM for DOTA-E-c(nRGDfK), and 219 nM for the DOTA-peptidomimetic (Figure 2). The IC
50
 value 
of DOTA-E-c(nRGnDnFnK) was > 10 mM. Calculated K
i
 values using Cheng-Prusoff equation 
were 8.92 nM for DOTA-E-c(RGDfK), 403 nM for DOTA-E-c(nRGDfK), and 8.62 nM for DOTA-
peptidomimetic.
Figure 2. Competition of specific binding of 111In-DOTA-E-[c(RGDfK)]
2
 with DOTA-peptidomimetic,  
DOTA-E-c(nRGDfK), and DOTA-E-c(RGDfK).
Biodistribution studies
The results of the study of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-c(nRGDfK), and 111In-DOTA-
peptidomimetic in athymic mice with s.c. IGROV1 tumors are summarized in Figure 3. The 
111In-labeled peptide, the peptoid-peptide hybrid, the all-peptoid, and the peptidomimetic all 
cleared rapidly from the blood (0.02 ± 0.003 %ID/g, 0.02 ± 0.0003 %ID/g, 0.01 ± 0.002 %ID/g, and 
0.07 ± 0.008 %ID/g, 2 h p.i.). The uptake in the tumor of the peptide (1.73 ± 0.37 %ID/g) and the 
peptidomimetic (2.04 ± 0.30 %ID/g) were higher than that of the peptoid-peptide hybrid (0.45 ± 
0.07 %ID/g). The all-peptoid had the lowest uptake in the tumor (0.11 ± 0.04 %ID/g). As the blood 
level of the peptide was lower than the blood level of the peptidomimetic 2 h p.i., the tumor-to-
blood ratio of the peptide was higher (74.0 ± 16.5) than that of the peptidomimetic (29.7 ± 3.23). 
The tumor-to-blood ratio of the peptoid-peptide hybrid was 24.5 ± 3.7. Coinjection of an excess of 
unlabeled compound resulted in a significant decrease of radioactivity in the tumor, indicating that 
the uptake of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-c(nRGDfK), and 111In-DOTA-peptidomimetic 
in the tumor was α
v
β
3
-mediated. Uptake in normal organs such as spleen, liver, intestine, and colon 
was also reduced in the presence of an excess cold DOTA-E-c(RGDfK), DOTA-E-c(nRGDfK), and 
DOTA-peptidomimetic, indicating that part of the uptake in these tissues was also α
v
β
3
-mediated.
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Uptake of 111In-DOTA-E-c(nRGnDnFnK) in the tumor was not α
v
β
3
-mediated, since coinjection 
of an excess of unlabeled DOTA-E-c(nRGnDnFnK) showed no significant decrease of the activity 
concentration in the tumor (0.12 ±0.04 %ID/g).
Figure 3A. Biodistribution of 111In-DOTA-E-c(RGDfK) in the absence and presence of an excess of unlabeled DOTA-E-
c(RGDfK) at 2 h p.i. in athymic mice with s.c. IGROV1 tumors.
Figure 3B. Biodistribution of 111In-DOTA-E-c(nRGDfK) in the absence and presence of an excess unlabeled DOTA-E-
c(nRGDfK) at 2 h p.i. in athymic mice with s.c. IGROV1 tumors.
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Figure 3C. Biodistribution of 111In-DOTA-peptidomimetic in the absence and presence of an excess unlabeled DOTA-
peptidomimetic at 2 h p.i. in athymic mice with s.c. IGROV1 tumors.
Discussion
Here, we describe the synthesis of four α
v
β
3
 integrin binding compounds (Scheme 1 and 2). The 
radiolabeling, the stability and the in vitro and in vivo tumor targeting characteristics of these 
compounds were determined.
The binding affinity for α
v
β
3
 of the four compounds was determined in a solid-phase competitive 
binding assay. The DOTA-peptidomimetic and DOTA-E-c(RGDfK) had the highest affinity. 
The IC
50
 of c(nRGDfK)-E was more than 20 times higher, indicating that the substitution of the 
arginine residue by its peptoid residue analog markedly affected the affinity for the α
v
β
3
 integrin. 
Apparently, the altered position of the amino acid side chain greatly affected α
v
β
3
 binding. This 
could be due to the unfavorable location of the side chain of the peptoid, the increased flexibility 
of the peptoid-peptide hybrid compared to the peptide, or to the fact that a potential hydrogen 
bond cannot be formed since there is no hydrogen atom present on the backbone nitrogen atom 
[16]. The last two factors could also explain the fact that the all-peptoid has no affinity for α
v
β
3
 
as determined in vitro. Recently, Xiong et al. described that each residue of the Arg-Gly-Asp 
sequence participates extensively in the interaction with the α
v
β
3
 integrin [28]. This could explain 
that minor modifications in the RGD sequence, such as in the peptoid-peptide hybrid, reduce the 
affinity for the α
v
β
3
 integrin. The IC
50
 values of the compounds were relatively high compared to 
other α
v
β
3
 binding ligands. However, K
i
 values calculated from these IC
50
 values are in the single 
digit nanomolar range for DOTA-E-c(RGDfK) and DOTA-peptidomimetic, indicating that these 
compounds have a relatively high affinity for the α
v
β
3
 integrin.
Stability tests revealed good stability of 111In-DOTA-E-c(RGDfK) and 111In-DOTA-E-(nRGDfK) 
after incubation for 6 h in human serum. In serum, 111In-DOTA-peptidomimetic showed some 
degradation after 6 h.
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The tumor targeting potential of the radiolabeled cyclic RGD peptide, the peptoid-peptide hybrid 
analog, and the peptidomimetic integrin α
v
β
3
 receptor antagonist were evaluated in athymic mice 
with s.c. IGROV1 tumors. The IGROV1 tumor consistently expresses α
v
β
3
 at a relatively high level. 
In this model, the cyclic RGD peptide and the peptidomimetic showed the highest uptake in the 
tumor, 1.73 ± 0.4 %ID/g and 2.04 ± 0.3 %ID/g, respectively. Apparently, the in vitro minor instability 
of DOTA-peptidomimetic does not hamper in vivo tumor targeting. The uptake of the peptoid-
peptide hybrid was significantly lower: 0.45 ± 0.07 %ID/g. This is in line with its lower affinity. The 
all-peptoid had no detectable affinity for α
v
β
3
 (IC
50
 > 10 mM) and this compound did not show 
specific tumor uptake in this model.
In the presence of an excess of unlabeled compound, the specificity of the tumor targeting of 
the peptide and the peptidomimetic could be demonstrated. Even for the peptoid-peptide hybrid 
the uptake in the presence of an excess cold agent was significantly reduced, indicating that this 
compound also showed some specific localization in the tumor. Remarkably, non-tumor tissues 
such as liver, spleen, and colon also showed specific uptake of the three compounds, suggesting 
α
v
β
3
 expression in these tissues. Indeed, α
v
β
3
 expression on the vasculature of these tissues in 
humans was described by Max et al. [29]. Presumably, the murine tissues such as lung, liver, spleen, 
and colon also express α
v
β
3
 on their vasculature, causing specific uptake in these tissues of the 
radiolabeled compounds.
The four compounds cleared rapidly from the blood via the kidneys. 111In-DOTA-
peptidomimetic cleared slower from the blood than 111In-DOTA-E-c(RGDfK) and 111In-DOTA-
c(nRGDfK)-E, resulting in lower tumor-to-blood ratios for 111In-DOTA-peptidomimetic. Recently, 
Chen et al. studied the 64Cu-labeled RGD peptide 64Cu-DOTA-c(RGDyK) in a MDA-MB-435 breast 
cancer xenograft model. Although tested in another model, our RGD peptide showed a similar 
biodistribution compared to their compound [30]. In contrast to 111In-DOTA-E-c(RGDfK), 64Cu-
DOTA-c(RGDyK) showed persistent activity in liver and kidney. The uptake in these organs could 
be reduced by PEGylating the compound [31, 32].
In conclusion, in vivo α
v
β
3
 targeting of the non-amino acid containing peptidomimetic was as 
high as that of the native DOTA-conjugated cyclic RGD peptide. Modification of the cyclic RGD 
peptide to a peptoid-peptide hybrid resulted in loss of affinity for α
v
β
3
 and thus lower tumor 
uptake. The all-peptoid analog has no affinity for α
v
β
3
 and no tumor targeting.
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Scheme 1. Synthesis of the peptide, peptoid-peptide hybrid, and the all-peptoid.
_____  Chapter 2  _____________________________________________________________________________
52
_____________________  Synthesis and biological evaluation of potent α
v
β
3
 integrin receptor antagonists _____ 
53
Scheme 2. Synthesis and coupling of Boc-Glu-NHMe to the peptide, peptoid-peptide hybrid, and the all-peptoid and 
subsequent DOTA-conjugation.
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Abstract
The integrin α
v
β
3 
is expressed on sprouting endothelial cells and on various tumor cell types. Due 
to the restricted expression of α
v
β
3 
in tumors, α
v
β
3 
is considered a suitable receptor for tumor 
targeting. In this study, the α
v
β
3
 binding characteristics of an 111In-labeled monomeric, dimeric, 
and tetrameric RGD analog were compared.
Methods: A monomeric (E-c(RGDfK)), dimeric (E-[c(RGDfK)]
2
), and tetrameric (E{E[c(RGDfK)]
2
}
2
) 
RGD peptide were synthesized, conjugated with DOTA, and radiolabeled with 111In. In vitro α
v
β
3
 
binding characteristics were determined in a competitive binding assay. In vivo α
v
β
3
 targeting 
characteristics of the compounds were assessed in mice with SK-RC-52 xenografts.
Results: The IC
50
 values for DOTA-E-c(RGDfK), DOTA-E-[c(RGDfK)]
2
, and DOTA-E{E[c(RGDfK)]
2
}
2 
were 120 nM, 69.9 nM, and 19.6 nM, respectively. At all time points, the tumor uptake of the dimer 
was significantly higher as compared to that of the monomer. Tumor uptake of the tetramer (7.40 
± 1.12 %ID/g) was significantly higher than that of the monomer (2.30 ± 0.34 %ID/g), P<0.001 and 
the dimer (5.17 ± 1.22 %ID/g), P<0.05 at 8 h p.i.. At 24 h p.i. the tumor uptake was significantly 
higher for the tetramer (6.82 ± 1.41 %ID/g), compared to that of the dimer (4.22 ± 0.96 %ID/g), 
P<0.01 and the monomer (1.90 ± 0.29 %ID/g).
Conclusions: Multimerization of c(RGDfK) resulted in enhanced affinity for α
v
β
3
 as determined 
in vitro. Tumor uptake of a tetrameric RGD peptide was significantly higher compared to that of 
the monomeric and dimeric analogs, presumably due to the enhanced statistical likelihood for 
rebinding to α
v
β
3
.
Introduction
The α
v
β
3
 integrin is a transmembrane protein consisting of two non-covalently bound subunits, 
α and β. Integrin α
v
β
3
 is preferentially expressed on proliferating endothelial cells [1], whereas it is 
absent on quiescent endothelial cells. For growth beyond the size of 1-2 mm in diameter, tumors 
require the formation of new blood vessels. Consequently, α
v
β
3
 expression on tumor vasculature is 
considered as a marker of tumor-induced angiogenesis [2-4]. In addition, α
v
β
3
 is expressed on the 
cell membrane of various tumor cell types, such as ovarian cancer, neuroblastoma, breast cancer, 
melanoma, a.o.. Due to this restricted expression of α
v
β
3
 in tumors, α
v
β
3
 is considered a suitable 
target for tumor targeting [5]. This integrin can bind to the arginine-glycine-aspartic acid (RGD) 
amino acid sequence present in extracellular matrix proteins such as vitronectin, fibrinogen, and 
laminin [6]. Based on the RGD tripeptide sequence a series of small peptides have been designed 
to antagonize the function of the α
v
β
3
 integrin [7]. Especially the cyclic peptide derivatives have a 
relatively high affinity for the α
v
β
3
 integrin. A series of RGD sequence containing peptides has been 
tested for their ability to bind the α
v
β
3
 integrin. It was found that the cyclic derivative cyclic(Arg-
Gly-Asp-D-Phe-Val) was a 100-fold better inhibitor of cell adhesion to vitronectin than the linear 
variant, having an IC
50
 value in the nanomolar range [8, 9].
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In previous studies we have shown that radiolabeled c(RGDfK)-peptides specifically accumulated 
in α
v
β
3
-positive ovarian cancer xenografts in athymic mice [10]. The aim of this study was to 
develop modified ligands for improved α
v
β
3
 integrin targeting by preparing multimers of cyclic 
RGD peptides. A multimeric RGD peptide could theoretically bind multivalently and thus more 
avidly to the target cell. However, the distance between the RGD units of the multivalent RGD 
peptides is too short to allow simultaneous binding to multiple α
v
β
3
 integrins on the cell surface. 
Therefore, in this chapter we avoid to use the term avidity and only use affinity.
Multivalent interactions are frequently used in nature to increase the affinity of weak ligand-
receptor interactions [11, 12]. For example, the attachment of an influenza virus to its target 
cell occurs through multiple simultaneous interactions between hemagglutinin (HA) and sialic 
acid (SA) [12]. Multivalent structures for the design of drugs and research agents have become 
a new focus of investigation. Several research groups, including ours, have applied multivalent 
compounds to enhance the interaction between the ligand and the target cell [13]. Goel et al. 
radiolabeled divalent and tetravalent scFv’s of monoclonal antibody (MAb CC49 with 99mTc and 
analyzed the imaging potential of these novel radioimmunoconjugates. Biodistribution studies 
demonstrated that 99mTc-[sc(Fv)
2
]
2
 had approximately 3-fold higher tumor localization than 
99mTc-sv(Fv)
2
 [14]. Recently, a new multivalent synthetic inhibitor of epidemic keratoconjunctivitis-
causing adenovirus was evaluated by Johansson et al. [11]. Their results clearly indicated that 
the inhibition is significantly increased with higher orders of valency. Similarly, Kok et al. and 
Maheshwari et al. showed increased affinity of RGD ligands with the target cell due to multivalent 
interactions [15, 16].
Here we describe the synthesis of a monomeric, E-c(RGDfK), dimeric, E-[c(RGDfK)]
2
, and 
tetrameric RGD peptide, E{E[c(RGDfK)]
2
}
2
. The RGD peptides were conjugated with 1,4,7,10-
tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA) and radiolabeled with 111In. 
Subsequently, the in vitro affinity and the in vivo tumor targeting characteristics of the peptides to 
α
v
β
3
 expressing tumors were determined.
Materials and methods
Synthesis of DOTA-conjugated RGD peptides
The monomeric RGD peptide was synthesized using Fmoc-based solid-phase peptide synthesis as 
described previously [17]. The structural formula of DOTA-E-c(RGDfK) is shown in Figure 1a.
The synthesis of the dimeric cyclic RGD peptide E-[c(RGDfK)]
2
 conjugated with DOTA was 
described previously [18]. The structural formula of DOTA-E-[c(RGDfK)]
2
 is shown in Figure 1b.
The synthesis of the tetrameric cyclic RGD peptide E{E[c(RGDfK)]
2
}
2
 conjugated with DOTA was 
described previously [19]. The structural formula of DOTA-E{E[c(RGDfK)]
2
}
2
 is shown in Figure 
1c.
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Figure 1a. Structural formula of the DOTA-conjugated monomeric RGD peptide, DOTA-E-c(RGDfK).
Figure 1b. Structural formula of the DOTA-conjugated dimeric RGD peptide, DOTA-E-[c(RGDfK)]
2
.
Figure 1c. Structural formula of the DOTA-conjugated tetrameric RGD peptide, DOTA-E{E[c(RGDfK)]
2
}
2
.
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Radiolabeling of the RGD peptides
111In-DOTA-E-c(RGDfK) was prepared by adding 14 MBq 111InCl
3
 (Mallinckrodt, Petten, The 
Netherlands) to 15 µg (13.3 nmol) DOTA-E-c(RGDfK) dissolved in 300 µL 0.5 M ammonium 
acetate buffer, pH 6.0, containing 0.6 mg/mL gentisic acid. DOTA-E-[c(RGDfK)]
2
 and DOTA-
E{E[c(RGDfK)]
2
}
2
 were radiolabeled with 111InCl
3
 analogously with minor modifications. DOTA-
E-[c(RGDfK)]
2
 (28 µg, 16.4 nmol) and DOTA-E{E[c(RGDfK)]
2
}
2
 (15 µg, 4.79 nmol) were dissolved 
in 500 µL 0.5 M ammonium acetate buffer pH 6.0, containing 0.6 mg/mL gentisic acid. DOTA-E-
[c(RGDfK)]
2
 was radiolabeled with 17 MBq 111InCl
3
 and DOTA-E{E[c(RGDfK)]
2
}
2
 was radiolabeled 
with 13 MBq 111InCl
3
. The reaction mixtures were degassed and subsequently the mixtures were 
heated at 100 ºC for 15 minutes. 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 was further purified on a C-18 
SepPak cartridge (Waters, Milford, MA). After applying the sample on the methanol-activated 
cartridge, the cartridge was washed with 5 mL 25 mM ammonium acetate and eluted with 25% 
acetonitrile in 25 mM ammonium acetate. The radiochemical purity was determined by reversed-
phase high-performance liquid chromatography (RP-HPLC) (HP 1100 series, Hewlett Packard, Palo 
Alto, CA, USA) using a C18 column (RX-C18, 4.6 mm × 250 mm, Zorbax) eluted with a gradient 
mobile phase (8-20% B over 25 min or 8-100% B over 30 min, solvent A = 25 mM ammonium 
acetate buffer, solvent B = acetonitrile) at 1 mL/min. The radioactivity of the eluate was monitored 
using an in-line radiodetector (Flo-One Beta series, Radiomatic, Meriden, CT, USA).
Solid-phase αvβ3 binding assay
The affinity of DOTA-E-c(RGDfK), DOTA-E-[c(RGDfK)]
2
, and DOTA-E{E[c(RGDfK)]
2
}
2
 for α
v
β
3
 
was determined using a solid-phase competitive binding assay. 111In-labeled DOTA-E-[c(RGDfK)]
2
 
(3 MBq/µg) was prepared as described above and was used as the tracer in this assay. Microtiter 
96-well vinyl assay plates (Corning B.V., Schiphol-Rijk, The Netherlands) were coated with 100 
µL/well of a solution of purified human integrin α
v
β
3
 (150 ng/mL) in Triton X-100 Formulation 
(Chemicon International, Temecula, CA, USA) in coating buffer (25 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1 mM CaCl
2
, 0.5 mM MgCl
2
 and 1 mM MnCl
2
) for 17 h at 4 ºC. The plates were washed twice 
with binding buffer (0.1% bovine serum albumin (BSA) in coating buffer). The wells were blocked 
for 2 h with 200 µL blocking buffer (1% BSA in coating buffer). The plates were washed twice 
with binding buffer. Then 100 µL binding buffer containing 11.1 kBq of 111In-DOTA-E-[c(RGDfK)]
2
 
and appropiate dilutions of non-labeled DOTA-E-c(RGDfK), DOTA-E-[c(RGDfK)]
2
, and DOTA-
E{E[c(RGDfK)]
2
}
2
 in binding buffer were incubated in the wells at 37 ºC for 1 h. After incubation, 
the plates were washed three times with binding buffer. The wells were cut out and radioactivity 
in each well was determined in a γ-counter (1480 Wizard, Wallac, Turku, Finland). IC
50
 values of the 
RGD peptides were calculated by non-linear regression using GraphPad Prism (GraphPad Prism 4.0 
Software, San Diego, CA, USA). Each data point is the average of three determinations.
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Biodistribution studies
In the right flank of 6-8 weeks old female nude BALB/c mice, 0.2 mL of a cell suspension of 15 × 
106 cells/mL SK-RC-52 cells was injected subcutaneously (s.c.). Two weeks after inoculation of the 
tumor cells, mice were randomly divided into three groups (15 mice/group).
Mice received equivalent amounts of RGD binding units, resulting in similar amounts of mass 
(0.5 µg/mouse) 111In-DOTA-E-c(RGDfK) (0.52 MBq), 111In-DOTA-E-[c(RGDfK)]
2
 (0.43 MBq), or 
111In-DOTA-E{E[c(RGDfK)]
2
}
2
 (0.34 MBq) via a tail vein. Mice were killed by CO
2
 asphyxiation 2, 8, 
and 24 h postinjection (p.i.) (5 mice/group). Blood, tumor, and the major organs and tissues were 
collected, weighed, and counted in a γ-counter. The percentage injected dose per gram (%ID/g) 
was determined for each sample.
Statistical analysis
All mean values are given ± standard deviation (S.D.). Statistical analysis was performed using the 
One-way Analysis of Variance. Bonferroni corrections for multiple comparisons were applied. The 
level of significance was set at P<0.05.
Results
Radiolabeling
RP-HPLC analysis indicated that the radiochemical purity of 111In-DOTA-E-c(RGDfK), 111In-DOTA-
E-[c(RGDfK)]
2
, and 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 preparations used in these experiments was at 
least 93%. The elution profile of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]
2
, and 111In-
DOTA-E{E[c(RGDfK)]
2
}
2
 showed a single peak for each of the three compounds with an elution 
time of 14 min and 26 min for 111In-DOTA-E-c(RGDfK) and 111In-DOTA-E-[c(RGDfK)]
2
, respectively. 
The retention time of 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 was 15 min. Note that different gradients were 
used for elutions.
Solid-phase αvβ3 binding assay
The affinity of DOTA-E-c(RGDfK), DOTA-E-[c(RGDfK)]
2
, and DOTA-E{E[c(RGDfK)]
2
}
2
 for the 
α
v
β
3
 integrin was determined in a competitive binding assay. The results of these assays are 
summarized in Figure 2. Binding of 111In-labeled dimeric peptide, 111In-DOTA-E-[c(RGDfK)]
2
, to 
α
v
β
3
 was competed by DOTA-E-c(RGDfK), DOTA-E-[c(RGDfK)]
2
, and DOTA-E{E[c(RGDfK)]
2
}
2 
in 
a concentration dependent manner. The IC
50
 values were 120 nM for DOTA-E-c(RGDfK), 69.9 nM 
for DOTA-E-[c(RGDfK)]
2
, and 19.6 nM for DOTA-E{E[c(RGDfK)]
2
}
2
.
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Figure 2. Competition of specific binding of 111In-DOTA-E-[c(RGDfK)]
2
 with DOTA-E-c(RGDfK), DOTA-E-[c(RGDfK)]
2
, 
and DOTA-E{E[c(RGDfK)]
2
}
2
.
Biodistribution studies
The results of the biodistribution studies of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]
2
, 
and 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 in athymic mice with s.c. SK-RC-52 tumors are summarized in 
Table 1, Figure 3a, and 3b.
Table 1.  Biodistribution data of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]
2
, and 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 in 
the presence and absence of an excess of unlabeled DOTA-E-[c(RGDfK)]
2
 in athymic mice with s.c. SK-RC-52 tumors 2 h 
after injection. The organ uptake is expressed as %ID/g.
Monomer
Monomer
+ excess cold Dimer
Dimer
+ excess cold Tetramer
Tetramer
+ excess cold
Blood 0.04 ± 0.01 0.01 ± 0.01 0.10 ± 0.02 0.02 ± 0.01 0.09 ± 0.01 0.03 ± 0.01
Muscle 0.19 ± 0.02 0.17 ± 0.17 0.37 ± 0.06 0.03 ± 0.00 0.49 ± 0.06 0.07 ± 0.02
Tumor 2.70 ± 0.29 0.39 ± 0.05 5.61 ± 0.85 0.47 ± 0.08 7.32 ± 2.45 0.84 ± 0.12
Lung 0.38 ± 0.05 0.08 ± 0.01 1.12 ± 0.18 0.13 ± 0.01 1.37 ± 0.36 0.20 ± 0.05
Spleen 1.43 ± 0.10 0.16 ± 0.01 2.40 ± 0.38 0.22 ± 0.02 2.53 ± 0.31 0.28 ± 0.03
Kidney 1.85 ± 0.15 1.38 ± 0.07 3.56 ± 0.28 1.90 ± 0.33 6.15 ± 0.41 5.30 ± 0.53
Liver 1.32 ± 0.05 0.18 ± 0.01 2.71 ± 0.21 0.24 ± 0.03 2.41 ± 0.49 0.28 ± 0.03
Intestine 3.18 ± 0.68 0.21 ± 0.01 6.65 ± 1.11 0.20 ± 0.04 7.30 ± 0.73 0.49 ± 0.10
Colon 1.71 ± 0.11 0.18 ± 0.02 3.77 ± 0.79 0.16 ± 0.01 3.94 ± 0.54 0.67 ± 0.11
111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]
2
, and 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 all cleared rapidly 
from the blood. At 8 h p.i. tumor uptake of the tetramer (7.40 ± 1.12 %ID/g) was significantly 
higher compared to the monomer (2.30 ± 0.34 %ID/g), P<0.001 and the dimer (5.17 ± 1.22 %ID/g), 
P<0.05. Furthermore, uptake of the dimer in the tumor was significantly higher compared to the 
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monomer, P<0.01 (Figure 3a). At 24 h p.i. uptake in the tumor was significantly higher for the 
tetramer (6.82 ± 1.41 %ID/g), compared to the dimer (4.22 ± 0.96 %ID/g), P<0.01 and the monomer 
(1.90 ± 0.29 %ID/g), P<0.001 (Figure 3b). Coinjection of an excess unlabeled DOTA-E-[c(RGDfK)]
2
 
(50 µg) along with 0.5 µg of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]
2
 or 111In-DOTA-
E{E[c(RGDfK)]
2
}
2
 resulted in a significant decrease of radioactivity concentration in the tumor, 
indicating that uptake of the major fraction of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]
2
, 
and 111In-DOTA-E{E[c(RGDfK)]
2
}
2 
in the tumor was α
v
β
3
-mediated. Uptake in non-target organs 
like lung, spleen, and intestine was also reduced in the presence of an excess of unlabeled RGD 
peptide, indicating that the uptake in these tissues was also at least partly α
v
β
3
-mediated.
Figure 3a. Biodistribution of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]
2
, and 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 at 8 
h p.i. in athymic mice with s.c. SK-RC-52 tumors (5 mice/group).
Figure 3b. Biodistribution of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]
2
, and 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 at 24 
h p.i. in athymic mice with s.c. SK-RC-52 tumors (5 mice/group).
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Discussion
In this study, the potential advantage of using multimeric RGD peptides for targeting of the α
v
β
3
 
integrin receptor was investigated. The binding affinity of DOTA-E{E[c(RGDfK)]
2
}
2
 (IC
50
 = 19.6 nM), 
as determined in a solid-phase competitive binding assay, was about 4 times higher compared to 
DOTA-E-[c(RGDfK)]
2
 (IC
50
 = 69.9 nM) and about six times higher compared to DOTA-E-c(RGDfK) 
(IC
50
 = 120 nM). Enhanced affinity of α
v
β
3
 expressing cells for multiple RGD sequences on a protein 
backbone as compared to the monomeric RGD peptides was demonstrated by Kok et al. [15]. 
They postulated that the enhanced affinity was due to cooperative binding of multiple RGD units. 
Recently, Thumshirn et al. [20] synthesized multimeric RGD peptides by oxime ligation. These 
multimeric RGD peptides showed retained affinity for the α
v
β
3
 integrin. Their tetrameric RGD 
compound with a Hegas spacer showed enhanced affinity as compared to the monomeric and 
the dimeric analog. However, the tetrameric RGD compound with an aminohexanoic acid spacer 
showed a lower affinity than the dimeric analog [20], indicating clearly the importance of the 
proper choice of the spacer unit.
In athymic mice with s.c. SK-RC-52 tumors, all three RGD peptides of this study showed 
specific uptake in the tumor: in the presence of an excess of unlabeled DOTA-E-[c(RGDfK)]
2
, 
the specificity of the tumor targeting of the monomeric, dimeric, and tetrameric RGD peptide 
was clearly demonstrated. The tumor uptake of 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 beyond 2 h p.i. was 
significantly higher compared to that of 111In-DOTA-E-[c(RGDfK)]
2
. Similarly, the tumor uptake of 
111In-DOTA-E-[c(RGDfK)]
2
 was significantly higher compared to 111In-DOTA-E-c(RGDfK) at all time 
points (Figure 4). 
Figure 4. Tumor uptake of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]
2
, and 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 at 2, 8, 
and 24 h after injection in athymic mice with s.c. SK-RC-52 tumors. Results are reflected as mean %ID/g ± SD. Values were 
analyzed using One-way Analysis of Variance, * = P<0.05, ** = P<0.01, # = P<0.05, ## = P<0.01. P-values refer to differences in 
tumor uptake between 111In-DOTA-E-c(RGDfK) and 111In-DOTA-E-[c(RGDfK)]
2
 or differences in tumor uptake between 
111In-DOTA-E-[c(RGDfK)]
2
 and 111In-DOTA-E{E[c(RGDfK)]
2
}
2
.
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Thus, the higher the binding affinity for α
v
β
3
, the higher the accumulation of the compound in 
α
v
β
3
 expressing tumors. It appears that the enhanced uptake in the tumor of the tetrameric RGD 
peptide is mainly determined by early uptake in the tumor, while retention in the tumor at later 
time points of the monomer, dimer, and tetramer was similar.
Recently, Wu and coworkers tested 64Cu-DOTA-E{E[c(RGDfK)]
2
}
2
 for PET imaging of α
v
β
3
 
expression in athymic nude mice with s.c. U87MG glioma xenografts [19]. 64Cu-DOTA-
E{E[c(RGDfK)]
2
}
2
 accumulated rapidly and efficiently in the tumor (9.93 ± 1.05 %ID/g at 30 min 
p.i.). At 2 h p.i. the uptake of this 64Cu-labeled compound in the tumor was 7.61 ± 0.68 %ID/g, 
slowly decreasing to 4.56 ± 0.51 %ID/g at 24 h p.i.. Although our compound was labeled with 
another radionuclide and tested in another animal model, the uptake in the tumor during 24 h 
after injection was very similar. At 2 h p.i. the uptake in the tumor of 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 
was 7.32 ± 2.45 %ID/g and decreased to 6.82 ± 1.41 %ID/g at 24 h p.i..
One may argue that the enhanced tumor uptake of 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 might be due to 
the higher molecular weight of the tetramer resulting in longer blood circulation time. However, not 
only the uptake in the tumor, but also the tumor-to-blood ratio of 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 (402 
± 96, 24 h p.i.) was significantly higher compared to that of 111In-DOTA-E-[c(RGDfK)]
2
 (287 ± 30) and 
111In-DOTA-E-c(RGDfK) (223 ± 39) (P<0.05 and P<0.01, respectively; Figure 5).
Figure 5. Tumor-to-blood ratios of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]
2
, and 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 at 
2, 8, and 24 h after injection in athymic mice with s.c. SK-RC-52 tumors. Each bar represents the mean values ± SD. Values 
were analyzed using One-way Analysis of Variance, * = P<0.05.
While the potential benefits of multivalency of targeting vehicles are universally accepted, the 
cause of the enhanced affinity is not yet clear [21]. Multivalent compounds could have enhanced 
affinity due to subsite binding, statistical rebinding, or due to receptor clustering [12, 22]. Subsite 
binding refers to binding of a ligand to sites other than the binding site. It is not likely that this 
mechanism is responsible for the enhanced uptake of RGD multimers in α
v
β
3
 expressing tumors, 
because subsites have not been identified for these peptides.
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Cells can form a cluster of many monovalent receptors on a small area of the cell surface [22] and 
multivalent ligands that can span the required distance between binding sites could then bind 
multiple receptors simultaneously. However, it is unlikely that the multivalent RGD peptides used 
in this study could bind multiple α
v
β
3
 integrins simultaneously, because the distance between the 
RGD units is very short. Therefore, statistical rebinding might be the most likely explanation for 
the enhanced affinity of the multimeric RGD peptides. The receptor binding of one RGD unit will 
significantly enhance the local concentration of the other RGD unit in the vicinity of the receptor. 
This could lead to a higher “on rate” of receptor binding and/or a lower “off rate” of the RGD 
multimer [19].
The three RGD peptides showed a remarkable difference in uptake in the kidneys. The uptake 
of 111In-DOTA-E{E[c(RGDfK)]
2
}
2
 is at all time points significantly higher compared to that of 111In-
DOTA-E-[c(RGDfK)]
2
 and 111In-DOTA-E-c(RGDfK). Uptake in the kidney was not α
v
β
3
-mediated, 
thus the enhanced α
v
β
3
 affinity can not explain the enhanced kidney uptake. Most likely, the 
difference in charge between the three peptides could cause the difference in renal uptake. It 
has been shown that positively charged peptides are more efficiently reabsorbed by the proximal 
renal tubular cell than neutral peptides [23]. Due to the presence of more guanidine groups, 
the tetrameric RGD peptide is more positively charged than the dimeric and monomeric RGD 
peptide.
In conclusion, the present study shows that multimeric RGD peptides have enhanced affinity 
for the α
v
β
3
 integrin, most likely due to statistical rebinding of these RGD peptides. The tetrameric 
RGD peptide demonstrated improved tumor targeting compared to the dimeric RGD peptide. 
Analogously, the dimeric RGD peptide exhibits improved tumor targeting compared to the 
monomeric RGD peptide. The tetrameric RGD peptide is the favorable ligand for α
v
β
3
 targeting 
in vivo. The uptake in the kidneys and intestines of this compound is relatively high and could 
hamper imaging of tumors in the abdomen.
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Abstract
This chapter describes the design and synthesis of a series of α
v
β
3
 integrin-directed monomeric, 
dimeric and tetrameric cyclo[Arg-Gly-Asp-D-Phe-Lys] dendrimers using “click chemistry”. It was 
found that the unprotected N-ε-azido derivative of cyclo[Arg-Gly-Asp-D-Phe-Lys] underwent a 
highly chemoselective conjugation to amino acid-based dendrimers bearing terminal alkynes using 
a microwave-assisted Cu(I)-catalyzed 1,3-dipolar cycloaddition. The α
v
β
3
 binding characteristics 
of the dendrimers were determined in vitro and their in vivo α
v
β
3
 targeting properties were 
assessed in nude mice with subcutaneously growing human SK-RC-52 tumors. The multivalent 
RGD dendrimers were found to have enhanced affinity toward the α
v
β
3
 integrin receptor as 
compared to the monomeric derivative as determined in an in vitro binding assay. In case of the 
DOTA-conjugated 111In-labeled RGD dendrimers, it was found that the radiolabeled multimeric 
dendrimers showed specifically enhanced uptake in α
v
β
3
 integrin expressing tumors in vivo. These 
studies showed that the tetrameric RGD dendrimer had better tumor targeting properties than its 
dimeric and monomeric congeners.
Introduction
Integrins are a class of heterodimeric transmembrane proteins [1] which play an important role 
in cell-signaling, cell-cell adhesion, apoptosis and cell-matrix interactions [2]. Integrin α
v
β
3
, which 
binds to the Arg-Gly-Asp (RGD) tripeptide motif containing ligands [3], plays a pivotal role in 
tumor angiogenesis [2] and metastasis. α
v
β
3
 Integrin expressed on endothelial cells modulate 
cell migration and survival during angiogenesis, while α
v
β
3
 integrin expressed on carcinoma cells 
potentiate metastasis by facilitating invasion and movement across blood vessels. The α
v
β
3
 integrin 
is expressed on activated endothelial cells during tumor-induced angiogenesis, whereas it is absent 
on quiescent endothelial cells and normal tissues. In addition, α
v
β
3
 is expressed on various tumor 
cell types (e.g. breast, ovarian, and prostate cancers). Evidence exists that inhibition of α
v
β
3
 integrin 
function prevents tumor growth and induces tumor regression by antagonizing angiogenesis [4]. 
Several peptidic [5] and peptidomimetic [6] α
v
β
3
 antagonists have been synthesized. Among 
these, the cyclo[Arg-Gly-Asp-D-Phe-Val] (c[RGDfV]), as developed by Kessler and coworkers, 
is one of the most active and selective antagonists for the α
v
β
3
 integrin [7]. Structure-activity 
relationship studies on this cyclic pentapeptide showed that the exchange of the valine by a lysine 
residue (Lys, K) did not significantly influence activity and selectivity [8].  Because the ε-amino 
moiety of the lysine residue can be easily modified, numerous applications of c[RGDfK] have been 
studied for tumor targeting and imaging [9].
Multivalency is a well accepted approach to increase the interaction of weakly interacting 
individual ligands with their respective receptors [10]. Dendrimers are macromolecules consisting 
of multiple perfectly branched monomers and this architecture makes them versatile constructs 
_____  Chapter 4  _____________________________________________________________________________
72
_________________________   Synthesis of DOTA-conjugated multivalent cyclic RGD peptide dendrimers _____ 
73
for the simultaneous presentation of receptor binding ligands and other biologically relevant 
molecules [11].  Additionally, dendrimers might serve as promising molecular scaffolds containing 
a number of ligands thereby inducing an apparent increase of ligand concentration and increasing 
the probability of statistical rebinding [10b-e, 12]. Alternatively, dendrimers may align these ligands 
and induce multivalency when receptor clustering occurs or is initiated after initial monovalent 
binding [10b-e]. To improve tumor targeting efficacy and to obtain better in vivo imaging 
properties, several studies explored the multivalency effect by using dimeric and tetrameric 
RGD peptides with affinity toward the α
v
β
3
 integrin [13]. These studies clearly demonstrated the 
multivalency effect, since the in vivo affinity significantly increased going from monomer via dimer 
to tetramer. Moreover, also with respect to tumor-uptake and tumor-to-organ ratios a similar 
increase was observed. These are promising results in view of the development of integrin targeted 
radionuclide therapy [12]. 
To decorate the dendrimer end-groups with biologically relevant peptides as ligands, it is of 
crucial importance to have the disposal of efficient and chemoselective conjugation chemistry to 
ensure the complete attachment of the ligands to the dendrimer. In cases of completely amino 
acid- or peptide-based dendrimers [14, 15],  this is often achieved using peptide coupling reagents, 
however, in most cases, the peptide ligands are attached to dendrimers by chemoselective 
reaction of sulfhydryl groups of cysteine residues with maleimide or iodoacetamide functionalities 
[16], by thiol-disulfide exchange, by native chemical ligation [17] or via a chemoselective oxime 
[13d,l,m] respectively hydrazone [18] ligation. However, new bioconjugation reactions with 
mutually reactive conjugation partners with increased efficiency and chemoselectivity which are 
synthetically easily accessible would be very welcome.
Recently, the well-known reaction between an alkyne and an azide to yield 1,4-disubstituted 
1,2,3-triazoles, was reinvestigated independently by Meldal [19a] and Sharpless [19b]. They found 
that an alkyne and an azide in the presence of Cu(I) undergo a 1,3-dipolar cycloaddition to the 
corresponding triazole under very mild reaction conditions with very high chemoselectivity and 
efficiency which make this reaction particularly suitable for bioconjugations. So far, this 1,3-
dipolar cycloaddition denoted as “click reaction” [20] has led to a plethora of applications in the 
literature [21]. Recently, the synthesis of multivalent dendrimeric peptides [22a] (up to octa- and 
hexadecavalent systems) respectively triazole-linked glycodendrimers [22b] via a microwave-
assisted 1,3-dipolar cycloaddition between azido peptides respectively glycosyl azides and 
dendrimeric alkynes was described as an alternative approach to functionalize dendrimers [22c]. 
Here we describe the synthesis of monomeric, dimeric and tetrameric c[RGDfK] dendrimers via a 
microwave-assisted 1,3-dipolar cycloaddition of dendrimeric alkynes with the N-ε-azido derivative 
of cyclo[Arg-Gly-Asp-D-Phe-Lys] and their subsequent evaluation as α
v
β
3
 integrin antagonists. 
Additionally, the RGD dendrimers were conjugated with a 1,4,7,10-tetraazacyclododecane-
N,N’,N’’,N’’’-tetraacetic acid (DOTA)-moiety. These analogs were radiolabeled with 111In to evaluate 
the in vitro receptor binding characteristics and in vivo tumor targeting properties.
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Results and discussion
Synthesis
Scheme 1 and 2 illustrate the approach for the convergent synthesis of amino acid based dendrimers 
[23] and their corresponding DOTA-conjugated derivatives. The monovalent dendrimer 2 and the 
divalent dendrimer 3 respectively, were synthesized starting from 3-hydroxy benzoic acid or 3,5-
dihydroxy benzoic acid via their corresponding methyl esters followed by alkylation in the presence 
of propargylbromide/K
2
CO
3
 and were obtained in 95 and 81% yield. Since these two dendrimers 
were also used as synthons in further syntheses, the resulting methyl esters 2 and 3 were treated with 
Tesser’s base [24] to yield acids 4 and 5 in nearly quantitative yield. After treatment of the previously 
described 6 [23c] with TFA to remove both Boc-functionalities, the resulting bisamine TFA salt was 
coupled to acid 5 in the presence of BOP/DIPEA to give the tetravalent dendrimer 7 with 75% yield. 
To conjugate the tetravalent dendrimer with a DOTA-moiety at a later stage of the synthesis, its 
methyl ester was saponified with Tesser’s base and acid 8 was obtained quantitatively.
Scheme 1. Synthesis of the mono-, di- and tetravalent dendrimeric alkynes 2, 3 and 7.
_____  Chapter 4  _____________________________________________________________________________
74
_________________________   Synthesis of DOTA-conjugated multivalent cyclic RGD peptide dendrimers _____ 
75
Scheme 2. Synthesis of the DOTA-conjugated dendrimeric alkynes 13, 14 and 16.
The DOTA-moiety was connected to the dendrimer core via a short ethylene spacer. For this 
purpose, 1,2-diaminoethane was converted into the mono-protected Boc derivative 10, which 
was obtained in 56% yield. Unfortunately, although a large excess of the amine was used, the bis-
protected side product was obtained in a considerable amount. Compound 10 was coupled in 
the presence of BOP/DIPEA to either the monovalent, divalent or tetravalent dendrimer acids 4, 5 
or 8 to obtain the corresponding amides 11, 12 or 15, respectively, generally in yields higher than 
90%. The Boc-protected dendrimers were treated with TFA to obtain the corresponding amines 
and they were treated with BOP/DIPEA in the presence of 2-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-
1,4,7,10-tetraazacyclododecan-1-yl) acetic acid (DOTA(OtBu)
3
) to give the DOTA-conjugated 
mono-, di- and tetravalent dendrimers 13, 14 and 16 respectively. It is important to note that the 
solubility of the DOTA-conjugated dendrimer is an important factor that determines the yield 
of the coupling reaction. Compounds 13 and 14 were isolated in very high yields (>94%) but 
compound 16 was isolated with a modest yield of 60% due to its low solubility in solvents like 
EtOAc and CH
2
Cl
2
.
The next step in the synthesis was the preparation of the N-ε-azido cyclo(Arg-Gly-Asp-D-Phe-
Lys) peptide 19 (Scheme 3). To obtain this compound, peptide resin 17 was synthesized using 
Fmoc/tBu SPPS based on the protocol of Liu et al. [25]. It was decided to cleave the protected 
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peptide acid from the resin by HFIP/CH
2
Cl
2 
[26] instead of AcOH/TFE to avoid premature 
acetylation during the BOP/DIPEA-mediated macrolactamization step. Cyclic peptide 18 was 
obtained in 36% overall yield based on the initial resin loading of 0.64 mmol/g. Subsequently, the 
ε-amine of the lysine residue was selectively converted into the azide moiety by a diazotransfer 
[27].  At pH 10, the ε-amine can be deprotonated in the presence of a guanidino functionality, 
since the latter is a much stronger base and will not act as nucleophile in the diazotransfer reaction. 
Finally, the peptide N-ε-azido cyclo(Arg-Gly-Asp-D-Phe-Lys) 19 was obtained in 21% yield after 
purification by HPLC and was characterized by 1H-NMR (500 MHz) and mass spectrometry (LC-
MS). Incorporation of Fmoc-Lys(N
3
)-OH, to avoid the diazo transfer as the final reaction step, did 
not substantially improve the isolated yield.
Scheme 3. Synthesis of the N-ε-azido cyclo[Arg-Gly-Asp-D-Phe-Lys] peptide 19.
At this stage of the synthesis, the challenge was the chemoselective coupling of the different 
dendrimeric alkynes (2, 3, 7, 13, 14, or 16) to the cyclic RGD azido peptide (19) to furnish the 
�
�
�
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DOTA-conjugated dendrimeric cyclo-RGD peptides as α
v
β
3
 integrin antagonists as shown in 
Scheme 4. The first experiments were based on the literature procedure [19b] in which acetylene 
3 was coupled to azido glycine ethyl ester (ethyl-2-azidoacetate) in the presence of CuSO
4
/Na-
ascorbate/Cu-wire in tert-BuOH/H
2
O for 16 h at room temperature. Monitoring the reaction by 
TLC showed that formation of the monovalent cycloadduct proceeded rapidly, but the conversion 
into the divalent product was sluggish. However, a tremendous improvement was achieved by 
running this reaction under microwave irradiation. After 10 min at 100 °C using DMF/H
2
O as 
solvent in the presence of CuSO
4
/Na-ascorbate, the divalent cycloaddition product was obtained 
in 96% yield. This microwave-assisted cycloaddition of dendrimeric alkynes and azido peptides 
was recently reported as a versatile approach to obtain multivalent dendrimeric peptides [22a, c]. 
The optimized reaction conditions were used to couple the cyclic RGD azido peptide (19) to the 
different dendrimeric alkynes (2, 3, 7, 13, 14, or 16).
Scheme 4. Synthesis of the mono-, di- and tetravalent cyclo[RGDfK] peptide dendrimers 20, 21 and 22 and their 
respective DOTA-conjugated counterparts 23, 24 and 25.
In case of alkynes 2, 3 and 7 the formation of the cycloadducts 20, 21 and 22 could be followed 
by TLC and LC-MS. It turned out that the formation of 20 and 21 was complete after 10 to 20 
min microwave irradiation at 100 °C, whereas the formation of 22 was complete after 30 min. 
�
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Although HPLC analysis of the crude cycloaddition products evidenced a complete conversion as 
judged by the absence of the alkyne starting material, the RGD dendrimers 20 – 22 were obtained 
in yields varying between 14 to 57%. Then, the DOTA-conjugated alkyne dendrimers 13, 14 and 
16 were subjected to the cycloaddition reaction conditions in the presence of azido peptide 19. 
It should be emphasized that the carboxyl functionalities of the DOTA-moiety needed to be 
protected by tert-butyl groups to avoid premature and irreversible sequestering of the Cu2+ ions. 
Chelated copper(II) will result in a lower efficiency of the Cu(II)/Cu(I) redox couple to generate the 
active Cu(I)-catalyst. More importantly, it will hamper the radiolabeling of the DOTA-moiety of 
compounds 23 – 25 with trivalent radiometals such as 111In, 90Y or 177Lu. As a result, after the click 
reaction an additional reaction step was needed in which the partially protected cycloadducts 
were treated with TFA, in the presence of suitable scavengers, to give the unprotected DOTA-
conjugated RGD dendrimers 23 – 25.
The cycloaddition reaction of the DOTA-conjugated dendrimeric alkynes 13, 14 and 16 was 
difficult to monitor by mass spectrometry. As was described above, reaction times of 10 to 30 
min were used and the cycloaddition reaction was directly followed by a TFA-treatment without 
isolation of the cycloaddition intermediates. The isolated yield (13%) of monovalent 23 was rather 
disappointing. Recently, optimized conditions with respect to the generation of the catalytic 
active Cu(I) species were published [28] and these conditions were applied in the cycloaddition of 
14 and 19. Unfortunately, an increase of the isolated yield was not observed using these modified 
reaction conditions. As was mentioned earlier, the cycloaddition reaction was complete according 
to HPLC analysis, and the low isolated yield was mainly due to the difficult purification. The 
DOTA-conjugated RGD dendrimers were obtained in yields varying between 11 and 36%.
Radiolabeling of the RGD dendrimers
Dendrimers 23, 24 and 25 were radiolabeled by dissolving these compounds in an NH
4
OAc buffer 
of pH 6.0 and 22.2-37 MBq 111InCl
3
 was added to each of the reaction mixtures. The reaction 
mixtures were degassed and subsequently heated at 100 ºC for 15 min. Reversed-phase HPLC 
analysis showed a single peak for each of the three 111In-labeled compounds with an elution time 
of 25.9 min, 29.5 min and 29.4 min for the 111In-labeled monovalent 23, divalent 24, and tetravalent 
25, RGD peptide dendrimers respectively.
Solid-phase αVβ3 binding assay
The affinity of the DOTA-conjugated RGD dendrimers 23, 24, and 25 for the α
v
β
3
 integrin was 
determined in a competitive binding assay. The results of these analyses are shown in Figure 
1. Binding of the 111In-labeled dimeric peptide, 111In-DOTA-E-[c(RGDfK)]
2 
[29], to α
v
β
3
 was 
competed by unlabeled 23, 24, and 25 
 
in a concentration dependent manner. The IC
50
 values 
were 212 nM for monovalent 23, 356 nM for divalent 24, and 50 nM for tetravalent 25. The 
dendrimer containing four c[RGDfK] units (25) showed an increased affinity for α
v
β
3
 compared 
to the dendrimers containing one (23) or two (24) c[RGDfK] units. Multimerization of c[RGDfK] 
resulted in enhanced affinity for α
v
β
3
 as was evidenced by a decrease of the IC
50
 concentration.
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Figure 1. Competition of specific binding of 111In-DOTA-E-[c(RGDfK)]
2
 with RGD dendrimers 23, 24, and 25.
Biodistribution studies
In athymic mice with subcutaneously (s.c.) growing SK-RC-52 renal cell carcinoma, the tumor 
uptake of the 111In-labeled tetrameric RGD dendrimer 25 at 2 h postinjection (p.i.; 7.27 ± 2.06 
%ID/g) was significantly higher (P<0.05) compared to that of the 111In-labeled monomeric RGD 
dendrimer 23 (1.69 ± 0.41 %ID/g) as shown in Figure 2A. At 2 h p.i., the tumor uptake of tetrameric 
RGD dendrimer 25 was also significantly higher (P<0.05) than the dimeric analog 24 (3.15 ± 0.51 
%ID/g). The tumor-to-blood ratios of the tetramer 25 (5.66 ± 1.74, 34.73 ± 5.95) were significantly 
higher (P<0.05) −both at 2 h p.i. and at 24 h p.i.− than those of the monomer 23 (3.12 ± 1.92, 19.65 
± 12.42) and dimer 24 (1.70 ± 0.50, 14.66 ± 0.25). At 24 h p.i., the tumor uptake of the tetrameric 
RGD dendrimer 25 (5.83 ± 1.18 %ID/g) was significantly higher compared to the dimeric RGD 
dendrimer 24 (2.82 ± 0.59 %ID/g, P<0.05) and the monomeric RGD dendrimer 23 (1.19 ± 0.31 
%ID/g, P<0.01) which is shown in Figure 2B. Coinjection of an excess of non-radiolabeled RGD 
peptide (DOTA-E-[c(RGDfK)]
2
) to saturate all α
v
β
3
 receptors in vivo, resulted in a significantly 
reduced tumor uptake of each of the three compounds: 23: 0.46 ± 0.04 %ID/g (2 h p.i.), 0.36 ± 
0.31 %ID/g (24 h p.i.), 24: 0.76 ± 0.09 %ID/g (2 h p.i.), not determined (24 h p.i.) and 24: 1.56 ± 0.02 
%ID/g (2 h p.i.), 1.19 ± 0.03 %ID/g (24 h p.i.), indicating that each of the three RGD dendrimers 
of this study showed receptor specific uptake in the tumor. These in vivo results were in line with 
the in vitro binding assay. The tetrameric RGD dendrimer showed enhanced affinity for α
v
β
3
, 
as compared to the monomeric and dimeric RGD dendrimer, respectively. The results of this 
study correlated perfectly with the results observed in a previous study in which we evaluated 
multimeric RGD peptides in the same animal model [13o].
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Figure 2A. Biodistribution of 111In-labeled monomer 23, dimer 24, and tetramer 25 at 2 h p.i. in athymic mice with s.c. 
SK-RC-52 tumors.
Figure 2B. Biodistribution of 111In-labeled monomer 23, dimer 24, and tetramer 25 at 24 h p.i. in athymic mice with s.c. 
SK-RC-52 tumors. 
The affinity of the dendrimers as determined in a vitro binding assay are in agreement with the 
results obtained from the in vivo experiment. The IC
50
 concentration of the tetrameric RGD 
dendrimer 25 was lower compared to those of the monomeric 23 and dimeric 24 analogs, 
resulting in a significant higher uptake of the former in α
v
β
3
 expressing tumors and better tumor 
to blood ratios compared to the monomeric and dimeric RGD dendrimers.
In conclusion, a series of α
v
β
3
 integrin-directed monomeric, dimeric and tetrameric cyclo[Arg-
Gly-Asp-D-Phe-Lys] dendrimers using “click chemistry” was successfully synthesized, since 
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the unprotected N-ε-azido derivative of cyclo[Arg-Gly-Asp-D-Phe-Lys] underwent a highly 
chemoselective conjugation to amino acid-based dendrimers bearing terminal alkynes using a 
microwave-assisted Cu(I)-catalyzed 1,3-dipolar cycloaddition. The α
v
β
3
 binding characteristics 
and α
v
β
3
 targeting properties of the dendrimers were determined both in vitro and in vivo. In 
case of the DOTA-conjugated 111In-labeled RGD dendrimers, it was found that the radiolabeled 
multimeric dendrimers showed specifically enhanced uptake in α
v
β
3
 integrin expressing tumors 
in vivo. These studies showed that the tetrameric RGD dendrimer had better tumor targeting 
properties than its dimeric and monomeric congeners.
Experimental section
Instruments and methods
Peptides were synthesized on an ABI 433A automatic Peptide Synthesizer using the FastMoc 
solid-phase peptide synthesis protocols. Microwave-assisted reactions were carried out in a 
Biotage microwave reactor. Analytical HPLC runs were carried out on a Shimadzu HPLC system 
and preparative HPLC runs were performed on a Gilson HPLC workstation. Analytical HPLC runs 
were performed on Alltech Prosphere C4 or C8 and Adsorbosphere XL C18 columns (250 × 4.6 
mm, pore size 300Å, particle size: 5 µm) or on a Merck LiChroCART CN column (250 × 4.6 mm, 
pore size 100Å, particle size: 5 µm) at a flow rate of 1.0 mL/min using a linear gradient of buffer 
B (0 – 100% in 25 min) in buffer A (buffer A: 0.1% TFA in H
2
O, buffer B: 0.1 % TFA in CH
3
CN/H
2
O 
95:5 v/v). Preparative HPLC runs were performed on an Alltech Prosphere C4 or C8 column (250 
× 22 mm, pore size 300Å, particle size: 10 µm), and semi-prep HPLC runs were performed on an 
Alltech Adsorbosphere XL C18 column (250 × 10 mm, pore size 300Å, particle size: 10 µm) or on 
a Merck LiChroCART CN column (250 × 10 mm, pore size 100Å, particle size: 10 µm) at a flow 
rate of 10.0 mL/min (semi-prep HPLC: 4.0 mL/min) using a linear gradient of buffer B (0 – 100% 
in 50 min) in buffer A (buffer A: 0.1% TFA in H
2
O, buffer B: 0.1 % TFA in CH
3
CN/H
2
O 95:5 v/v). 
Liquid chromatography electrospray ionization mass spectrometry was measured on a Shimadzu 
LCMS-QP8000 single quadrupole bench-top mass spectrometer operating in a positive ionization 
mode. LC/MS(MS) runs were performed on a Finnigan LCQ Deca XP MAX LC/MS equipped 
with a Shimadzu 10A VP analytical HPLC system. The samples were dissolved in 10% formic acid 
in CH
3
CN/H
2
O 1:1 v/v and analyzed using a Phenomenex Gemini C18 column (150 × 4.6 mm, 
particle size: 3 µm, pore size: 110Å) at a flow rate of 1.0 mL/min using a linear gradient of 100% 
buffer A (0.1% TFA in H
2
O/CH
3
CN 95:5 v/v) to 100% buffer B (0.1% TFA in CH
3
CN/H
2
O 95:5 v/v) in 
50 min. MALDI-TOF analysis was performed on a Kratos Axima CFR apparatus with bradykinin(1-
7) (monoisotopic [M + H]+ 757.399), human ACTH(18-39) (monoisotopic [M + H]+ 2465.198) and 
bovine insulin oxidized B chain (monoisotopic [M + H]+ 3494.651) as external references and α-
cyano-4-hydroxycinnamic acid or sinapinic acid as matrices. 1H NMR spectra were recorded on a 
Varian G-300 (300 MHz) spectrometer and chemical shifts are given in ppm (δ) relative to TMS. 13C 
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NMR spectra were recorded on a Varian G-300 (75.5 MHz) spectrometer and chemical shifts are 
given in ppm relative to CDCl
3
 (77.0 ppm). The 13C NMR spectra were recorded using the attached 
proton test (APT) sequence. 1H NMR spectra in H
2
O/D
2
O 9:1 v/v were recorded on a Varian Inova-
500 (500 MHz) spectrometer and chemical shifts are given in ppm (δ) relative to 3-(trimethylsilyl)-
1-propanesulfonic acid sodium salt (0.00 ppm). Peak assignments are based on DQF-COSY, TOCSY 
(mixing times: 20 or 60 ms) and ROESY (mixing times: 150 or 250 ms) spectra. HSQC and HMBC 
spectra were measured on a Varian Inova-500 spectrometer and chemical shifts are given in ppm 
(δ) relative to 3-(trimethylsilyl)-1-propanesulfonic acid sodium salt (0.00 ppm). Fourier transform 
infrared spectra (FTIR) were measured on a Bio-Rad FTS-25 spectrophotometer. Melting points 
were measured on a Büchi Schmelzpunktbestimmungsapparat and are uncorrected. Elemental 
analyses were done by Kolbe Mikroanalytisches Labor (Mülheim/Ruhr, Germany). R
f
 values were 
determined by thin layer chromatography (TLC) on Merck precoated silica gel 60F254 plates. Spots 
were visualized by UV-quenching, ninhydrin or Cl
2
/TDM [30]. The 2-chlorotrityl chloride resin 
(Hecheng Science & Technology Company) was used in all solid-phase syntheses. The coupling 
reagents 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) 
and benzotriazol-1-yloxy-tris-(dimethylamino)phosphonium hexafluorophosphate (BOP) were 
obtained from Biosolve. N-hydroxybenzotriazole (HOBt) was from Advanced ChemTech and Nα-
9-fluorenylmethyloxycarbonyl (Fmoc) amino acids were obtained from MultiSynTech. The side 
chain protecting groups were chosen as tert-butyl for aspartic acid, tert-butyloxycarbonyl (Boc) 
for lysine and 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf) for arginine. Peptide-
grade tert-butanol (tBuOH), dichloromethane, N,N-dimethylformamide (DMF), 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP) tert-butyl methylether (MTBE), N-methylpyrrolidone (NMP), and 
trifluoroacetic acid (TFA) and HPLC-grade acetronitrile were purchased from Biosolve. 2-(4,7,10-
tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl) acetic acid (DOTA(OtBu)
3
) was 
purchased from Macrocyclics. Piperidine, N,N-diisopropylethylamine (DIPEA), CuSO
4
 and sodium 
ascorbate were obtained from Acros Organics. Triisopropylsilane (TIS) and HPLC-grade TFA were 
obtained from Merck. Triflic anhydride and propargylbromide were purchased from Aldrich.
Radiolabeling of the RGD dendrimers
Dendrimers 23 (25 µg, 20 nmol), 24 (25 µg, 13 nmol), and 25 (120 µg, 33 nmol) were radiolabeled by 
dissolving these compounds in 500 µL 0.5 M NH
4
OAc buffer, pH 6.0, containing 0.6 mg/mL gentisic 
acid. Then 22.2-37 MBq 111InCl
3
 was added to each of the reaction mixtures. The reaction mixtures 
were degassed and subsequently heated at 100 ºC for 15 min. The 111In-labeled dendrimers were 
further purified on a Waters C-18 SepPak cartridge (Milford, MA). After applying the sample on 
the methanol-activated cartridge, the cartridge was washed with 5 mL 25 mM NH
4
OAc and eluted 
with 25% CH
3
CN in 25 mM NH
4
OAc. The radiochemical purity was determined by reversed-phase 
HPLC (HP 1100 series, Hewlett Packard, Palo Alto, CA, USA) using a Zorbax RX-C18 column (250 × 
4.6 mm) eluted with a linear gradient of buffer B (8 − 20% in 25 min or 8 − 100% in 30 min in buffer 
A (buffer A: 25 mM NH
4
OAc, buffer B: CH
3
CN) at a flow rate of 1 mL/min. The radioactivity of the 
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eluate was monitored using an in-line radiodetector (Flo-One Beta series, Radiomatic, Meriden, 
CT, USA).
Solid-phase αVβ3 binding assay
The affinity of the DOTA-conjugated monovalent 23, divalent 24 and tetravalent 25 RGD 
dendrimers for the α
v
β
3
 integrin was determined using a solid-phase competitive binding assay. 
111In-labeled DOTA-E-[c(RGDfK)]
2
 (3 MBq/µg) was prepared as described above and was used 
as the tracer in the assay. Microtiter 96-well vinyl assay plates (Corning B.V., Schiphol-Rijk, The 
Netherlands) were coated with 100 µL/well of a solution of purified human integrin α
v
β
3
 (150 
ng/mL) in Triton X-100 Formulation (Chemicon International, Temecula, CA, USA) in coating 
buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl
2
, 0.5 mM MgCl
2
 and 1 mM MnCl
2
) for 
17 h at 4 ºC. The plates were washed twice with binding buffer (0.1% bovine serum albumin (BSA) 
in coating buffer). The wells were blocked for 2 h with 200 µL blocking buffer (1% BSA in coating 
buffer). The plates were washed twice with binding buffer. Then 100 µL binding buffer containing 
11.1 kBq of 111In-DOTA-E-[c(RGDfK)]
2
 and appropriate dilutions of non-labeled monovalent 23, 
divalent 24 and tetravalent 25 RGD dendrimers in binding buffer were incubated in the wells at 37 
ºC for 1 h. After incubation, the plates were washed three times with binding buffer. The retained 
radioactivity in each well was determined in a γ-counter (1480 Wizard, Wallac, Turku, Finland). 
The IC
50
 values of the RGD dendrimers were calculated by non-linear regression using GraphPad 
Prism (GraphPad Prism 4.0 Software, San Diego, CA, USA). Each data point represents the average 
of three individual determinations.
Biodistribution studies
In the right flank of 6-8 weeks old female nude BALB/c mice, 0.2 mL of a cell suspension of 8.5 × 
106 cells/mL SK-RC-52 cells was injected subcutaneously (s.c.). Two weeks after inoculation of the 
tumor cells, mice were randomly divided into three groups. The mice were injected with 0.25-0.29 
MBq of the 111In-labeled dendrimers 23, 24, or 25 via a tail vein. The mice were euthanized by CO
2
 
asphyxiation, 2 and 24 h postinjection (p.i.) (3-5 mice/group). Blood, tumor, and the major organs 
and tissues were collected, weighed, and counted in a γ-counter. The percentage injected dose per 
gram (%ID/g) was determined for each sample. To investigate whether the uptake of each of the 
three RGD dendrimers is α
v
β
3
-mediated, a separate group of mice was coinjected with an excess 
(50 µg) of non-radiolabeled DOTA-E-[c(RGDfK)]
2
 to saturate all the α
v
β
3
 integrin receptors.
Statistical analysis
All mean values are given ± standard deviation (S.D.). Statistical analysis was performed using the 
One-way Analysis of Variance. Tukey corrections for multiple comparisons were applied. The level 
of significance was set at P<0.05.
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Syntheses
methyl 3-(prop-2-ynyloxy)benzoate (2): methyl 3-hydroxy benzoate [23c] (2.35 g, 15.5 mmol) was 
dissolved in dry DMF (25 mL) and anhydrous K
2
CO
3
 (2.63 g, 19.8 mmol, 1.3 equiv) was added. To 
this suspension, a solution of propargylbromide in toluene (2 mL, 17.9 mmol, 1.15 equiv) was added 
dropwise. The reaction mixture was stirred for 16 h at room temperature. Then, DMF was removed by 
evaporation and the residue was redissolved in EtOAc (75 mL) and the organic phase was washed with 
H
2
O (3 × 25 mL), 1N KHSO
4
 (3 × 25 mL) and brine (3 × 25 mL), dried (Na
2
SO
4
) and evaporated in vacuo. 
Propargyl ether 2 was obtained as a pale brownish waxy solid in 95% yield (2.80 g). R
f
(EtOAc/hexane 
4:1 v/v): 0.69; 1H-NMR (CDCl
3
) δ 2.56 (t (J 2.47 Hz), 2H, CH), 3.90 (s, 3H, OCH
3
), 4.72 (d (J 2.47 Hz), 4H, 
~O-CH
2
), 7.16 (m, 1H, arom H), 7.35 (d (J 7.81 Hz), 1H, arom H), 7.62 (s, 1H, arom H), 7.66 (d (J 7.81 Hz), 
1H, arom H); 13C-NMR (CDCl
3
) δ 52.0, 55.8, 76.0, 75.8, 115.1, 120.0, 122.7, 131.4, 157.3; MS analysis: calcd 
for C
11
H
10
O
3
 190.20, found ES-MS 191.38 [M + H]+.
methyl 3,5-bis(prop-2-ynyloxy)benzoate (3): This compound was synthesized as described for 2 on 
a 130 mmol scale (methyl 3,5-dihydroxy benzoate [23c], 21.4 g) in dry DMF (250 mL) in the presence of 
anhydrous K
2
CO
3
 (45 g, 330 mmol, 2.5 equiv) and a solution of propargylbromide in toluene (35 mL, 
314 mmol, 2.5 equiv). Dipropargyl ether 3 was obtained as off-white crystals in 81% yield (25.2 g). M.p.: 
110 °C; R
f
(EtOAc/hexane 4:1 v/v): 0.76; R
f
(CH
2
Cl
2
/MeOH 98:2 v/v): 0.87; R
f
(CHCl
3
/MeOH/AcOH 95:20:
3 v/v): 0.83; 1H-NMR (CDCl
3
) δ 2.55 (t (J 2.47 Hz), 2H, CH), 3.91 (s, 3H, OCH
3
), 4.72 (d (J 2.47 Hz), 4H, 
~O-CH
2
), 6.81 (t (J 2.20 Hz), 1H, arom H4), 7.29 (d (J 2.20 Hz), 2H, arom H2/H6); 13C-NMR (CDCl
3
) δ 
52.4, 56.0, 76.0, 77.9, 107.5, 108.8, 132.0, 157.8, 158.4; MS analysis: calcd for C
14
H
12
O
4
 244.24, found ES-MS 
244.99 [M + H]+; Elemental analysis: calcd for C
14
H
12
O
4
 C 68.83, H 4.95, found C 68.76, H 4.95.
3-(prop-2-ynyloxy)benzoic acid (4): Compound 2 (1.0 g, 5.24 mmol) was dissolved in dioxane/MeOH 
(50 mL, 14:5 v/v) and 4N NaOH (2 mL, 1.5 equiv) was added in one portion. The obtained reaction 
mixture was stirred for 5 h at room temperature. Then, the reaction mixture was neutralized by the 
addition of 1N HCl and the solvents were removed by evaporation. The residue was redissolved in 
EtOAc (50 mL) and the organic phase was washed with 1N KHSO
4
 (3 × 20 mL) and brine (3 × 20 mL), 
dried (Na
2
SO
4
) and evaporated in vacuo. The residual solid was obtained in 97% yield (900 mg) and 
used without further purification in the next synthesis step. M.p.: 126-131 °C; R
f
(EtOAc/hexane 7:3 v/v): 
0.65; 1H NMR (CDCl
3
) δ: 2.55 (s, 1H, CH), 4.77 (s, 2H, ~O-CH
2
), 7.25 (m, 1H, arom H), 7.42 (t, 1H, arom 
H5), 7.72 (m, 1H, arom H), 7.77 (d, 1H, arom H); 13C NMR (CDCl
3
) δ: 56.0, 76.0, 78.0, 115.6, 121.2, 123.5, 
129.6, 130.6, 157.5, 171.9; Elemental analysis: calcd for C
10
H
8
O
3
 C 68.18, H 4.58, found C 67.87, H 4.70.
3,5-bis(prop-2-ynyloxy)benzoic acid (5): Methyl ester 3 (5.66 g, 23.2 mmol) was saponified as 
described for compound 4. The acid 5 was obtained in 96% yield (5.13 g) and used without further 
purification in the next synthesis step. M.p.: 171-174 °C; R
f
(CH
2
Cl
2
/MeOH 9:1 v/v): 0.26; 1H-NMR 
(DMSO-d
6
) δ: 3.59 (broad s, 2H, CH), 4.85 (d (J 2.20 Hz), 4H, ~O-CH
2
), 6.86 (t (J 2.47 Hz), 1H, arom H4), 
7.17 (d (J 2.47 Hz), 2H, arom H2/H6); 13C-NMR (DMSO-d
6
) δ: 55.8, 78.6, 78.9, 107.0, 108.4, 132.9, 158.2, 
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166.8; MS analysis: calcd for C
14
H
12
O
4
 230.22, found ES-MS 231.01 [M + H]+; Elemental analysis: calcd for 
C
13
H
10
O
4
 C 67.82, H 4.38, found C 67.56, H 4.11.
methyl 3,5-bis(2-(3,5-bis(prop-2-ynyloxy)benzamido)ethoxy)benzoate (7): To a solution of 3,5-bis-
(2-tert-butyloxycarbonylamino-ethoxy) methyl benzoate [23c] (6; 2.27 g, 5.0 mmol) in CH
2
Cl
2
 (25 mL), 
TFA (25 mL) was added to remove the Boc functionalities. After 1 h of stirring at room temperature, 
the volatiles were removed by evaporation and the residue was coevaporated with CH
2
Cl
2
 to remove 
any residual TFA. The obtained solid was used without further purification. Acid 5 (2.53 g, 11 mmol, 
2.2 equiv) was dissolved in CH
2
Cl
2
 (100 mL) and the TFA-salt (dissolved in 50 mL CH
2
Cl
2
) followed by 
DIPEA (3.53 mL, 25 mmol, 5 equiv) were added. Finally, BOP (4.86 g, 11 mmol) was added and the 
obtained reaction mixture was stirred for 16 h at room temperature. Then, the solvent was removed in 
vacuo and the residue was redissolved in EtOAc (150 mL) and this solution was subsequently washed 
with H
2
O (3 × 75 mL), 1N KHSO
4
 (3 × 75 mL), H
2
O (3 × 75 mL), 5% NaHCO
3
 (3 × 75 mL) and brine 
(3 × 75 mL), dried (Na
2
SO
4
) and evaporated to dryness. The residue was crystallized from MeOH and 
was obtained as a white solid in 75% yield (2.54 g). M.p.: 113-124 °C; R
f
(EtOAc/hexane 4:1 v/v): 0.49; 
R
f
(CH
2
Cl
2
/MeOH 98:2 v/v): 0.13; R
f
(CHCl
3
/MeOH/AcOH 95:20:3 v/v): 0.80; 1H NMR (DMSO-d
6
) δ: 3.58 
(s, 4H, CH), 3.65 (m, 4H, ~CH
2
~), 3.84 (s, 3H, OCH
3
), 4.19 (m, 4H, ~CH
2
~), 4.85 (s, 8H, ~O-CH
2
), 6.80 (s, 
2H, arom H4’), 6.87 (s, 1H, arom H4), 7.12 (s, 2H, arom H2/H6), (s, 4H, arom H2’/H6’), 8.67 (m, 2H, NH 
amide); 13C-NMR (CDCl
3
) δ: 40.4, 53.2, 56.9, 57.6, 77.0, 78.8, 106.3, 107.1, 107.6, 109.0 132.9, 137.4, 159.6, 
160.3, 167.4, 168.1; MS analysis: calcd for C
38
H
34
N
2
O
10
 678.22, found ES-MS 679.40 [M + H]+, 701.45 [M 
+ Na]+; MALDI-TOF 679.298 [M + H]+, 701.245 [M + Na]+; Elemental analysis: calcd for C
38
H
34
N
2
O
10
 C 
67.25, H 5.05, N 4.13 found C 66.92, H 5.09, N 4.10.
3,5-bis(2-(3,5-bis(prop-2-ynyloxy)benzamido)ethoxy)benzoic acid (8): Methyl ester 7 (1.36 g, 2 
mmol) was saponified as described for compound 4. Acid 8 was obtained as a white powder with 
nearly quantitative yield (1.33 g). M.p.: 163-168 °C; R
f
(CH
2
Cl
2
/MeOH 9:1 v/v): 0.23; 1H NMR (DMSO-d
6
) 
δ: 3.58 (s, 4H, CH), 3.65 (m, 4H, ~CH
2
~), 4.19 (m, 4H, ~CH
2
~), 4.85 (s, 8H, ~O-CH
2
), 6.80 (s, 2H, arom 
H4’), 6.83 (s, 1H, arom H4), 7.11 (s, 2H, arom H2/H6), 7.15 (s, 4H, arom H2’/H6’), 8.66 (m, 2H, NH amide); 
13C-NMR (DMSO-d
6
) δ: 38.9, 55.8, 66.3, 78.4, 78.9, 105.0, 105.8, 106.8, 107.8, 132.9, 136.3, 158.2, 159.6, 
165.8, 166.9; MS analysis: calcd for C
37
H
32
N
2
O
10
 664.66, found ES-MS 665.75 [M + H]+, 687.60 [M + Na]+; 
Elemental analysis: calcd for C
37
H
32
N
2
O
10
 C 66.86, H 4.85, N 4.21 found C 66.76, H 4.72, N 4.11.
tert-butyl 2-aminoethylcarbamate (10): To a solution of 1,2-diaminoethane (13.4 mL, 200 mmol) in 
dioxane (100 mL) a solution of Boc
2
O (5.46 g, 25 mmol) in dioxane (100 mL) was added dropwise over 
a period of 2 h. After the addition was complete, the obtained reaction mixture was stirred for 16 h 
at room temperature. Then, the solvent was removed by evaporation and the residue was suspended 
in H
2
O (100 mL) and the white precipitate (bis-substitution product) was removed by filtration. The 
aqueous solution was extracted with CH
2
Cl
2
 (3 × 50 mL), and the collected organic layers were washed 
with brine (1 × 50 mL), dried (MgSO
4
) and evaporated to dryness. Compound 10 was obtained as a 
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yellowish oil with 56% yield (2.25 g). R
f
(CH
2
Cl
2
/MeOH 94:6 v/v): 0.24 1H NMR (CDCl
3
) δ: 1.45 (broad s, 
11H, (CH
3
)
3
 Boc/~NH
2
), 2.79 (m, 2H, ~CH
2
-NH
2
), 3.16 (m, 2H, ~NH-CH
2
~), 5.32 (m, 1H, NH urethane); 
13C-NMR (CDCl
3
) δ 28.2, 41.6, 43.1, 78.9, 156.2; MS analysis: calcd for C
7
H
16
N
2
O
2
 160.12, found ES-MS 
161.15 [M + H]+.
tert-butyl 2-(3-(prop-2-ynyloxy)benzamido)ethylcarbamate (11): Acid 4 (774 mg, 4.40 mmol) and 
amine 10 (704 mg, 4.40 mmol) were dissolved in CH
2
Cl
2
 (25 mL) and BOP (1.95 g, 4.41 mmol) followed 
by DIPEA (1.77 mL, 10 mmol, 2.27 equiv) were added and the obtained reaction mixture was stirred 
for 16 h. Then, the solvent was removed by evaporation and the residue was redissolved in EtOAc (50 
mL) and subsequently washed with H
2
O (3 × 20 mL), 1N KHSO
4
 (3 × 20 mL), H
2
O (3 × 20 mL), 5% 
NaHCO
3
 (3 × 20 mL) and brine (3 × 20 mL), dried (Na
2
SO
4
) and evaporated to dryness. The residue was 
purified by column chromatography (eluens: EtOAc/hexane 1:1 v/v) and was obtained as a white solid 
with 98% yield (1.38 g). M.p.: 118-121 °C; R
f
(EtOAc/hexane 1:1 v/v): 0.20; 1H NMR (CDCl
3
) δ: 1.42 (s, 9H, 
(CH
3
)
3
 Boc), 2.54 (s, 1H, CH), 3.38 (m, 2H, ~NH-CH
2
-CH
2
~), 3.54 (m, 2H, ~CH
2
-CH
2
-NH~), 4.70 (s, 2H, 
~O-CH
2
), 5.35 (m, 1H, NH urethane), 7.10 – 7.47 (broad m, 5H, arom H/NH amide); 13C NMR (CDCl
3
) 
δ: 28.3, 39.9, 41.7, 55.8, 75.7, 78.1, 79.7, 113.4, 118.3, 119.8, 129.4, 135.6, 157.3, 157.6, 167.5; MS analysis: 
calcd for C
17
H
22
N
2
O
4
 318.16, found ES-MS 319.27 [M + H]+, 341.33 [M + Na]+; Elemental analysis: calcd 
for C
17
H
22
N
2
O
4
 C 64.13, H 6.97, N 8.80 found C 63.81, H 6.81, N 8.63.
tert-butyl 2-(3,5-bis(prop-2-ynyloxy)benzamido)ethylcarbamate (12): This compound was 
synthesized using acid 5 (506 mg, 2.20 mmol) and amine 10 (352 mg, 2.20 mmol) as described for 11. 
Compound 12 was obtained in 96% yield (760 mg) after column chromatography with EtOAc/hexane 
8:2 v/v as eluens. M.p.: 128-134 °C; R
f
(EtOAc/hexane 7:3 v/v): 0.31; 1H NMR (CDCl
3
) δ: 1.42 (s, 9H, (CH
3
)
3
 
Boc), 2.55 (s, 2H, CH), 3.37 (m, 2H, ~NH-CH
2
-CH
2
~), 3.52 (m, 2H, ~CH
2
-CH
2
-NH~), 4.68 (s, 4H, ~O-CH
2
), 
5.30 (m, 1H, NH urethane), 6.72 (s, 1H, arom H4), 7.06 (s, 2H, arom H2/H6), 7.44 (m, 1H, NH amide); 13C 
NMR (125 MHz, CDCl
3
) δ: 28.3, 40.0, 41.7, 56.0, 75.9, 78.0, 79.8, 105.5, 106.6, 136.4, 157.3, 158.6, 167.2; 
MS analysis: calcd for C
20
H
24
N
2
O
5
 372.17, found ES-MS 373.24 [M + H]+, 395.27 [M + Na]+; Elemental 
analysis: calcd for C
20
H
24
N
2
O
5
 C 64.50, H 6.50, N 7.52 found C 63.61, H 6.21, N 7.05.
tert-butyl-2,2’,2’’-(10-(2-oxo-2-(2-(3-(prop-2-ynyloxy)benzamido)ethylamino)ethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (13): To a solution of compound 11 (100 mg, 0.31 
mmol) in CH
2
Cl
2
 (5 mL), TFA (5 mL) was added to remove the Boc protecting group. After 1 h of stirring 
at room temperature, the volatiles were removed by evaporation and the residue was coevaporated 
with CH
2
Cl
2
 to remove any residual TFA. The obtained solid was used without further purification. 
Then, the TFA-salt was dissolved in CH
2
Cl
2
 (10 mL) and 2-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-
1,4,7,10-tetraazacyclododecan-1-yl) acetic acid (DOTA(OtBu)
3
; 177 mg, 0.31 mmol), BOP (137 mg, 0.31 
mmol) followed by DIPEA (220 µL, 1.24 mmol, 4 equiv) were added and the obtained reaction mixture 
was stirred for 16 h at room temperature. Subsequently, the solvent was removed by evaporation and 
the residue was redissolved in EtOAc (50 mL) and this solution was washed with H
2
O (3 × 20 mL), 1N 
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KHSO
4
 (3 × 20 mL), H
2
O (3 × 20 mL), 5% NaHCO
3
 (3 × 20 mL), brine (3 × 20 mL) and dried (Na
2
SO
4
). 
Finally, the solvent was evaporated in vacuo after which 13 was obtained as a pale yellow oil with 94% 
yield (227 mg). R
f
(CH
2
Cl
2
/MeOH 9:1 v/v): 0.49; R
t
: 18.10 min (C8); 1H NMR (CDCl
3
) δ: 1.42 (s, 27H, (CH
3
)
3
 
tBu), 2.20 – 3.70 (broad s, 28H, CH
2
 DOTA (24H)/~NH-CH
2
-CH
2
-NH~(4H)), 2.52 (s, 1H, CH), 4.75 (s, 2H, 
~O-CH
2
), 6.85 (m, 1H, NH), 7.08 (m, 1H, arom H), 7.25 – 7.32 (m, 2H, arom H), 7.51 (m, 2H, arom H/NH); 
13C NMR (CDCl
3
) δ: 27.9, 39.6, 39.7, 55.6, 55.8, 56.0, 75.5, 78.4, 81.8, 112.9, 118.9, 120.3, 129.6, 135.5, 157.6, 
167.4, 172.0, 172.4; MS analysis: calcd for C
40
H
64
N
6
O
9
, 772.47, found ES-MS 773.90 [M + H]+.
tert-butyl 2,2’,2’’-(10-(2-(2-(3,5-bis(prop-2-ynyloxy)benzamido)ethylamino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (14): This compound was synthesized as described for 
13 starting from 12 (107 mg, 0.30 mmol). Compound 14 was obtained as a yellowish solid with nearly 
quantitative yield (250 mg). M.p.: 74-84 °C; R
f
(CHCl
3
/MeOH/AcOH 95:20:3 v/v/v): 0.45; R
t
: 18.70 min (C8); 
1H NMR (CDCl
3
) δ: 1.43 (s, 27H, (CH
3
)
3
 tBu), 2.04 – 3.70 (broad s, 28H, CH
2
 DOTA (24H)/~NH-CH
2
-CH
2
-
NH~(4H)), 2.52 (s, 2H, CH), 4.73 (s, 4H, ~O-CH
2
), 6.73 (m, 2H, arom H4/NH), 7.10 (s, 2H, arom H2/H6), 
7.11 (m, 1H, NH); 13C NMR (CDCl
3
) δ: 27.9, 39.6, 50.0*, 55.6, 55.8, 56.2, 75.6, 78.4, 81.9, 106.4, 106.5, 136.4, 
158.7, 167.2, 172.0, 172.4 (*broad signal: CH
2
 DOTA); MS analysis: calcd for C
43
H
66
N
6
O
10
, 826.48, found ES-
MS 827.65 [M + H]+; Elemental analysis: calcd for C
43
H
66
N
6
O
10
⋅K
2
SO
4
 C 51.58, H 6.64, N 8.39 found C 52.05, 
H 6.54, N 8.04.
tert-butyl-2 (3,5-bis(2-(3,5-bis(prop-2-ynyloxy)benzamido)ethoxy)benzamido)ethylcarbamate 
(15): This compound was synthesized as described for 11 using amine 10 (292 mg, 2.0 mmol) and acid 
8 (460 mg, 2.0 mmol). Compound 15 was obtained as a pale yellow solid with 91% yield (1.46 g). M.p.: 
110 °C; R
f
(EtOAc/hexane 4:1 v/v): 0.53; R
t
: 18.38 min (C8); 1H NMR (DMSO-d
6
) δ: 1.37 (s, 9H, (CH
3
)
3
 Boc), 
3.10 (m, 2H, ~NH-CH
2
-CH
2
-NH~), 3.28 (m, 2H, ~NH-CH
2
-CH
2
-NH~), 3.58 (s, 4H, CH), 3.65 (m, 4H, ~O-
CH
2
-CH
2
-NH~), 4.17 (m, 4H, ~O-CH
2
-CH
2
-NH~), 4.85 (s, 8H, ~O-CH
2
), 6.72 (m, 1H, arom H4), 6.80 (m, 
2H, arom H2/H6), 6.90 (m, 1H, NH urethane), 7.05 (m, 2H, arom H4’), 7.15 (m, 4H, arom H2’/H6’), 8.44 
(m, 1H, NH amide), 8.68 (m, 2H, NH amide); 13C NMR (DMSO-d
6
) δ: 28.0, 39.2, 55.9, 75.8, 75.9, 77.8, 79.6, 
104.7, 105.4, 105.9, 106.7, 135.9, 136.1, 157.2, 158.5, 159.5, 167.7, 167.8, 168.0, 168.1; MS analysis: calcd for 
C
44
H
46
N
4
O
11
, 806.32, found ES-MS 807.65 [M + H]+, 707.55 [(M – C
5
H
8
O
2
) + H]+; Elemental analysis: calcd 
for C
44
H
46
N
4
O
11
 C 65.50, H 5.75, N 6.94 found C 65.28, H 5.71, N 6.80.
tert-butyl 2,2’,2’’-(10-(2-(2-(3,5-bis(2-(3,5-bis(prop-2-ynyloxy)benzamido)ethoxy)benzamido)et
hylamino)-2-oxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (16): Compound 16 
was synthesized as described for 13 starting from 15 (242 mg, 0.30 mmol). After workup, the crude 
product was purified by column chromatography (eluens DCM/MeOH 98:2 v/v  DCM/MeOH 9:1 v/v) 
to yield a white solid (227 mg, 60%). M.p.: 108-114 °C; R
f
(CH
2
Cl
2
/MeOH 9:1 v/v): 0.30; R
t
: 19.70 min (C8); 
1H NMR (CDCl
3
) δ: 1.45 (s, 27H, (CH
3
)
3
 tBu), 2.04 – 4.50 (broad s, 36H, CH
2
 DOTA (24H)/~NH-CH
2
-CH
2
-
NH~(4H)/~O-CH
2
-CH
2
-NH~(8H)), 2.55 (s, 4H, CH), 4.72 (m, 8H, ~O-CH
2
), 6.60 (m, 1H, arom H4), 6.70 
(m, 2H, arom H2/H6), 7.18 – 7.33 (m, 6H, arom H2’/H4’/H6’), 7.80 (m, 2H, NH), 8.75 (m, 2H, NH); 13C 
_____  Chapter 4  _____________________________________________________________________________
86
_________________________   Synthesis of DOTA-conjugated multivalent cyclic RGD peptide dendrimers _____ 
87
NMR (CDCl
3
) δ: 27.9, 28.0, 38.8, 39.3, 39.7, 55.7, 55.9, 56.2, 66.5, 75.8, 76.0, 78.3, 82.0, 106.0, 106.3, 106.5, 
106.7, 136.3, 136.8, 158.6, 159.4, 166.7, 166.9, 171.5, 172.3; MS analysis: calcd for C
67
H
88
N
8
O
16
, 1260.63, 
found ES-MS 1261.75 [M + H]+; Elemental analysis: calcd for C
67
H
88
N
8
O
16
⋅H
2
SO
4
 C 59.19, H 6.67, N 8.24 
found C 59.60, H 6.82, N 7.71.
H-Asp(OtBu)-D-Phe-Lys(Boc)-Arg(Pbf)-Gly-O-2-chlorotrityl resin (17): The 2-chlorotrityl 
chloride resin was treated with SOCl
2
/CH
2
Cl
2
 (1:1 v/v; 2 × 6 mL, 10 min) to convert it completely into 
the chloride form prior loading of the first amino acid. To remove any residual SOCl
2
, the resin was 
extensively washed with CH
2
Cl
2
 (6 × 10 mL, 10 min). Then, Fmoc-Gly-OH (430 mg, 1.44 mmol) was 
dissolved in CH
2
Cl
2
 (10 mL) and DIPEA (510 µL, 2.88 mmol) followed by the 2-chlorotrityl chloride 
resin (360 mg (1 mmol/g), 0.36 mmol) were added and the obtained slurry was gently swirled for 2 h 
at room temperature. The resin was subsequently washed with CH
2
Cl
2
/MeOH/DIPEA (17:2:1 v/v/v; 3 × 
10 mL, 10 min) to cap any remaining linked tritylchloride, followed by CH
2
Cl
2
 (3 × 10 mL, 2 min), DMF 
(3 × 10 mL, 2 min) and CH
2
Cl
2
 (3 × 10 mL, 2 min). The loading of the resin, as calculated from an Fmoc 
determination, was 64% (0.64 mmol/g). The linear peptide sequence H-Asp(OtBu)-D-Phe-Lys(Boc)-
Arg(Pbf)-Gly-OH was synthesized according to the FastMoc solid-phase peptide synthesis protocols 
[31] and the final Fmoc-group was removed to obtain peptide resin 17.
cyclo(Arg-Gly-Asp-D-Phe-Lys) (18): Peptide resin 17 was treated twice with HFIP/CH
2
Cl
2
 (32 mL, 1:
4 v/v) for 45 min each to cleave the protected peptide acid from the resin. After this, the resin was 
washed with CH
2
Cl
2
 (3 × 20 mL, 10 min) and all fractions were collected and evaporated to dryness. 
The crude protected peptide acid (MS analysis: calcd for C
49
H
75
N
9
O
13
S, 1030.24, found ES-MS 1031.55 
[M + H]+) was obtained with 85% yield (202 mg, 0.20 mmol). This crude peptide was dissolved in 
CH
2
Cl
2
 (30 mL) and HOBt (30 mg, 0.20 mmol), BOP (41 mg, 0.20 mmol) followed by DIPEA (80 µL, 
0.45 mmol, 2.25 equiv) were added and the obtained reaction mixture was stirred for 16 h at room 
temperature. Subsequently, the solvent was partly removed by evaporation and the oily residue was 
dissolved in CHCl
3
 (50 mL) and washed with 1N KHSO
4
 (3 × 20 mL), H
2
O (3 × 20 mL) and brine (3 × 
20 mL). After the final wash steps, the solvent was removed in vacuo a white solid was obtained. This 
compound was dissolved in TFA/H
2
O/TIS (10 mL; 95:2.5:2.5 v/v/v) and stirred for 3 h to remove the side 
chain protecting groups. The crude cyclic peptide was isolated by precipitation with MTBE/hexane 1:
1 v/v at −20°C. After centrifugation, the pellet was dissolved in tert-BuOH/H
2
O 1:1 v/v, lyophilized and 
subsequently purified by HPLC (C8). Cyclic peptide 18 was obtained in 42% (51 mg) yield. R
t
: 9.97 min 
(C4); R
t
: 15.26 min (CN); MS analysis: calcd for C
27
H
41
N
9
O
7
, 603.31, found ES-MS 604.60 [M + H]+.
N-ε-azido cyclo(Arg-Gly-Asp-D-Phe-Lys) (19): Cyclic peptide 18 (200 mg, 0.33 mmol) was dissolved 
in tert-BuOH/H
2
O (5 mL; 1:1 v/v) and the pH was adjusted to 10 by the addition of 1N NaOH. To this 
solution were added: CuSO
4
.5H
2
O (8 mg, 0.03 mmol, 0.1 equiv) and a solution of triflic azide (587 mg, 
3.3 mmol, 10 equiv) in CH
2
Cl
2
 (freshly prepared from triflic anhydride (555 µL, 3.3 mmol, 10 equiv) 
and NaN
3
 (975 mg, 15 mmol, 4.5 equiv) in CH
2
Cl
2
/H
2
O (13 mL; 10:3 v/v) [27]. The obtained two-phase 
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reaction mixture was firmly stirred for 16 h at room temperature. Then, the solvents were removed 
by evaporation and the residue was mixed with tert-BuOH/H
2
O and subsequently lyophilized to yield 
202 mg (97%) crude reaction product. Pure azido peptide 19 was obtained in 21% yield (44 mg) after 
purification by HPLC (C8). R
f
(CHCl
3
/MeOH/AcOH 90:20:3 v/v/v): 0.25; R
t
: 16.81 min (C4); R
t
: 17.33 min 
(CN); FTIR (KBr) υ: 2100 cm-1; 1H NMR (500 MHz, H
2
O/D
2
O 9:1 v/v, 293 K, 6.4 mM, pH 4): Arg, δ: 1.43 
(m, 2H, γCH
2
), 1.65/1.86 (double m, 2H, βCH
2
), 3.18 (m, 2H, δCH
2
), 4.36 (m, 1H, αCH), 7.20 (t (J 5.8 Hz), 
1H, δNH), 8.04 (d (J 8.7 Hz), 1H, αNH); Gly, δ: 3.49 (dd (J 4.5 Hz, J 14.8 Hz), 1H, αCH
2
), 4.21 (dd (J 7.7 Hz, 
J 14.8 Hz), 1H, αCH
2
), 8.33/8.36 (dd, (J 4.7 Hz, J 7.4 Hz), 1H, αNH); Asp, δ: 2.63/2.66 (dd (J 6.7 Hz, J 16.4 
Hz), 1H, βCH
2
), 2.79/2.83 (dd (J 7.7 Hz, J 16.4 Hz), 1H, βCH
2
), 4.73 (m, 1H, αCH), 8.12 (d, (J 8.8 Hz), 1H, 
αNH); D-Phe, δ: 2.93/2.98 (dd (J 10.3 Hz, J 13.2 Hz), 1H, βCH
2
), 3.07/3.10 (dd (J 5.9 Hz, J 13.2 Hz), 1H, 
βCH
2
), 4.45 (m, 1H, αCH), 7.25 (d (J 7.3 Hz), 2H, arom H), 7.33-7.38 (m, 3H, arom H), 8.42 (d (J 5.9 Hz), 
1H, αNH); azido Lys, δ: 0.95 (m, 2H, γCH
2
), 1.46/1.65 (double m, 2H, βCH
2
), 1.49 (m, 2H, δCH
2
), 3.24 (t 
(J 7.1 Hz), 2H, εCH
2
), 3.85 (m, 1H, αCH), 8.44 (d (J 5.6 Hz), 1H, αNH); 13C NMR (H
2
O/D
2
O 9:1 v/v, 293 K, 
6.4 mM, pH 4): Arg, δ: 29.8 γC, 30.0 βC, 43.3 δC, 55.2 αC, 176.0 αCO, 176.3 guanidino C; Gly, δ: 46.3 αC, 
172.9 αCO; Asp, δ: 38.5 βC, 52.9 αC, 175.1 αCO, 178.6 βCO; D-Phe, δ: 39.6 βC, 58.1 αC, 130.0 arom CH, 
131.5 arom CH, 131.9 arom CH, 138.8 arom qC, 176.5 αCO; azido Lys, δ: 25.1 γC, 27.2 δC, 32.6 βC, 53.3 
εC, 58.2 αC, 177.9 αCO; MS analysis: calcd for C
27
H
39
N
11
O
7
, 629.30, found ES-MS 630.55 [M + H]+, 652.70 
[M + Na]+, 668.25 [M + K]+.
General procedure for the microwave-assisted click reaction: [22] the alkyne (1 equiv) and the 
azide (1.3 equiv per arm) were dissolved in DMF/H
2
O. To this solution, CuSO
4
.5H
2
O (0.05 equiv) 
and Na-ascorbate (0.50 equiv) were added. The reaction mixture was placed in a microwave reactor 
and irradiated during 10 – 30 min at 100°C. The cycloaddition was monitored on TLC and LC-MS for 
completion of the reaction.
monovalent cyclo[RGDfK] peptide dendrimer (20): Alkyne 2 (1.3 mg, 6.6 µmol) and azido peptide 
19 (5.4 mg, 7.3 µmol, 1.1 equiv) were dissolved in DMF (500 µL) and 0.05 M Na-ascorbate (66 µL, 
3.3 µmol, 0.50 equiv) followed by 6 mM CuSO
4
.5H
2
O (55 µL, 0.33 µmol, 0.05 equiv) were added. The 
reaction mixture was placed in the microwave reactor and irradiated for 30 min at 100°C. Then, the 
solvents were removed under reduced pressure and the residue was dissolved in tert-BuOH/H
2
O 1:1 v/v 
and lyophilized and subsequently purified by semi-prep HPLC (C18). Yield: 3.1 mg (57%). R
t
: 18.85 min 
(CN); MS analysis: calcd for C
38
H
49
N
11
O
10
, 819.366, found ES-MS 820.60 [M + H]+, found MALDI-TOF 
820.641 [M + H]+, 842.620 [M + Na]+.
divalent cyclo[RGDfK] peptide dendrimer (21): For this synthesis, alkyne 3 (0.8 mg, 3.3 µmol) 
and azido peptide 19 (6.3 mg, 8.5 µmol, 1.3 equiv) were used. After purification by semi-prep HPLC 
compound 21 was obtained with 40% yield (1.9 mg). R
t
: 18.97 min (C4); R
t
: 20.30 min (CN); MS analysis: 
calcd for C
68
H
90
N
22
O
18
, 1502.680, found MALDI-TOF 1503.646 [M + H]+.
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tetravalent cyclo[RGDfK] peptide dendrimer (22): For this synthesis, alkyne 7 (1.10 mg, 1.6 µmol) 
and azido peptide 19 (6.3 mg, 8.5 µmol, 1.3 equiv) were used. After purification by semi-prep HPLC 
compound 22 was obtained with 14% yield (0.7 mg). R
t
: 21.23 min (CN); MS analysis: calcd for 
C
146
H
190
N
46
O
38
, 3195.435 (M
ave
), found MALDI-TOF 3196.573 [M + H]
ave
+.
DOTA-conjugated monovalent cyclo[RGDfK] peptide dendrimer (23): Alkyne 13 (5.5 mg, 7.1 µmol) 
and azido peptide 19 (6.0 mg, 8.1 µmol, 1.1 equiv) were dissolved in DMF (500 µL) and 0.05 M Na-
ascorbate (72 µL, 3.6 µmol, 0.50 equiv) followed by 6 mM CuSO
4
.5H
2
O (60 µL, 0.36 µmol, 0.05 equiv) 
were added. The reaction mixture was placed in the microwave reactor and irradiated for 3 × 5 min 
at 100°C. Then, the solvents were removed under reduced pressure and the residue was dissolved in 
tert-BuOH/H
2
O 1:1 v/v and lyophilized. The obtained fluffy solid was dissolved in TFA/H
2
O (1 mL; 95:
5 v/v) and stirred for 4 h at room temperature. Subsequently, the reaction mixture was concentrated 
in vacuo and the residue was redissolved in tert-BuOH/H
2
O 1:1 v/v, lyophilized and purified by semi-
prep HPLC (C18) to give compound 23 in 13% yield (1.1 mg). R
t
: 10.27 min (C18); MS analysis: calcd for 
C
55
H
79
N
17
O
16
, 1234.340 (M
ave
), found MALDI-TOF 1234.807 [M + H]
ave
+.
DOTA-conjugated divalent cyclo[RGDfK] peptide dendrimer (24) [28]: Alkyne 14 (4.9 mg, 5.9 
µmol) and azido peptide 19 (11 mg, 14.8 µmol, 1.3 equiv) were dissolved in DMF/2,6-lutidine (1 mL, 
7:3 v/v) and to this solution the following reagents were subsequently added: CuOAc (1.8 mg, 14.7 
µmol, 2.5 equiv), Na-ascorbate (5.9 mg, 29.8 µmol, 5.1 equiv) and DIPEA (9.8 µL, 7.1 µmol, 1.2 equiv). 
The obtained reaction mixture was heated by microwave irradiation to 100°C for 3 × 5 min. Then, the 
solvents were removed under reduced pressure and the residue was dissolved in tert-BuOH/H
2
O 1:1 v/v 
and lyophilized. The obtained fluffy solid was dissolved in TFA/H
2
O (1 mL; 95:5 v/v) and stirred for 4 h 
at room temperature. Subsequently, the reaction mixture was concentrated in vacuo and the residue 
was redissolved in tert-BuOH/H
2
O 1:1, lyophilized and purified by semi-prep HPLC (C18) to obtain 
compound 24 in 11% yield (1.3 mg). R
t
: 12.08 min (C18); MS analysis: calcd for C
85
H
120
N
28
O
24
, 1918.067 
(M
ave
), found MALDI-TOF 1918.516 [M + H]
ave
+.
DOTA-conjugated tetravalent cyclo[RGDfK] peptide dendrimer (25): Alkyne 16 (3.8 mg, 3.0 µmol) 
and azido peptide 19 (11 mg, 14.8 µmol, 1.2 equiv) were dissolved in DMF (500 µL) and to this solution, 
0.05 M Na-ascorbate (30 µL, 1.5 µmol, 0.50 equiv) followed by 6 mM CuSO
4
.5H
2
O (25 µL, 0.15 µmol, 
0.05 equiv) were added. The obtained reaction mixture was heated by microwave irradiation to 100°C 
for 2 × 5 min. Then, the solvents were removed under reduced pressure and the residue was dissolved 
in tert-BuOH/H
2
O 1:1 v/v and lyophilized. The obtained fluffy solid was dissolved in TFA/H
2
O (1 mL; 95:
5 v/v) and stirred for 4 h at room temperature. Subsequently, the reaction mixture was concentrated 
in vacuo and the residue was redissolved in tert-BuOH/H
2
O 1:1 v/v, lyophilized and purified by semi-
prep HPLC (C18) to give compound 25 in 36% yield (3.9 mg). R
t
: 11.6 min (C18); MS analysis: calcd for 
C
163
H
220
N
52
O
44
, 3611.873 (M
ave
), found MALDI-TOF 3612.530 [M + H]
ave
+.
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Abstract
Due to selective expression of α
v
β
3
 integrin in tumors, radiolabeled RGD peptides are attractive 
candidates for tumor targeting. Minor modifications of these peptides could have major impact on 
the in vivo characteristics. In this study, the effect of linker modification between two cyclic RGD 
sequences and DOTA on the in vitro and in vivo characteristics of the tracer was systematically 
investigated.
Methods: A dimeric RGD peptide was synthesized and conjugated either directly with DOTA or 
via different linkers: PEG
4
, glutamic acid, and lysine. The RGD peptides were radiolabeled with 111In 
and their in vitro and in vivo α
v
β
3
 binding characteristics were determined.
Results: LogP values varied between -2.82 ± 0.06 and –3.95 ± 0.33. IC
50
 values for DOTA-E-
[c(RGDfK)]
2
, DOTA-PEG
4
-E-[c(RGDfK)]
2
, DOTA-E-E-[c(RGDfK)]
2
, and DOTA-K-E-[c(RGDfK)]
2
 were 
comparable. 2 h p.i. Tumor uptake of the 111In-labeled compounds was not significantly different. 
Kidney accumulation of 111In-DOTA-K-E-[c(RGDfK)]
2
 (4.05 ± 0.20 %ID/g) was significantly higher 
compared to 111In-DOTA-E-[c(RGDfK)]
2
 (2.63 ± 0.19 %ID/g, P<0.05) and 111In-DOTA-E-E-
[c(RGDfK)]
2
 (2.16 ± 0.21 %ID/g, P<0.01). Liver uptake of 111In-DOTA-E-E-[c(RGDfK)]
2
 (2.12 ± 0.09 
%ID/g) was significantly higher compared to 111In-DOTA-E-[c(RGDfK)]
2
 (1.64 ± 0.1 %ID/g, P<0.05) 
and 111In-DOTA-K-E-[c(RGDfK)]
2
 (1.52 ± 0.04 %ID/g, P<0.01).
Conclusions: Linker variation did not affect the affinity for α
v
β
3
 and the tumor uptake. Insertion 
of K caused enhanced kidney retention, while insertion of E resulted in enhanced retention in the 
kidneys. PEG
4
 appeared to be the most suitable linker compared to E and K, because of the highest 
tumor-to-blood ratio and the lowest uptake in kidney and liver.
Introduction
Integrins are a group of adhesion molecules consisting of two non-covalently bound subunits, α 
and β. They are involved in signal transduction as well as in cell/cell- and cell/matrix-interactions 
[1]. A prominent member of this receptor class is the α
v
β
3
 integrin. The α
v
β
3
 integrin
 
is preferentially 
expressed on proliferating endothelial cells [2], whereas it is absent on quiescent endothelial cells. 
For growth beyond the size of 1-2 mm in diameter, tumors require the formation of new blood 
vessels. Consequently, α
v
β
3
 expression on tumor vasculature is considered to be a marker of 
tumor-induced angiogenesis [3-5]. In addition, α
v
β
3
 is expressed on the cell membrane of various 
tumor cell types. Due to this restricted expression of α
v
β
3
 in tumors, α
v
β
3
 is considered a suitable 
target for tumor targeting [6]. This α
v
β
3
 integrin interacts with the arginine-glycine-aspartic acid 
(RGD) amino acid sequence present in extracellular matrix proteins such as vitronectin, fibrinogen, 
and laminin [7]. Based on the RGD tripeptide sequence a series of small cyclic peptides have been 
designed that have a high and specific affinity for the α
v
β
3
 integrin [8]. Several radiolabeled RGD 
peptides as radiopharmaceuticals for SPECT and PET imaging applications have been developed 
to visualize and quantify α
v
β
3
 expression non-invasively [9, 10].
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It is important for a peptide-based radiopharmaceutical to clear rapidly from the blood and non-
target organs, preferably via the kidneys. One method to modify the route and rate of excretion of 
these peptides is glycosylation. For example, the radioiodinated RGD peptide [125I]-3-iodo-D-Tyr4-
cyclo(-Arg-Gly-Asp-D-Tyr-Val-) cleared mainly via the hepatobiliary route, which limited its further 
application [11]. Glycosylation of this compound resulted in a more hydrophilic compound that 
cleared mainly via the renal route [12]. The hydrophilicity of peptides can also be enhanced by 
linking them to polyethylene glycol (PEG) chains, an approach called PEGylation. Furthermore, 
peptides can be modified by introduction of specific hydrophilic or lipophilic amino acids into 
the peptide chain [13]. In addition, by altering the overall charge of a peptide by inserting basic or 
acidic amino acids, the route of excretion and/or kidney retention can be modified. Modification 
of a peptide by PEGylation, glycosylation or addition or substitution of amino acids could affect 
the affinity of a peptide for the receptor.
To improve the efficacy of tumor targeting and to obtain better in vivo imaging properties, 
several research groups have applied multivalent RGD peptides to enhance the targeting between 
the ligand and the α
v
β
3
 expressing tumor. In a previous study, we demonstrated enhanced tumor 
retention of a dimeric RGD peptide compared to its monomeric counterpart [14].
The aim of the present study is to systematically study the effect of modification of the linker 
between the two cyclic RGD sequences and the DOTA chelator on the in vitro and in vivo 
characteristics. To investigate the effect of a hydrophilic linker, PEG
4
 was used as a linker. Furthermore, 
to investigate the effect of charge the amino acids glutamic acid and lysine were inserted as a linker, 
because of their different charge under physiological conditions. Here, we synthesized a dimeric RGD 
peptide and conjugated this peptide either directly to 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-
tetraacetic acid (DOTA) or via a hydrophilic, acidic, or basic linker: PEG
4
, glutamic acid, or lysine, 
respectively. Subsequently, the RGD peptides were radiolabeled with 111In and the in vivo tumor 
targeting characteristics of the peptides to α
v
β
3
 expressing tumors were determined.
Materials and methods
Synthesis of DOTA-conjugated RGD peptides
The synthesis of the dimeric cyclic RGD peptide E-[c(RGDfK)]
2
 conjugated with DOTA was described 
previously [15]. For the coupling of each of the linkers to E-[c(RGDfK)]
2
, (0.51 mmol) of Boc-PEG
4
-
OH, Boc-Glu(OtBu)-OH, or H-Lys(Boc)-OH and 57.4 mg (0.50 mmol) N-hydroxysuccinimide were 
placed in a rondbottom flask. Then, 109 mg (0.53 mmol) 1,3-Dicyclohexylcarbodiimide (DCC) 
was dissolved in 5 mL dichloromethane (DCM) and added to each of the Boc-protected linker and 
N-hydroxysuccinimide (HOSu). After stirring for 2 h at room temperature, the reaction mixtures 
were concentrated in vacuo and the residues were titurated in EtOAc. These were filtrated and the 
filtrates were concentrated in vacuo. The residues were redissolved in 5 mL DCM. The unprotected 
dimeric RGD peptide, E-[c(RGDfK)]
2
, and 131 µL N,N-diisopropylethylamine (DiPEA) (0.75 mmol) 
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were dissolved in 5 mL dimethylformamide (DMF). Subsequently, this mixture was added to each 
of the Boc-protected succinimydyl ester dissolved in 5 mL DCM.
DOTA-conjugation
The protected compounds were deprotected by dissolving the compound in DCM/trifluoroacetic 
acid (TFA; 1:1). After stirring for 2.5 h at room temperature, the reaction mixtures were concentrated 
in vacuo and coevaporated with CHCl
3
. 84.8 mg (0.22 mmol) 2-(1H-benzotriazol-1-yl) -1,1,3,3-
tetramethyluroniumhexafluorophosphate (HBTU) and 70 µL (0.40 mmol) DiPEA were dissolved 
in 10 mL dry DMF. 1 mL of this solution was added to 14 mg (24 µmol) DOTA-tris(tertBu) 
(Macrocyclics, Dallas, TX, USA) and stirred for 5 minutes at room temperature. PEG
4
-E-[c(RGDfK)]
2
, 
E-E-[c(RGDfK)]
2
 or K-E-[c(RGDfK)]
2
 was added and the mixtures were stirred for 4.5 h under nitrogen 
at room temperature. Then, the reaction mixture was concentrated in vacuo and the residue was 
dissolved in 4.75 mL TFA and 250 µL H
2
O for deprotection of the Boc-group. These reaction mixture 
were stirred under nitrogen for 5 h. Subsequently, the reaction mixtures were concentrated in vacuo 
and the residues were dissolved in MeCN/H
2
O (1/1) and lyophilized to afford a fluffy solid. The 
crude DOTA-conjugated PEG
4
-E-[c(RGDfK)]
2
, E-E-[c(RGDfK)]
2
, and K-E-[c(RGDfK)]
2
 were purified 
by preparative RP-HPLC and analyzed by analytical HPLC and mass spectrometry. The structures of 
the DOTA-conjugated RGD peptide analogs are shown in Figure 1.
Figure 1. Structural formula of the DOTA-conjugated dimeric RGD peptide, DOTA-E-[c(RGDfK)]
2
 (A), and its analogs 
containing different linkers: DOTA-PEG
4
-E-[c(RGDfK)]
2
 (B), DOTA-E-E-[c(RGDfK)]
2
 (C), and DOTA-K-E-[c(RGDfK)]
2
 (D).
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Radiolabeling of the RGD peptides
DOTA-E-[c(RGDfK)]
2
 was radiolabeled with InCl
3
 by adding 20.2 MBq InCl
3
 (Mallinckrodt, Petten, 
The Netherlands) to 28 µg (16.4 nmol) DOTA-E-[c(RGDfK)]
2
 dissolved in 500 µL 0.5 M ammonium 
acetate buffer pH 6.0, containing 0.6 mg/mL gentisic acid. The compounds containing the linkers 
were radiolabeled analogously with minor modifications. These compounds were prepared 
by adding 7.4 to 11.1 MBq InCl
3
 to 5.1 to 8.2 nmol of DOTA-PEG
4
-E-[c(RGDfK)]
2
, DOTA-E-E-
[c(RGDfK)]
2
, or DOTA-K-E-[c(RGDfK)]
2
 dissolved in 200 to 300 µL ammonium acetate buffer, pH 
6.0, containing 0.6 mg/mL gentisic acid. 
The reaction mixtures were degassed and subsequently the mixtures were heated at 100 ºC for 
15 minutes. 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
, and 111In-DOTA-K-E-[c(RGDfK)]
2
 were further purified 
on a C-18 SepPak cartridge (Waters, Milford, MA). After applying the sample on the methanol-
activated cartridge, the cartridge was washed with 5 mL 25 mM ammonium acetate and eluted with 
5 mL 25% acetonitrile in 25 mM ammonium acetate. The radiochemical purity was determined by 
reversed-phase high-performance liquid chromatography (RP-HPLC) (HP 1100 series, Hewlett 
Packard, Palo Alto, CA, USA) using a C18 column (RX-C18, 4.6 mm × 250 mm, Zorbax) eluted 
with a gradient mobile phase (8-20% B over 25 min or 8-100% B over 30 min, solvent A = 25 mM 
ammonium acetate buffer, solvent B = acetonitrile) at 1 mL/min. The radioactivity of the eluate was 
monitored using an in-line radiodetector (Flo-One Beta series, Radiomatic, Meriden, CT, USA).
Octanol-water partition coefficient
To determine the lipophilicity of 111In-DOTA-E-[c(RGDfK)]
2
, 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
, 111In-
DOTA-E-E-[c(RGDfK)]
2
, and 111In-DOTA-K-E-[c(RGDfK)]
2
, approximately 300,000 cpm of each of 
the preparations were diluted with phosphate-buffered saline (PBS) to a total volume of three mL. 
An equal volume of octanol was added and the resulting biphasic system was mixed vigorously for 
one minute and gently for another ten minutes. The two phases were separated by centrifugation 
(5 min, 1000 rpm) and the counts in 250 µL aliquots (n=3) of the organic and the inorganic layer 
were determined by use of a γ-counter (1480 Wizard, Wallac, Turku, Finland). The logP values of 
the compounds were determined in at least two independent experiments.
Solid-phase αvβ3 binding assay
The affinity of DOTA-E-[c(RGDfK)]
2
, DOTA-PEG
4
-E-[c(RGDfK)]
2
, DOTA-E-E-[c(RGDfK)]
2
, and 
DOTA-K-E-[c(RGDfK)]
2
 for α
v
β
3
 was determined using a solid-phase competitive binding assay. 
111In-labeled DOTA-E-[c(RGDfK)]
2
 (3 MBq/µg) was prepared as described above and was used 
as the tracer in this assay. Microtiter 96-well vinyl assay plates (Corning B.V., Schiphol-Rijk, The 
Netherlands) were coated with 100 µL/well of a solution of purified human integrin α
v
β
3
 (150 
ng/mL) in Triton X-100 Formulation (Chemicon International, Temecula, CA, USA) in coating 
buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl
2
, 0.5 mM MgCl
2
 and 1 mM MnCl
2
) for 
17 h at 4 ºC. The plates were washed twice with binding buffer (0.1% bovine serum albumin (BSA) 
in coating buffer). The wells were blocked for 2 h with 200 µL blocking buffer (1% BSA in coating 
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buffer) at room temperature. The plates were washed twice with binding buffer. Then 100 µL 
binding buffer containing 11.1 kBq of 111In-DOTA-E-[c(RGDfK)]
2
 and appropiate dilutions of non-
labeled DOTA-E-[c(RGDfK)]
2
, DOTA-PEG
4
-E-[c(RGDfK)]
2
, DOTA-E-E-[c(RGDfK)]
2
, and DOTA-K-
E-[c(RGDfK)]
2
 in binding buffer were incubated in the wells at 37 ºC for 1 h. After incubation, 
the plates were washed three times with binding buffer. The retained radioactivity in each well 
was determined in a γ-counter. IC
50
 values of the RGD peptides were calculated by non-linear 
regression using GraphPad Prism (GraphPad Prism 4.0 Software, San Diego, CA, USA). Each data 
point is the average of three determinations. K
i
 values were calculated from IC
50
 values using the 
Cheng-Prusoff equation as described by Cheng [16, 17]. The Hill slope (K) of DOTA-E-[c(RGDfK)]
2
 
concentration-response curve was 0.6.
Biodistribution studies
In the right flank of 6-8 weeks old female nude BALB/c mice, 0.2 mL of a cell suspension of 10 × 
106 cells/mL SK-RC-52 cells was injected subcutaneously (s.c.). Two weeks after inoculation of the 
tumor cells mice were randomly divided into four groups (3 mice/group).
Mice received 0.5 µg/mouse of 111In-DOTA-E-[c(RGDfK)]
2
 (0.38 MBq), 111In-DOTA-PEG
4
-E-
[c(RGDfK)]
2
 (0.48 MBq), 111In-DOTA-E-E-[c(RGDfK)]
2
 (0.36 MBq), or 111In-DOTA-K-E-[c(RGDfK)]
2
 
(0.29 MBq) via a tail vein. Mice were killed by CO
2
 asphyxiation 2 h postinjection (p.i.). Blood, 
tumor, and the major organs and tissues were collected, weighed, and counted in a γ-counter. 
The percentage injected dose per gram (%ID/g) was determined for each sample. All animal 
experiments were approved by the local animal welfare committee in accordance with the Dutch 
legislation and carried out in accordance with their guidelines.
Statistical analysis
All mean values are given ± standard deviation (S.D.). Statistical analysis was performed using the 
One-way Analysis of Variance. Bonferroni corrections for multiple comparisons were applied. The 
level of significance was set at P<0.05.
Results
Radiolabeling
The RP-HPLC elution profile of 111In-DOTA-E-[c(RGDfK)]
2
, 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
, 111In-
DOTA-E-E-[c(RGDfK)]
2
, and 111In-DOTA-K-E-[c(RGDfK)]
2
 showed a single peak for each of the four 
compounds with an elution time of 26 min, 29 min, and 22 min for 111In-DOTA-E-[c(RGDfK)]
2
, 
111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
, and 111In-DOTA-E-E-[c(RGDfK)]
2
, respectively. The retention time 
of 111In-DOTA-K-E-[c(RGDfK)]
2 
was 14 min. Note that different gradients were used for elutions.
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Octanol-water partition coefficient
All the compounds were relatively hydrophilic, as indicated from octanol-water partition 
coefficient measurements. The dimeric RGD peptide with no additional linker was the most 
hydrophilic compound. The PEGylated dimeric RGD peptide was the most hydrophobic 
compound. LogP values for 111In-DOTA-E-[c(RGDfK)]
2
, 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
, 111In-
DOTA-E-E-[c(RGDfK)]
2
, and 111In-DOTA-K-E-[c(RGDfK)]
2
 are given in Table 1.
Table 1. The LogP values of 111In-DOTA-E-[c(RGDfK)]
2
, 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
, 111In-DOTA-E-E-[c(RGDfK)]
2
, and 
111In-DOTA-K-E-[c(RGDfK)]
2
.
Compound LogP value
DOTA-E-[c(RGDfK)]
2
-3.95 ± 0.33
DOTA-PEG
4
-E-[c(RGDfK)]
2
-2.82 ± 0.06
DOTA-E-E-[c(RGDfK)]
2
-3.55 ± 0.03
DOTA-K-E-[c(RGDfK)]
2
-3.06 ± 0.13
Solid-phase αvβ3 binding assay
The affinity of DOTA-E-[c(RGDfK)]
2
, DOTA-PEG
4
-E-[c(RGDfK)]
2
, DOTA-E-E-[c(RGDfK)]
2
, and 
DOTA-K-E-[c(RGDfK)]
2
 for the α
v
β
3
 integrin was determined in a competitive binding assay. The 
results of these assays are summarized in Figure 2. 
Figure 2. Competition of specific binding of 111In-DOTA-E-[c(RGDfK)]
2
 with DOTA-E-[c(RGDfK)]
2
 (), DOTA-PEG
4
-E-
[c(RGDfK)]
2
 (), DOTA-E-E-[c(RGDfK)]
2
 (), and DOTA-K-E-[c(RGDfK)]
2
 ().
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Binding of 111In-labeled dimeric peptide, 111In-DOTA-E-[c(RGDfK)]
2
, to α
v
β
3
 was competed 
by DOTA-E-[c(RGDfK)]
2
, DOTA-PEG
4
-E-[c(RGDfK)]
2
, DOTA-E-E-[c(RGDfK)]
2
, and DOTA-K-E-
[c(RGDfK)]
2
 in a concentration dependent manner. The IC
50
 values were 69.9 nM for DOTA-E-
[c(RGDfK)]
2
, 66.8 nM for DOTA-PEG
4
-E-[c(RGDfK)]
2
, 129.5 nM for DOTA-E-E-[c(RGDfK)]
2
, and 
51.9 nM for DOTA-K-E-[c(RGDfK)]
2
. Calculated K
i
 values using Cheng-Prusoff equation were 1.63 
nM for DOTA-E-[c(RGDfK)]
2
, 1.56 nM for DOTA-PEG
4
-E-[c(RGDfK)]
2
, 3.01 nM for DOTA-E-E-
[c(RGDfK)]
2
, and 1.21 nM for DOTA-K-E-[c(RGDfK)]
2
.
Biodistribution studies 
The results of the biodistribution studies of 111In-DOTA-E-[c(RGDfK)]
2
, 111In-DOTA-PEG
4
-E-
[c(RGDfK)]
2
, 111In-DOTA-E-E-[c(RGDfK)]
2
, and 111In-DOTA-K-E-[c(RGDfK)]
2
 in athymic mice with 
s.c. SK-RC-52 tumors at 2 h p.i. are summarized in Table 2. All compounds cleared rapidly from the 
blood and had similar uptake in the tumor at 2 h p.i. (4.65 ± 0.33 %ID/g, 5.15 ± 1.05 %ID/g, 4.36 
± 0.95 %ID/g, and 4.04 ± 0.05 %ID/g, respectively). Coinjection of an excess of non-radiolabeled 
DOTA-E-[c(RGDfK)]
2
 with 111In-DOTA-E-[c(RGDfK)]
2
, 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
, 111In-DOTA-
E-E-[c(RGDfK)]
2
, or 111In-DOTA-K-E-[c(RGDfK)]
2
 resulted in a significant decrease of radioactivity 
in tumor for all four compounds, indicating that uptake in the tumor is α
v
β
3
-mediated. In 
addition, uptake of all compounds in normal organs such as spleen, liver, intestine, and colon was 
significantly reduced in the presence of an excess non-radioactive DOTA-E-[c(RGDfK)]
2
, indicating 
that uptake in these organs is at least partly α
v
β
3
-mediated.
Table 2. Biodistribution data of 111In-DOTA-E-[c(RGDfK)]
2
, 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
, 111In-DOTA-E-E-[c(RGDfK)]
2
, 
and 111In-DOTA-K-E-[c(RGDfK)]
2
 in the presence and absence of an excess of unlabeled DOTA-E-[c(RGDfK)]
2
 (+ xs) in 
athymic mice with s.c. SK-RC-52 tumors 2 h after injection. The organ uptake is expressed as %ID/g.
No linker + xs PEG
4
+ xs E + xs K + xs
Blood 0.07 ± 0.01 0.02 0.10 ± 0.03 0.05 0.13 ± 0.30 0.07 0.13 ± 0.02 0.14
Muscle 0.48 ± 0.37 0.04 1.32 ± 1.40 0.61 0.29 ± 0.04 0.07 0.31 ± 0.04 1.78
Tumor 4.65 ± 0.33 0.58 5.15 ± 1.05 0.76 4.36 ± 0.95 0.53 4.04 ± 0.05 0.75
Lung 0.70 ± 0.04 0.17 1.43 ± 0.37 0.37 0.88 ± 0.05 0.19 0.92 ± 0.11 0.35
Spleen 1.56 ± 0.19 0.31 2.07 ± 0.50 0.62 1.78 ± 0.19 0.26 1.67 ± 0.16 0.47
Kidney 2.63 ± 0.19 1.86 3.23 ± 0.70 2.09 2.16 ± 0.21 1.86 4.05 ± 0.20 3.93
Liver 1.64 ± 0.10 0.30 1.75 ± 0.27 0.63 2.12 ± 0.09 0.29 1.52 ± 0.04 0.45
Intestine 4.87 ± 0.61 0.68 5.59 ± 0.49 0.78 3.99 ± 0.48 0.47 4.77 ± 0.14 0.78
Colon 1.89 ± 0.21 0.32 2.96 ± 0.52 0.29 3.10 ± 1.41 0.24 2.06 ± 0.29 0.55
At 2 h p.i. the blood activity of  111In-DOTA-E-E-[c(RGDfK)]
2
 and 111In-DOTA-K-E-[c(RGDfK)]
2
 was 
slightly higher compared to 111In-DOTA-E-[c(RGDfK)]
2
, resulting in a significantly higher tumor-to-
blood ratio for 111In-DOTA-E-[c(RGDfK)]
2
 (71.9 ± 6.80) compared to 111In-DOTA-E-E-[c(RGDfK)]
2
 
_____  Chapter 5  _____________________________________________________________________________
102
_______________________________________________   Influence of linker variation of a RGD peptide _____ 
103
(34.3 ± 8.88, P<0.001) and 111In-DOTA-K-E-[c(RGDfK)]
2
 (31.2 ± 4.29, P<0.001). In addition, the 
tumor-to-blood ratio of 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
 (54.5 ± 6.53) was significantly higher 
compared to 111In-DOTA-E-E-[c(RGDfK)]
2
 (P<0.05) and 111In-DOTA-K-E-[c(RGDfK)]
2
 (P<0.05).
The kidney uptake of 111In-DOTA-K-E-[c(RGDfK)]
2
 (4.05 ± 0.20 %ID/g) was significantly higher 
as compared to 111In-DOTA-E-[c(RGDfK)]
2
 (2.63 ± 0.19 %ID/g, P<0.05) and 111In-DOTA-E-E-
[c(RGDfK)]
2
 (2.16 ± 0.21 %ID/g, P<0.01). The liver uptake of 111In-DOTA-E-E-[c(RGDfK)]
2
 (2.12 ± 
0.09 %ID/g) was significantly higher as compared to 111In-DOTA-E-[c(RGDfK)]
2
 (1.64 ± 0.1 %ID/g, 
P<0.05) and 111In-DOTA-K-E-[c(RGDfK)]
2
 (1.52 ± 0.04 %ID/g, P<0.01).
Figure 3A. Tumor uptake of 111In-DOTA-E-[c(RGDfK)]
2
, 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
, 111In-DOTA-E-E-[c(RGDfK)]
2
, 
and 111In-DOTA-K-E-[c(RGDfK)]
2
 at 2 h p.i. in the presence (black bars) and absence (white bars) of an excess of non-
radiolabeled DOTA-E-[c(RGDfK)]
2
.
Figure 3B. Kidney uptake of 111In-DOTA-E-[c(RGDfK)]
2
, 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
, 111In-DOTA-E-E-[c(RGDfK)]
2
, 
and 111In-DOTA-K-E-[c(RGDfK)]
2
 at 2 h p.i.. Results are reflected as mean %ID/g ± SD. Values were analyzed using One-
way Analysis of Variance, * = P<0.05. P-value refers to difference in kidney uptake between 111In-DOTA-E-[c(RGDfK)]
2
 and 
111In-DOTA-K-E-[c(RGDfK)]
2
.
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Figure 3C. Liver uptake of 111In-DOTA-E-[c(RGDfK)]
2
, 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
, 111In-DOTA-E-E-[c(RGDfK)]
2
, and 
111In-DOTA-K-E-[c(RGDfK)]
2
 at 2 h p.i.. Results are reflected as mean %ID/g ± SD. Values were analyzed using One-way 
Analysis of Variance, * = P<0.05. P-value refers to difference in liver uptake between 111In-DOTA-E-[c(RGDfK)]
2
 and 111In-
DOTA-E-E-[c(RGDfK)]
2
.
Discussion
In this study the effect of the modification of the linker between a dimeric RGD peptide and the 
chelator DOTA on the in vitro and in vivo characteristics was investigated.
A prominent difference in renal handling between the RGD peptide containing the glutamic 
acid residue and the RGD peptide containing the lysine residue was observed in this study. The 
incorporation of a positively charged lysine residue between the DOTA-moiety and the dimeric 
RGD peptide E-[c(RGDfK)]
2
, resulted in increased kidney uptake. This is in line with the reports 
that in general, positively charged peptides are more efficiently reabsorbed in the proximal 
renal tubular cells [18]. This would suggest that the uptake in the kidneys could be reduced 
by introducing negatively charged amino acids in the RGD peptide. However, in this study the 
RGD peptide containing the glutamic acid linker showed similar renal accumulation compared 
to the native dimeric RGD peptide E-[c(RGDfK)]
2
. Recently, Béhé and coworkers demonstrated 
that removal of glutamic acid residues 2-5 could reduce the high renal uptake of 111In-DTPA-D-
Glu1-minigastrin [19]. Apparently, the tubular reabsorption of a peptide is very subtle. However, 
it has been shown by Akiziwa and coworkers that the substitution of only one amino acid in 
111In-DTPA-octreotide derivatives significantly affected the renal accumulation of the peptides 
[20]. 111In-DOTA-E-E-[c(RGDfK)]
2
 had a significantly higher liver uptake compared to 111In-DOTA-
E-[c(RGDfK)]
2
 and 111In-DOTA-K-E-[c(RGDfK)]
2
. However, 111In-DOTA-E-E-[c(RGDfK)]
2
 was more 
hydrophilic, as indicated from its octanol-water partition coefficient (logP = -3.55 ± 0.03). In this 
study, the accumulation in the kidneys of each of the RGD peptides is low compared to that 
of other 111In-labeled peptides. For example, in mice the uptake of 111In-DTPA-octreotide in the 
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kidney at 2 h p.i. exceeds 25 %ID/g [21]. Apparently, the RGD peptides used in our study are not 
efficiently reabsorbed in the renal tubular cells.
The peptides containing glutamic acid or lysine as a linker demonstrated a significantly higher 
blood activity and concomitant lower tumor-to-blood ratios compared to the native peptide. 
Introduction of the PEG
4
 linker did not significantly affect the tumor-to-blood ratio compared to 
the native dimeric RGD peptide. Recently, Chen et al. showed similar blood clearance for a 64Cu-
labeled dimeric RGD peptide, 64Cu-DOTA-E-[c(RGDyK)]
2
 compared to its PEGylated counterpart, 
64Cu-DOTA-PEG-E-[c(RGDyK)]
2
 [22]. However, for the monomeric RGD peptide, the PEGylated 
analog 64Cu-DOTA-PEG-RGD showed a more rapid blood clearance than 64Cu-DOTA-RGD [23]. 
Probably, the effect of PEGylation is more pronounced in a smaller molecule.
The binding affinity of DOTA-PEG
4
-E-[c(RGDfK)]
2
, DOTA-E-E-[c(RGDfK)]
2
, and DOTA-K-E-
[c(RGDfK)]
2
 was similar to that of the lead compound DOTA-E-[c(RGDfK)]
2
, indicating that 
introduction of a PEG
4
 moiety, glutamic acid residue, or lysine residue did not affect the affinity 
for the α
v
β
3
 integrin. The K
i
 values of all four compounds are in the single digit nanomolar range, 
indicating that these compounds have a relatively high affinity for the α
v
β
3
 integrin.
In conclusion, this study demonstrates that optimization of a dimer RGD peptide for α
v
β
3
 
targeting by systematic linker variation can alter the in vivo kinetics of the tracers, without 
influencing the α
v
β
3
 targeting potential. Results suggest that 111In-DOTA-PEG
4
-E-[c(RGDfK)]
2
 and 
111In-DOTA-E-E-[c(RGDfK)]
2
 are the most suitable ligands for α
v
β
3
 targeting because of the highest 
tumor-to-blood ratio and the lowest uptake in kidney and liver.
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Abstract
Ovarian cancer is the fourth most common cause of cancer deaths among females in the Western 
world after cancer of the breast, colon and lung. The inability to control the disease within the 
peritoneal cavity is the major cause of treatment failure in patients with ovarian cancer. The 
majority of ovarian carcinomas express the α
v
β
3
 integrin. Here we studied the tumor targeting 
potential of an 111In-labeled cyclic RGD peptide in athymic BALB/c mice with intraperitoneally 
(i.p.) growing NIH:OVCAR-3 human ovarian carcinoma tumors.
Methods: The cyclic RGD peptide, c(RGDfK)E, was synthesized, conjugated with DOTA, and 
radiolabeled with 111In. The targeting potential of 111In-DOTA-E-c(RGDfK) was studied in athymic 
mice with i.p. growing NIH:OVCAR-3 xenografts and the optimal dose of this compound was 
determined (0.01 µg up to 10 µg). The biodistribution at optimal peptide dose was determined 
at various time points (0.5 up to 72 h). Furthermore, the therapeutic potential of 177Lu-DOTA-E-
c(RGDfK) was studied in this model.
Results: Two hours after i.p. administration, 111In-DOTA-E-c(RGDfK) showed high and specific 
uptake in the i.p. growing tumors. Optimal uptake in the i.p. growing tumors was observed at a 
0.03-0.1 µg dose range. Tumor uptake of 111In-DOTA-E-c(RGDfK) peaked 4 h p.i. (38.8 ± 2.7 %ID/g), 
gradually decreasing at later time points (24.0 ± 4.1 %ID/g at 48 h p.i.).
Conclusions: I.p. growth of OVCAR-3 could be significantly delayed by injecting 37 MBq 177Lu-
labeled peptide i.p.. Radiolabeled DOTA-E-c(RGDfK) is suitable for targeting of i.p. growing tumors 
and potentially can be used for peptide-receptor radionuclide therapy of these tumors.
Introduction
Ovarian cancer remains the most lethal gynecological malignancy in the Western world [1]. About 
90% of ovarian cancer originates from malignant transformation of the ovarian surface epithelium 
and in most patients the disease is diagnosed in an advanced stage [2]. Most patients with stage 
III and IV ovarian cancer achieve a clinical complete remission after cytoreductive surgery and 
combination chemotherapy. Unfortunately, in the majority of these patients the disease relapses 
[3].  Over the past 25 years the principal treatment of advanced ovarian cancer has been surgery 
followed by chemotherapy. At the moment, paclitaxel combined with cisplatin or carboplatin is 
the standard first-line treatment in most countries [4], resulting in response rates of 70 to 80%. In 
comparison with former regimens, response rates have ameliorated and tolerability has improved. 
However, only small improvements in overall survival have been achieved. Further progress will 
depend on new treatments that eradicate residual disease after surgery and chemotherapy. The use 
of radiolabeled antibodies to achieve this goal has been investigated in past decades. For example, 
Epenetos et al. found that patients who achieve complete remission with conventional therapy 
had a relatively long-mean survival when treated with intraperitoneal radioimmunotherapy using 
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90Y-labeled anti MUC1 antibody [5]. However, the promising results of this phase I/II study were 
not confirmed in a recently completed phase III trial [6].
During the past decade radiolabeled receptor binding peptides have emerged as an important 
class of radiopharmaceuticals for diagnosis and therapy. Peptides used for tumor targeting offer 
considerable advantages over antibodies, as they are not immunogenic, accumulate rapidly in the 
target tissue, and clear rapidly from the blood and non-target tissues.
For peptide receptor-targeted radiotherapy (PRRT) peptides with specific affinity for tumor-
associated receptors on cancer cells, labeled with cytotoxic radionuclides can be used. Due to 
the restricted expression of the α
v
β
3
 integrin in tumors, α
v
β
3
 is considered a suitable receptor for 
tumor targeting. RGD peptides contain the amino acid sequence Arg-Gly-Asp and preferentially 
bind to the α
v
β
3
 integrin receptor. In previous studies we have shown that the radiolabeled cyclic 
RGD peptides specifically accumulated in subcutaneously (s.c.) growing α
v
β
3
 expressing tumors 
in athymic mice [7]. Here we studied the tumor targeting potential of an 111In-labeled cyclic RGD 
peptide in athymic BALB/c nude mice with intraperitoneally (i.p.) growing NIH:OVCAR-3 ovarian 
carcinoma tumors. Furthermore, in this mouse model, the therapeutic potential of the 177Lu-
labeled cyclic RGD peptide was investigated.
Material and methods
Radiolabeling of DOTA-E-c(RGDfK)
111In-DOTA-E-c(RGDfK) was prepared by adding 18.5 MBq 111InCl
3
 (Mallinckrodt, Petten, 
The Netherlands) to 5 µg (4.4 nmol) DOTA-E-c(RGDfK) (Figure 1) dissolved in 300 µL 0.5 M 
ammonium acetate buffer, pH 6, containing 0.6 mg/mL gentisic acid. 177Lu-DOTA-E-c(RGDfK) 
was prepared by adding 1.3 GBq (35.5 mCi) 177LuCl
3
 (NRG, Petten, The Netherlands) to 9 µg (8.0 
nmol) DOTA-E-c(RGDfK) dissolved in 300 µL 0.5 M ammonium acetate buffer, pH 5, containing 
0.6 mg/mL gentisic acid.
The reaction mixtures were degassed and the mixtures were heated at 100 °C for 15 minutes. The 
radiochemical purity was determined by reversed-phase high-performance liquid chromatography 
(RP-HPLC) (HP 1100 series, Hewlett Packard, Palo Alto, CA, USA) using a C18 column (RX-C18, 
4.6 × 250 mm, Zorbax) eluted with a gradient mobile phase (8-20% B over 25 min, solvent A = 
25 mM ammonium acetate buffer, solvent B = acetonitrile) at 1 mL/min. The radioactivity of the 
eluate was monitored using an in-line radiodetector (Flo-One Beta series, Radiomatic, Meriden, 
CT, USA).
_____  Chapter 6  _____________________________________________________________________________
110
__________   α
v
β
3
 Integrin targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide _____ 
111
Figure 1. Structural formula of the DOTA-conjugated RGD peptide, DOTA-E-c(RGDfK).
Nude mouse tumor model
To ensure a reproducible growth of tumors in the mice, NIH:OVCAR-3 ovarian carcinoma cells 
were serially transplanted i.p. in female BALB/c nude mice. On day 0, OVCAR-3 cells were harvested 
from a mouse with ascitic tumor, and 6-8 weeks old mice were inoculated intraperitoneally with 
0.2 mL of a cell suspension of NIH:OVCAR-3 cells (5×107 cells/mL). The radiolabeled DOTA-E-
c(RGDfK) was administered 10 or 11 days after tumor inoculation.
Biodistribution studies
Ten or eleven days after tumor inoculation mice were randomly divided in seven groups and 
received 0.01, 0.03, 0.1, 0.3, 1, 3 (n=4-5) or 10 µg (n=2) DOTA-E-c(RGDfK) i.p.. Therefore, 111In-
labeled DOTA-E-c(RGDfK)  was prepared as described above (140 kBq/nmol) and peptide dose 
was adjusted by adding non-radiolabeled DOTA-E-c(RGDfK). Mice were killed by CO
2
 asphyxiation 
two hours postinjection (p.i.) and the OVCAR-3 cells were harvested by rinsing the abdominal 
cavity twice with 5 mL 0.9% NaCl. Cells were spun down (1200 rpm, 5 min), and the activity in 
pellet and the supernatant was determined. In addition, blood and the major organs and tissues 
were collected, weighed, and counted in a γ-counter (1480 Wizard, Wallac, Turku, Finland). The 
percentage injected dose per gram (%ID/g) was determined for each sample. At seven time points 
p.i. (0.5, 2, 4, 8, 24, 48 and 72 h) the biodistribution of the optimal dose of 111In-DOTA-E-c(RGDfK) 
was determined in 5 mice/group. In addition, to investigate whether the localization of 111In-
DOTA-E-c(RGDfK) is receptor-mediated, the biodistribution of the optimal dose of 111In-DOTA-
E-c(RGDfK) in the presence of an excess of unlabeled RGD peptide was determined at each time 
point (2 mice/group). Furthermore, at 2 h p.i. the effect of the route of administration was studied 
in one group of mice (n=5). This group received 0.1 µg 111In-DOTA-E-c(RGDfK) intravenously 
(i.v.).
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Radionuclide therapy study
One group of mice with i.p. OVCAR-3 tumors (n=10) received 37 MBq 177Lu-DOTA-E-c(RGDfK). 
A second group of mice with i.p. OVCAR-3 tumors (n=12) did not receive any treatment and 
served as control group. Twice a week the body weight of the mice in each group was recorded. 
When intraperitoneal ascitic tumor growth was apparent, mice were killed by CO
2
 asphyxiation. 
Differences in survival between groups were compared using a logrank test for survival analysis. 
The level of significance was set at P<0.05.
Autoradiography
To study the intratumoral distribution, three mice with i.p. growing OVCAR-3 tumors received 
1.1 MBq (0.3 µg) 111In-DOTA-E-c(RGDfK) i.p.. Mice were killed by CO
2
 asphyxiation two hours 
p.i.. One solid tumor deposit per mouse was removed and snap-frozen in liquid isopentane and 
cryofixed (OCT Tissue-Tek; SAKURA Finetek U.S.A. Inc.) The tumor was sectioned (5 µm) using a 
cryostatic microtome. After air drying, tumor sections were exposed to a storage phosphor imager 
screen overnight. The screen was scanned in a phosphor imaging system (Molecular Imager GS363, 
BioRad Laboratories, Hercules, CA) at a pixel size of 100 × 100 µm. Images were processed with 
Quantity One software (version 4.5.2, BioRad Laboratories, Hercules, CA).
Results
Radiolabeling of DOTA-E-c(RGDfK)
RP-HPLC analysis indicated that the radiochemical purity of 111In-DOTA-E-c(RGDfK) and 177Lu-
DOTA-E-c(RGDfK) preparations used in these experiments was at least 93%. The elution profile of 
111In-DOTA-E-c(RGDfK) and 177Lu-DOTA-E-c(RGDfK) showed a single peak for both compounds 
with an elution time of 14.0 min for the 111In-labeled compound (Figure 2) and 14.2 min for the 
177Lu-labeled compound.
Figure 2. RP-HPLC elution profile of 111In-DOTA-E-c(RGDfK).
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Biodistribution studies
The results of the peptide dose escalation study of 111In-DOTA-E-c(RGDfK) are summarized in 
Figure 3. The optimal tumor uptake was observed when a peptide dose of 0.03 µg and 0.1 µg was 
administered (20.6 ± 9.7 %ID/g and 18.5 ± 5.9 %ID/g, respectively). At 2 h p.i., the tumor-to-blood 
ratio at a peptide dose of 0.1 µg was 133 ± 46 (Figure 4). At higher peptide doses the uptake in 
the tumor was significantly lower, probably due to saturation of the α
v
β
3
 integrin receptors in the 
tumor.
The optimal dose of 0.1 µg per mouse was used to study the biodistribution of the radiolabeled 
peptide at 0.5, 2, 4, 8, 24, 48, and 72 h p.i.. The results are shown in Figure 5. Tumor uptake peaked 
at 4 h p.i. (38.8 ± 2.7 %ID/g) and gradually decreased with time to 19.3 ± 1.9 %ID/g at 72 h p.i.. 
Blood levels were 0.98 ± 0.20 %ID/g 0.5 h p.i. and rapidly decreased to 0.006 ± 0.001 %ID/g at 72 
h p.i.. Coinjection of an excess unlabeled RGD peptide (50 µg) along with 0.1 µg 111In-DOTA-E-
c(RGDfK) resulted in a significantly lower radioactivity concentration in the tumor, indicating that 
uptake of the major fraction of 111In-DOTA-E-c(RGDfK) in the tumor is α
v
β
3
-mediated (Figure 6).
The route of administration of 111In-DOTA-E-c(RGDfK) in the i.p. OVCAR-3 model was clearly 
in favor of the i.p. route (Figure 7). At 2 h p.i. tumor uptake after i.p. administration of 0.1 µg 111In-
DOTA-Ec(RGDfK) was 35.2 ± 3.8 %ID/g whereas after i.v. administration, the tumor uptake was 
0.98 ± 0.26 %ID/g.
Figure 3. Biodistribution of 111In-DOTA-E-c(RGDfK) in BALB/c nude mice with i.p. growing OVCAR-3 ovarian carcinoma 
at 2 h p.i. at various peptide doses.
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Figure 4. Tumor-to-blood ratios at various peptide doses at 2 h p.i. in BALB/c nude mice with i.p. growing OVCAR-3 
ovarian carcinoma.
Figure 5. Biodistribution of 0.1 µg 111In-DOTA-E-c(RGDfK) at different time points in BALB/c nude mice with i.p. growing 
OVCAR-3 ovarian carcinoma.
Figure 6. Tumor uptake of 0.1 µg 111In-DOTA-E-c(RGDfK) at different time points in the presence (dotted line) and 
absence (solid line) of an excess of unlabeled RGD peptide.
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Figure 7. Biodistribution of 111In-DOTA-E-c(RGDfK) in BALB/c nude mice with i.p. growing OVCAR-3 ovarian carcinoma 
2 h after i.v. (black bars) and i.p. (white bars) administration.
Survival study
The results of the survival study are given in Figure 8. Mice that received 37 MBq 177Lu-DOTA-
E-c(RGDfK) i.p. showed a statistically significant longer survival than the mice that received no 
treatment (P=0.017). The median survival for the untreated mice was 5 weeks, whereas the 
median survival for the treated mice was 21 weeks.
Figure 8. Kaplan-Meier survival plot of BALB/c nude mice with i.p. growing OVCAR-3 ovarian carcinoma. There is a 
significant increase in median survival between the treated and untreated group (21 weeks and 5 weeks, respectively; 
P=0.017).
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Autoradiography
In Figure 9, tumor sections from 3 tumor deposits are shown. In all tumor sections, 111In-
DOTA-E-c(RGDfK) showed a heterogeneous distribution throughout the tumor 2 h p.i., mainly 
accumulating in the periphery of the tumor deposit.
Figure 9. Autoradiographs showing the intratumoral distribution of 111In-DOTA-E-c(RGDfK) 2 h after i.p. administration.
Discussion
The 111In-labeled cyclic RGD peptide showed tumor targeting potential in i.p. growing ovarian 
carcinoma. Uptake of the peptide in the i.p. growing ascitic tumor was specific, dose dependent and 
saturable. Optimal tumor uptake of 111In-DOTA-E-c(RGDfK) was achieved at a peptide dose in the 
range of 0.03 µg and 0.1 µg. At higher peptide dose the uptake in the tumor was reduced, due to 
saturation of the α
v
β
3
 integrin receptors. At the lowest peptide dose, 0.01 µg, the blood levels were 
relatively high, which may be caused by a relevant fraction of the peptide associated with plasma 
proteins.
For peptide receptor-targeted radiotherapy, high uptake in the tumor is important, but retention 
of the radiolabel in the tumor is also crucial. With a peak in tumor uptake at 4 h p.i., followed by 
a slow decrease to 24.0 ±  4.1 %ID/g after 48 h, this cyclic RGD peptide fulfilled this requirement. 
The long retention of 111In-DOTA-E-c(RGDfK) in the tumor deposits may be due to internalization 
of the radiolabeled ligand. The internalization of radiolabeled RGD peptides and RGD-containing 
macromolecular conjugates by α
v
β
3
 expressing cells has been described [8, 9].
Coinjection of an excess of unlabeled RGD peptide resulted in a significant decrease of 
radioactivity in the tumor, clearly demonstrating that the uptake of 111In-DOTA-E-c(RGDfK) 
in the tumor was α
v
β
3
-mediated. It is noteworthy that the uptake of 111In-DOTA-E-c(RGDfK) 
in the i.p. growing tumor after i.p. administration was much higher compared to the uptake in 
subcutaneously (s.c.) growing OVCAR-3 tumors after i.v. administration. The uptake of 111In-
DOTA-E-c(RGDfK) at 2 h p.i. in the i.p. growing tumor was 35.2 ± 3.8 %ID/g, which is more than 
15-fold higher than the uptake in s.c. tumors (2.04 ± 0.3 %ID/g).
Radiolabeled antibodies directed against the mucin-1 antigen and other tumor-associated 
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glycoproteins, such as TAG-72 and gp-38 have been used to target ovarian cancer [10]. Several 
clinical trials on radioimmunotherapy (RIT) in patients with ovarian cancer have been published 
[11-18]. However, the use of monoclonal antibodies (MAbs) for tumor targeting show some 
disadvantages like the high molecular weight, which hinders rapid pharmacokinetics resulting 
in slow diffusion into the target tissue and comparatively high blood concentration. Another 
complicating factor for the application of radiolabeled antibodies is that MAbs are immunogenic. 
Although antibody fragments have been developed to overcome these problems, peptides have 
more favorable properties for tumor targeting. Peptides have a small size and a rapid clearance 
from blood and non-target tissues compared to proteins and antibodies. In addition, peptides 
have a low immunogenicity.
The effect of the route of administration has been the subject of various studies. These 
studies showed that for radiolabeled antibodies, the route of administration, i.v. vs. i.p. only 
has limited effect on the targeting of i.p. growing tumors [19-23]. Colcher et al. investigated the 
efficacy of intracavitary radiolabeled MAb administration and demonstrated the advantage 
of the concomitant use of intracavitary and i.v. administered MAbs for tumor targeting [19]. 
Furthermore, Koppe et al. showed that in nude mice with i.p. LS174T tumors the biodistribution 
of the monoclonal antibody MN-14 labeled with 131I, 186Re, and 88Y after i.v. and i.p. administration 
was not significantly different [20]. In a study in patients suspected of having primary or recurrent 
ovarian carcinoma were simultaneously injected i.v. and i.p. with 125I/131I-labeled chimeric antibody 
MOv18 [21]. In this study antibody uptake in i.p. tumor deposits was independent of the route 
of administration. The present study demonstrates that for radiolabeled peptides, the route of 
administration has a marked influence on tumor targeting. Tumor uptake after i.v. administration 
of 0.1 µg 111In-DOTA-E-c(RGDfK) at 2 h p.i. was 0.98 ± 0.26 %ID/g, whereas after i.p. administration 
tumor uptake was 35.2 ± 3.8 %ID/g (Figure 7). Due to the fast blood clearance of peptides 
compared to antibodies, the i.p. route of administration is preferred for peptides.
Compared to other studies investigating the tumor targeting potential of peptides, the i.p. 
tumor model showed excellent tumor uptake of 111In-DOTA-E-c(RGDfK) and low uptake in non-
target tissues. Especially, the kidney concentration of 111In-DOTA-E-c(RGDfK) is low compared to 
that of other 111In-labeled peptides. Apparently, this peptide is not efficiently reabsorbed in the 
renal tubular cells.
In this mouse model of ovarian cancer the therapeutic potential of the cyclic RGD peptide was 
also determined. In this i.p. OVCAR-3 model the tumor burden consisted of cell clusters in ascitic 
fluid and small omental solid tumor depositions. High energy particles such as 90Y (β
max
 2.3 MeV, 
t
1/2 
64 h) and 188Re (β
max
 2.1 MeV, t
1/2
 17 h) are considered more appropriate for the treatment of 
larger tumors whereas low energy particles such as 177Lu (β
max
 0.5 MeV, t
1/2 
161 h) and 131I (β
max
 0.6 
MeV, t
1/2
 192 h) could be more effective for the treatment of tumor cell clusters and small tumor 
lesions [24]. Therefore, DOTA-E-c(RGDfK) was radiolabeled with the β-emitting radionuclide 177Lu. 
In mice with i.p. growing OVCAR-3 tumors i.p. treatment with 177Lu-DOTA-E-c(RGDfK) resulted in 
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a statistically significant better survival as compared to untreated controls (P=0.017).
In conclusion, we demonstrated that 111In-DOTA-E-c(RGDfK) has high and specific uptake in nude 
mice with intraperitoneally growing OVCAR-3 tumors. PRRT experiments in this model of ovarian 
cancer indicated that i.p. tumor growth can be inhibited significantly by a therapeutic dose of 
177Lu-DOTA-E-c(RGDfK).
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Summary and general discussion
Radiolabeled receptor binding peptides have emerged as a new class of radiopharmaceuticals for 
tumor diagnosis and therapy. Several malignant tumors overexpress particular types of receptors 
on their cell surface, which can be targeted with radiolabeled peptides.
The α
v
β
3
 integrin receptor is an interesting candidate for tumor targeting, as it is expressed 
on the cell membrane of various tumor cell types such as ovarian cancer, neuroblastoma, breast 
cancer, melanoma, and others. Furthermore, for growth beyond the size of 1-2 mm in diameter, 
tumors require the formation of new blood vessels. The α
v
β
3
 integrin receptor is overexpressed on 
the endothelium of newly formed bloodvessels. α
v
β
3
 Integrin receptors expressed on endothelial 
cells modulate cell migration and survival during angiogenesis, while α
v
β
3
 integrin receptors 
expressed on carcinoma cells potentiate metastasis by facilitating invasion and movement across 
blood vessels. Radiolabeled ligands for this integrin receptor could be used as tracers to non-
invasively visualize α
v
β
3
 expression in tumors. Non-invasive determination of α
v
β
3
 expression 
potentially can be used to monitor treatment response to antiangiogenic drugs or even to select 
patients likely to respond to treatment with antiangiogenic drugs.
The α
v
β
3
 integrin specifically interacts with the arginine-glycine-aspartic acid (RGD) amino acid 
sequence present in extracellular matrix proteins such as vitronectin, fibrinogen, and laminin [1]. 
Based on the RGD tripeptide sequence, a series of small peptides has been designed to antagonize 
the function of the α
v
β
3
 integrin.
A few groups have systematically tested RGD containing peptides for their ability to bind 
the α
v
β
3
 integrin. It was shown that linear RGD peptides have a relatively low affinity for α
v
β
3
 
compared to cyclic RGD peptides. In addition, linear RGD peptides are often degraded rapidly in 
serum by proteases. Therefore, linear RGD peptides are considered suboptimal for α
v
β
3
 targeting. 
It appeared that cyclization of RGD peptides resulted in increased selectivity and affinity for 
the α
v
β
3
 integrin. Especially cyclic RGD peptides consisting of five amino acids have a high and 
selective affinity for α
v
β
3
. Furthermore, it was shown that besides the essential RGD sequence, a 
hydrophobic amino acid in position 4 increases the affinity, whereas the amino acid in position 5 
had no influence on the affinity [2]. The cyclo[Arg-Gly-Asp-D-Phe-Val] (c[RGDfV]), as developed 
by Kessler and coworkers, is one of the most active and selective antagonists for the α
v
β
3
 integrin 
[3]. Structure-activity relationship studies on this cyclic pentapeptide showed that the exchange 
of the valine amino acid (V) by lysine (K) did not significantly influence activity and selectivity. 
Because the ε-amino moiety of the lysine residue can easily be modified, numerous applications of 
c[RGDfK] are presented in the literature for tumor targeting and imaging.
In chapter 1, the criteria of peptide ligand development, the selection of radioisotopes, 
chelators, and chemical aspects of radiopeptide development are described. In addition, the 
current state of clinical use of radiopeptides for diagnosis and therapy of tumors is discussed.
In chapter 2, we developed RGD analogs with improved in vivo α
v
β
3
 targeting characteristics. 
Therefore, we synthesized apart from our lead compound c(RGDfK), three analogs: (I) a cyclic peptoid-
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peptide hybrid in which the arginine residue is replaced by the corresponding peptoid residue, (II) 
an all-peptoid in which all the amino acid residues are replaced by their corresponding peptoid 
residues, and (III) a peptidomimetic α
v
β
3
 receptor antagonist. The compounds were conjugated 
with 1,4,7,10-tetraazacyclododecane-N,N’,N”,N”’-tetaacetic acid (DOTA) and then radiolabeled 
with 111In. Subsequently, the in vitro and in vivo α
v
β
3
 binding characteristics were determined. 
The study demonstrated that modification of the cyclic RGD peptide to a peptoid-peptide hybrid 
resulted in reduced affinity for α
v
β
3
 and concomitant lower tumor uptake. The all-peptoid analog 
had no affinity for α
v
β
3
 and did not show any specific tumor uptake in vivo. In contrast, in vivo α
v
β
3
 
targeting of the non-amino acid containing peptidomimetic was as high as that of the native DOTA-
conjugated cyclic RGD peptide. The native cyclic RGD peptide and the non-amino acid containing 
peptidomimetic had the best characteristics for α
v
β
3
 targeting in tumors. Both compounds showed 
high uptake in non-target tissues such as intestine, colon, liver and spleen. Coinjection of an excess 
of non-radioactive compound resulted in a significantly lower uptake in these organs, indicating that 
the uptake is α
v
β
3
-mediated. In contrast, the accumulation of these two 111In-labeled compounds in 
the kidneys was apparently not α
v
β
3
-mediated, as the kidney uptake of both compounds was not 
significantly lower in the presence of an excess of non-radioactive compound. Compared to other 
radiolabeled receptor binding peptides (e.g. octreotide, minigastrin), the kidney concentration of 
these two 111In-labeled compounds was low, indicating that these compounds apparently are not 
efficiently reabsorbed in the renal tubular cells.
Multivalent interactions could increase the affinity of ligand-receptor interactions. Potentially, 
multivalent RGD peptides could have a higher affinity for α
v
β
3
 and could target α
v
β
3
 expressing 
tumors more efficiently. Therefore, we aimed to improve the tumor targeting properties of 
RGD peptides by multimerization (chapter 3). A DOTA-conjugated monomeric, dimeric, and 
tetrameric peptide were synthesized and radiolabeled with 111In. It was shown that multimerization 
of c(RGDfK) resulted in enhanced affinity for α
v
β
3
 as determined in vitro. Tumor uptake of the 
tetrameric RGD peptide was significantly higher compared to that of the monomeric and dimeric 
analogs. It is unlikely that the multivalent RGD peptides used in this study could bind multiple 
α
v
β
3
 integrins simultaneously, as the distance between the RGD units is very short (~20 bond 
distances). Therefore, statistical rebinding appears the most likely explanation for the enhanced 
affinity of the multimeric RGD peptides: the receptor binding of one RGD unit will significantly 
enhance the local concentration of the other RGD unit in the vicinity of the receptor. This will lead 
to a higher “on rate” of receptor binding and/or a lower “off rate” of the RGD multimer.
An alternative way to synthesize multimeric RGD peptides was studied by using dendrimers. 
Dendrimers are macromolecules consisting of multiple perfectly branched monomers and this 
architecture makes them versatile constructs for the simultaneous presentation of especially 
biologically relevant molecules.
In our study, a monomeric, dimeric, and tetrameric c(RGDfK) dendrimer was synthesized via a 
microwave-assisted 1,3-dipolar cycloaddition - denoted as “click reaction” - of dendrimeric alkynes 
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with the N-ε-azido derivative of c(RGDfK) (chapter 4). In this chapter, the enhanced affinity of 
the tetrameric dendrimer compared to its monomeric and dimeric analogs was demonstrated 
in vitro in a competitive binding assay. In athymic mice with subcutaneous SK-RC-52 tumors, 
the tetrameric RGD dendrimer showed a significantly higher tumor uptake compared to its 
monomeric and dimeric analog at 24 h p.i..
Currently, hexameric and octameric RGD peptides have been synthesized and tested in vitro for 
their α
v
β
3
 affinity. It appeared that the receptor binding affinity was not only dependent on the 
number of RGD moieties, but also on the spatial alignments of the RGD moieties [4]. Most likely, 
there is an upper limit on multimerization for in vivo tumor targeting. By multimerization of a 
compound, the molecular size will increase resulting in longer circulation times, which could lead 
to reduced tumor-to-background ratios.
An important aspect of the research on α
v
β
3
 targeted radiotracers is to improve tumor-to-
background ratios by modifying excretion kinetics of RGD peptides. Cyclic RGD peptides are 
generally composed of five amino acids. Apart from the RGD sequence, a variety of two additional 
amino acids have been used for different purposes such as radioiodination or linkage of chelators. 
These two amino acids may affect the three dimensional structure of the cyclic peptide and may 
thus affect the affinity and the in vivo behaviour of the peptide. It was shown that - besides the 
essential RGD sequence - a hydrophobic amino acid in position 4 increased the affinity, whereas 
the amino acid in position 5 had no influence on the affinity. The nature of these two amino acids 
can affect charge and hydrophilicity of the cyclic peptide. Apart from the two amino acids, a 
chelator and a linker between chelator and RGD peptide could also affect in vivo dynamics. It has 
been shown that introduction of a sugar moiety in a monomeric RGD peptide resulted not only in 
enhanced renal excretion, but also in enhanced tumor uptake of the radiotracer [5, 6].
In the study described in chapter 5, the effect of modification of the linker between the two cyclic 
RGD sequences and the DOTA chelator on the in vitro and in vivo characteristics was systematically 
investigated. A dimeric (E-[c(RGDfK)]
2
) RGD peptide was synthesized and conjugated either 
directly with DOTA or via different linkers: PEG
4
, glutamic acid, and lysine. It was demonstrated that 
optimization of the dimeric RGD peptide for α
v
β
3
 targeting by systemetic linker variation, affected 
the in vivo kinetics of the tracers without influencing the affinity for α
v
β
3
 and the α
v
β
3
 targeting 
potential. The RGD peptide containing lysine as a linker showed a significantly higher uptake in the 
kidneys compared to the native RGD peptide and the RGD peptide containing the glutamic acid 
residue in the linkage. The latter showed a significant higher uptake in the liver compared to the 
native RGD peptide and the RGD peptide containing lysine as a linker.
For peptide-receptor radionuclide therapy (PRRT), high tumor uptake is crucial, but a low kidney 
retention of the radiotracer is also very important. By incorporation of a linker, the retention in non-
target organs can be modified. This study showed that the native dimeric RGD peptide and the RGD 
peptide containing the PEG
4
 linker appeared to be the optimal radiotracers. The native dimeric RGD 
peptide could not be improved by introduction of glutamic acid or lysine as a linker.
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Ovarian cancer remains the most lethal gynecological malignancy in the Western world. Over the 
past 25 years the principal treatment of advanced ovarian cancer has been surgery followed by 
chemotherapy. Despite improvements in surgical management and advances in cytotoxic therapy, 
only small improvements in overall survival have been achieved. Further progress will depend 
on new treatments that eradicate residual disease after surgery and chemotherapy. The use of 
radiolabeled antibodies to achieve this goal has been investigated in the past decades.
In chapter 6, we studied the tumor targeting potential of the 111In-labeled cyclic RGD peptide 
in athymic BALB/c mice with intraperitoneally (i.p.) growing NIH:OVCAR-3 ovarian carcinoma 
tumors.
In mice with i.p. growing ovarian carcinoma the 111In-labeled cyclic RGD peptide showed excellent 
tumor targeting and tumor retention after i.p. administration. Several studies showed that for 
radiolabeled antibodies, the route of administration - meaning intravenous (i.v.) vs. intraperitoneal 
(i.p.) - had only limited effect on the targeting of intraperitoneally growing tumors. In contrast, 
for radiolabeled peptides the route of administration appeared to have a marked influence on the 
targeting of the i.p. tumor. At 2 h p.i. the tumor uptake after i.p. administration was more than 
30-fold higher than the tumor uptake after i.v. administration. In addition, the tumor uptake of 
the radiolabeled RGD peptide in the i.p. growing tumor after i.p. administration was more than 
15-fold higher compared to the uptake in subcutaneously (s.c.) growing OVCAR-3 tumors after i.v. 
administration. In view of the efficient targeting of the i.p. tumor with this RGD peptide, we studied 
whether this could be applied therapeutically. I.p. treatment of mice with i.p. growing ovarian 
carcinoma xenografts with the 177Lu-labeled RGD peptide resulted in a statistically significant better 
survival as compared to untreated controls. Peptides used for tumor targeting offer considerable 
advantages over antibodies, as they are not immunogenic, accumulate far more rapidly in the target 
tissue, and clear faster from the blood and non-target tissues. The faster clearance of peptides from 
the blood and non-target tissues compared to antibodies leads to higher tumor-to-background 
ratios. Therefore, peptide-receptor radionuclide therapy (PRRT) with α
v
β
3
 targeting peptides might 
be an alternative for antibody-based radioimmunotherapy (RIT) for the treatment of patients with 
i.p. tumors. However, α
v
β
3
 expression in non-target tissues such as lung, spleen and intestine might 
lead to unwanted radiation to normal organs and thus hamper PRRT.
In the last few years, significant progress has been made on the development of α
v
β
3
 targeting 
radiotracers for the visualization of α
v
β
3
 expression in tumors by single photon emission 
computed tomography (SPECT) or positron emission tomography (PET). [18F]Galacto-RGD 
has been under clinical investigations as the first α
v
β
3
 targeted radiotracer for non-invasive 
visualization of α
v
β
3
 in cancer patients. Radiolabeled α
v
β
3
 binding ligands are radiotracers with 
the potential for visualization of angiogenesis in tumors and early detection of rapidly growing and 
metastatic tumors. These tracers might have the potential to select patients who might benefit 
from treatment with antiangiogenic drugs and these tracers might also be used to monitor the 
therapeutic effect with α
v
β
3
 targeted drugs.
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The studies described in this thesis demonstrate that the α
v
β
3
 antagonists c(RGDfK) and  a non-
amino acid containing peptidomimetic had the best characteristics for α
v
β
3
 targeting in tumors. 
The former showed high and specific uptake in i.p. growing tumors. It appeared that i.p. tumor 
growth can be inhibited with a therapeutic dose of 177Lu-labeled c(RGDfK). The tetrameric analog 
of c(RGDfK), DOTA-E{E[c(RGDfK)]
2
}
2
, has optimal characteristics for the visualization of α
v
β
3
 
expression in tumors. Further studies should aim to radiolabel this compound with positron 
emitting nuclides such as 18F or 68Ga in order to image α
v
β
3
 expression in tumors using the best 
imaging technique, being PET. Furthermore, when labeled with a β-emitting radionuclide this 
compound might particularly be used for PRRT of i.p. growing tumors.
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Samenvatting
Radioactief gelabelde peptiden, die met hoge affiniteit binden aan receptoren op het celoppervlak 
van tumorcellen, vormen een nieuwe groep van radiofarmaca die gebruikt kan worden voor 
detectie en behandeling van tumoren. De α
v
β
3
 integrine receptor komt tot expressie op de 
celmembraan van tumorcellen van verschillende typen tumoren, zoals bijvoorbeeld eierstokkanker, 
neuroblastoom, borstkanker en melanoom. Bovendien komt de α
v
β
3
 integrine receptor tot 
expressie op de endotheelcellen van nieuw gevormde bloedvaten. Om te kunnen groeien, moeten 
in een tumor constant nieuwe bloedvaten worden aangemaakt, ook wel angiogenese genoemd. De 
α
v
β
3
 integrine receptor op endotheelcellen, regelt tijdens angiogenese de celmigratie en overleving 
van de endotheelcellen. De α
v
β
3
 integrine receptor die tot expressie komt op tumorcellen speelt 
een belangrijke rol bij invasie en de migratie (metastasering). Radioactief gelabelde liganden voor 
deze integrine receptor kunnen gebruikt worden om de expressie van α
v
β
3
 in tumoren zichtbaar 
te maken. Het bepalen van α
v
β
3
-expressie zou gebruikt kunnen worden voor het bepalen van 
het effect van angiogenese remmende stoffen en mogelijk het selecteren van patiënten voor 
behandeling met geneesmiddelen die de angiogenese remmen.
Het α
v
β
3
 integrine gaat een specifieke interactie aan met de aminozuursequentie arginine-
glycine-asparaginezuur, afgekort RGD. Deze RGD sequentie is aanwezig in extracellulaire 
matrixeiwitten zoals bijvoorbeeld vitronectine, fibrinogeen en laminine [1]. Er zijn verschillende 
kleine, RGD bevattende peptiden gesynthetiseerd die specifiek en met hoge affiniteit binden aan 
de α
v
β
3
 integrine receptor.
Enkele onderzoeksgroepen hebben op systematische wijze de α
v
β
3
-bindende eigenschappen 
van peptiden met de RGD sequentie getest. Het bleek dat lineaire RGD peptiden een relatief 
lage affiniteit voor α
v
β
3
 hebben in vergelijking met cyclische RGD peptiden. Bovendien worden 
lineaire RGD peptiden in serum relatief snel door proteases afgebroken. Daarom zijn lineaire RGD 
peptiden niet optimaal voor targeting van α
v
β
3
. Cyclische RGD peptiden daarentegen hebben over 
het algemeen een hogere selectiviteit en affiniteit voor het α
v
β
3
 integrine. Met name de cyclische 
RGD peptiden die bestaan uit vijf aminozuren hebben een hoge en selectieve affiniteit voor α
v
β
3
. 
Verder is gebleken dat naast de essentiële RGD sequentie, een hydrofoob aminozuur op positie 4 
leidt tot een verhoogde affiniteit [2]. Het door Kessler en medewerkers ontwikkelde cyclo[Arg-Gly-
Asp-D-Phe-Val] (c[RGDfV]) is één van de meest actieve en selectieve α
v
β
3
 integrine antagonisten 
(Figuur 1) [3]. Structuur-activiteit relatie studies van dit cyclische pentapeptide toonden aan dat 
vervanging van het aminozuur valine (V) door lysine (K), geen significante invloed had op de 
activiteit en selectiviteit. Aangezien de ε-amino groep van c[RGDfK] gemakkelijk gemodificeerd 
kan worden, is het cyclische pentapeptide c[RGDfK] een veel bestudeerd RGD peptide.
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Figuur 1. Structuurformule van het cyclische RGD peptide c(RGDfV).
In hoofdstuk 1 van dit proefschrift wordt een overzicht gegeven van verschillende gelabelde 
peptiden die ontwikkeld zijn voor medische toepassing. De volgende aspecten die van belang 
zijn bij het ontwikkelen van een radiopeptide worden besproken: de noodzakelijke eigenschappen 
van het peptide ligand, de selectie van het radionuclide en de chelator en de chemische aspecten 
die van belang zijn bij het ontwikkelen van een radiopeptide. Daarnaast wordt in dit hoofdstuk 
de klinische toepassing van enkele radiopeptiden voor diagnose en therapie van tumoren 
beschreven.
In hoofdstuk 2 is geprobeerd om RGD analoga met verbeterde α
v
β
3
-bindende eigenschappen 
te ontwikkelen. Daarvoor zijn, naast de referentie stof c(RGDfK), drie verschillende analoga 
gesynthetiseerd: (I) een cyclisch hybride van een peptoïde en een peptide waarvan het arginine 
residu is vervangen door het overeenkomstige peptoïde residu, (II) een peptoïde waarin alle 
aminozuur residuen zijn vervangen door de overeenkomstige peptoïde residuen, en (III) een 
peptidomimeticum. Alle verbindingen werden geconjugeerd met DOTA en radioactief gelabeld 
met 111In. Vervolgens werden in vitro en in vivo de α
v
β
3
-bindende eigenschappen van de gelabelde 
liganden bepaald.
In deze studie bleek het omzetten van het cyclische RGD peptide in een hybride te leiden tot 
een sterk verlaagde affiniteit voor het α
v
β
3
 integrine en een lagere opname van de verbinding in 
de tumor. Het peptoïde had geen affiniteit voor het α
v
β
3
 integrine en vertoonde dan ook geen 
specifieke opname in de tumor. In vitro vertoonden het peptidomimeticum en het cyclische 
RGD peptide de hoogste affiniteit voor het α
v
β
3
 integrine. Het natieve cyclische RGD peptide en 
het peptidomimeticum vertoonden ook in het muizenmodel de hoogste opname in de tumor. 
Beide verbindingen vertoonden echter ook een hoge opname in verschillende normale weefsels 
zoals dunne darm, dikke darm, lever en milt. Coinjectie van de radioactief gelabelde stof met een 
overmaat niet-radioactief gelabelde stof resulteerde in een significant lagere opname van het 
betreffende ligand in deze normale weefsels, waaruit blijkt dat de opname van deze liganden in 
deze weefsels α
v
β
3
-gemedieerd is. De nieropname van het 111In-gelabelde natieve RGD peptide en 
het peptidomimeticum bleek niet α
v
β
3
-gemedieerd.
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Multivalente interacties zouden de affiniteit van een ligand voor zijn receptor kunnen verhogen. 
Mogelijk zouden multivalente RGD peptiden een hogere affiniteit voor het α
v
β
3
 integrine kunnen 
hebben en daardoor α
v
β
3
-expresserende tumoren efficiënter kunnen targeten. Het doel van de 
studies beschreven in hoofdstuk 3 was door multimerisatie van RGD peptiden de tumoropname 
van RGD peptiden te verbeteren. Daarvoor werden een DOTA-geconjugeerd monomeer, dimeer 
en tetrameer RGD peptide gesynthetiseerd en radioactief gelabeld met 111In. In vitro bleek dat 
multimerisatie van c(RGDfK) resulteerde in een verhoogde affiniteit voor het α
v
β
3
 integrine. In 
naakte muizen met subcutane α
v
β
3
-positieve tumoren was de opname van het tetramere RGD 
peptide in de tumor hoger dan dat van het dimere en monomere RGD peptide. De afstand 
tussen de RGD eenheden is te kort om te veronderstellen dat meerdere RGD eenheden van een 
multivalent construct gelijktijdig aan verschillende α
v
β
3
 integrine receptoren binden. De meest 
voor de hand liggende verklaring voor de verhoogde affiniteit van multimere RGD peptiden 
voor α
v
β
3
 is derhalve dat de multivalente constructen een verhoogde kans hebben dat het ligand 
opnieuw bindt aan de α
v
β
3 
receptor. Met andere woorden: de binding aan de α
v
β
3
 receptor van 
één RGD eenheid zal de locale concentratie van RGD eenheden aan het celoppervlak verhogen. Dit 
resulteert in een hogere associatiesnelheid van het RGD multimeer.
Multimere RGD peptiden kunnen ook op een andere manier gesynthetiseerd worden. In 
hoofdstuk 4 wordt de synthese van een serie multimere RGD peptiden op basis van dendrimeren 
beschreven. Dendrimeren zijn macromoleculen die opgebouwd zijn uit volledig vertakte 
monomeren. 
In dit hoofdstuk wordt de synthese van een monomeer, dimeer en een tetrameer c(RGDfK) 
dendrimeer beschreven. Deze dendrimeren zijn gesynthetiseerd via een magnetron-geïnduceerde 
1,3-dipolaire cycloadditie reactie van dendrimere alkynen met het N-ε-azido derivaat van 
c(RGDfK). Deze reactie wordt ook wel een „click reactie“ genoemd. In vitro vertoonde de tetramere 
dendrimeer een verhoogde affiniteit voor α
v
β
3
 integrine ten opzichte van het monomere en 
dimere dendrimeer. Zowel 2 als 24 uur na injectie vertoonde het tetramere RGD dendrimeer in 
muizen met subcutane SK-RC-52 tumoren een significant hogere opname in de tumor dan het 
monomere en dimere dendrimeer.
In hoofdstuk 5 is op systematische wijze het effect van de linker tussen de twee RGD eenheden en 
de DOTA chelator op de in vitro en in vivo eigenschappen van een dimeer RGD peptide onderzocht. 
Het dimere RGD peptide werd óf direct met DOTA (natieve ligand) óf via verschillende linkers 
(PEG
4
, glutaminezuur of lysine) geconjugeerd (Figuur 2). De in vivo kinetiek van het dimere RGD 
peptide bleek afhankelijk van de aard van de linker, terwijl de affiniteit voor α
v
β
3
 niet afhankelijk 
bleek van de linker. Het RGD peptide met de lysine linker had een significant hogere opname in de 
nieren vergeleken met het natieve ligand en het RGD peptide met de glutaminezuur linker. Deze 
laatste vertoonde echter een significant hogere opname in de lever vergeleken met het natieve 
ligand en het RGD peptide met de lysine linker.
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Figuur 2. Schematische weergave van het dimere RGD peptide geconjugeerd met de DOTA chelator (boven) en het 
dimere RGD peptide geconjugeerd met de DOTA chelator via een linker (onder).
De linker tussen het peptide en de chelator, kan de retentie van het radiofarmacon in de normale 
organen beïnvloeden, hetgeen belangrijk is voor peptide receptor radionuclide therapie. Hierbij is 
niet alleen een hoge opname van het radiofarmacon in de tumor essentieel, maar is ook van belang 
dat het radiofarmacon weinig retentie in de nieren vertoont. In deze studie hadden het natieve 
peptide en het peptide met de PEG
4
 linker de meest gunstige eigenschappen.
In hoofdstuk 6 werd de tumortargeting van een 111In-gelabeld cyclisch RGD peptide bestudeerd 
in een model van intraperitoneaal (i.p.) groeiende ovariumtumoren in naakte muizen. Het 111In-
gelabelde RGD peptide bleek na i.p. toediening zeer efficiënt te accumuleren in i.p. groeiende 
OVCAR-3 tumoren.
Uit deze studies bleek dat de toedieningsroute van radioactief gelabelde peptiden een 
belangrijke invloed heeft op het targeten van i.p. groeiende tumoren. Twee uur na i.p. injectie 
was de accumulatie van het peptide in de tumor meer dan 30 keer hoger dan na intraveneuze 
(i.v.) toediening. Bovendien accumuleerde het peptide efficiënter in i.p. groeiende tumoren dan 
in subcutaan (s.c.) groeiende tumoren: na i.p. toediening van het peptide was de accumulatie 
in i.p. groeiende tumoren meer dan 15 keer hoger dan in s.c. groeiende tumoren. Vanwege de 
efficiënte tumortargeting door dit peptide, zijn de therapeutische mogelijkheden van dit peptide 
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onderzocht. De overleving van de muizen met het i.p. groeiende ovariumcarcinoom verbeterde 
inderdaad door behandeling met het 177Lu-gelabelde RGD peptide.
Peptide receptor radionuclide therapie (PRRT) met α
v
β
3
-bindende peptiden zou een alternatief 
kunnen zijn voor radioimmunotherapie (RIT) met behulp van antilichamen, omdat peptiden 
voor het targeten van tumoren betere eigenschappen hebben dan antilichamen: ze zijn over 
het algemeen niet immunogeen, accumuleren snel in tumoren en klaren snel uit de circulatie en 
normale weefsels.
In de afgelopen jaren zijn een aantal goede radiofarmaca voor de visualisatie van α
v
β
3
-expressie 
in tumoren met behulp van SPECT (single photon emission computed tomography) of PET 
(positron emission tomography) ontwikkeld. [18F]Galacto-RGD was het eerste α
v
β
3
-bindende 
radiofarmacon dat in klinische studies is toegepast.
Potentiële toepassingsgebieden van radioactief gelabelde α
v
β
3
-bindende liganden zijn het 
visualiseren van angiogenese in tumoren, het detecteren van snel groeiende en metastaserende 
tumoren en wellicht ook het selecteren van patiënten die baat zouden kunnen hebben bij de 
behandeling met antiangiogene geneesmiddelen.
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